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Abstract  
 
The essentiality of silicon and the toxicity of aluminium within humans are both topics of much debate; the 
current conception is that silicon is essential in ameliorating aluminium toxicity, however, the evidence for this 
remains inconclusive.  
To be able to elucidate the connection between silicon and aluminium in neurological disorders, it is first 
important to understand the relationship between the elements in healthy individuals. This research was 
designed to investigate whether supplementing the diet with a silicic acid-rich mineral water could be a non-
invasive means of reducing aluminium body burden in both healthy individuals and those suffering from multiple 
sclerosis.  
Drinking a silicic acid-rich mineral water significantly enhanced the urinary excretion of aluminium, in both 
healthy individuals and in multiple sclerosis.  
Collecting whole daily urinary excretions for healthy individuals indicated that aluminium was concomitantly 
excreted with silicon; this was most effective when the mineral water was consumed as a bolus, suggesting that 
the mineral water has greater influence when consumed in large quantities over a short time. In addition, 
reductions in urinary aluminium were also witnessed over time, supporting the use of silicic acid-rich mineral 
water in reducing and maintaining aluminium body burden at a lower level.  
Supplementing the diet with a silicon-rich mineral water, for a period of 12 weeks, reduced aluminium body 
burden in individuals with multiple sclerosis; concomitantly, in this short amount of time, disability scoring 
showed clinically relevant improvements in 2 out of 15 individuals. Longer-term studies, involving larger study 
populations, are now needed to see if these effects are long lasting; if improvements are seen over time, it could 
support the link between aluminium and multiple sclerosis.  
This research also presents preliminary evidence that sweat may be a more efficient excretory mechanism in 
lowering the body burden of aluminium in healthy individuals.  
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In conclusion, the results suggest that including a silicic acid-rich mineral water into the regular diet, without the 
need of following strict restrictions, could be a prophylactic therapy against aluminium toxicity in healthy 
individuals, and in addition, could be beneficial as a chelating agent for endogenous aluminium. 
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Chapter 1 – Introduction. The quintessential nature of silicon 
 
Silicon, is a chemical element, with the atomic number of 14. In 1808, the name silicium 
(from Latin: silex meaning a hard stone/flint) was first given to the element (Weeks 1968), with the –
ium word ending suggesting a metal like form, a name which is preserved in several languages. The 
English name, as we know it today was suggested in 1817 to conform to the properties of the physically 
similar elements, boron and carbon (Weeks 1932). Silicon was first characterised and prepared in its 
purity in 1823 and is a solid crystalline structure at room temperature with a boiling point of 3,265oC. 
Like water, its density is greater in the liquid state and expands when it freezes (Hull 1999). Silicon is 
described to be a metalloid, displaying both metal and non-metal properties. In its crystalline form, it 
is grey in colour and has a metallic lustre. The outer obital, like carbon, has 4 valence electrons. The 
1s, 2s, 2p and 3s subshells are filled completely, there are 2 electrons located in the 3p subshell out of 
a possible 6. Silicon is a semiconductor with a negative temperature coefficient of resistance, this is 
due to the increase in the number of free charge carriers with increase temperatures (Hull 1999).  
 
 
 
 
 
 
 
Figure 1.1 Structural image of silicon (Hong, Xiao 1993) 
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Silicon is the second most abundant in the Earth’s crust, but is rarely found in its elemental form due 
to its high affinity for oxygen, forming rocks and minerals; such as, quartz, aluminosilicates, 
sedimentary and igneous rocks which are not readily broken down unless exposed to substantial 
weathering. Chemical and biological weathering of these rocks and minerals, through algae, plants 
and lichens for example, release the element. This causes the bioavailability of silicon in the natural 
environment to increase (Jugdaohsingh 2007). The dissolution of silica from these minerals in water 
results in the formation of soluble silica species below 2mM (Jugdaohsingh 2007), such as orthsilicic 
acid, SiOH4 (see figure 1.2), this ‘free’ form of silicon is now in a form that is biologically available and 
can be actively taken up by plants and animals (Jugdaohsingh 2007). 
 
 
 
 
Fig 1.2: Structural view of orthosilicic acid 
 
Si is considered to be a beneficial element in biology (Neilsen 1984). Within the natural world it is 
known that there are various sea sponges and microorganisms such as diatoms which form skeletal 
structures composed of silica. Silica is also deposited in many plant tissues, thought to contribute to 
structural support in the vascular system (Pilon-Smits et al 2009). Silicified trichomes of Cannabis 
sativa, horsetails and many grass species are also seen (Cutter 1978). 
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1.1 Si essentiality in higher animals 
 
There has been much debate over the role of Si in higher animals. Epstein (1999) stated that ‘an 
element is defined as quasi-essential if it is ubiquitous in plants, and if a deficiency of it can be severe 
enough to result in demonstrable adverse effects or abnormalities in respect to growth, development, 
reproduction, or viability’. Research has shown that a Si deficient diet can result in poor growth, 
Carlisle found that by feeding chicks an identical diet accompanied by a Si supplement showed fifty 
percent higher growth and normal development.  
 
 
 
 
 
 
Fig 1.1.1 Carlisle’s Chicks: The chick on the right had been given a normal diet, whereas the chick on 
the left had been supplemented with Si (Carlisle 1972) 
 
Not only was there a clear size difference between the two chicks, see Figure 1.1.1, but the general 
health of the non-supplemented chick was poorer, with muddyish yellow subcutaneous skin as 
opposed to the healthy pinkish white of the supplemented chick (Carlisle 1972). Carlisle then began 
to investigate this further by looking at the effects of silicon supplemented diet on bone formation, 
looking in particular at the skull and bone (Carlisle 1980). The beaks and legs of the non-supplemented 
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chicks were thinner, paler, and more easily fractured than those of the supplemented chicks, see 
Figure 1.1.2. 
 
 
 
 
 
 
Figure 1.1.2: The top left skull and femur bones B are those of a chick consuming a normal diet, whilst 
the bottom left skull and femur bones A are taken from a Si supplemented chick of the same age. 
(Carlisle 1980) 
 
Silicon is regarded as a beneficial element for the human body, and has the primary function of 
developing and maintaining connective tissue and the structural system. There are a number of 
studies focusing on the effect of increased silicon on the human body. The effect on bone and cartilage 
has been explored in humans as early as 1979, when the activity of a soluble Si drink was studied 
against the trabecular bone volume (TBV) in men. The study noted a significant increase in TBV 
compared to the controls (Schiano et al 1979). Silicon has been described to be ‘essential’ for the 
strength and integrity of the tunica intima (Schwartz 1977), the inner layer of an artery, observing that 
there is an inverse relationship between the concentration of silicic acid in drinking water and the 
prevalence of cardiovascular disease in Finland. 
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The effect of silicon on skin, hair and nails appears regularly in literature, Lassus (1993) performed an 
open study with an oral Si colloidal solution during a 3 month period, from which he saw statistically 
significant improvements in turgor and thickness of the skin, hair and nails. 
 
This presents the argument whether silicon is beneficial or essential. Humans are exposed to silicon 
every day, through pharmaceuticals, cosmetics and dust, but, the major and most important source 
of exposure for the general population, is the diet. 
 
1.2 Si in the diet 
 
The vast majority of silicon we are exposed to comes from our diets. High levels of silicon are found in 
foods derived from plants, such as; grains, barley and rice, which is to no surprise when the abundance 
of silicon in the Earth’s crust is considered. Silicon in the bioavailable form of orthosilicic acid is at a 
high exposure in drinking water and beer. 
In the western world, an average daily intake of silicon is approximated at 20-50mg/day; (Bowen & 
Peggs, 1984; Pennington, 1991; Anasuya et al. 1996; Uthus & Seaborn, 1996; Van Dyck et al. 1999a; 
Robberecht et al. 2009) including around 60% of this value coming from cereals and grains, and 20% 
from water (Pennington, 1991; Uthus & Seaborn, 1996; Jugdaohsingh et al. 2002; Robberecht et al. 
2009). Due to differences in diet between the sexes, intake is generally lower in women than in men 
and has been suggested to decrease with age (Pennington, 1991; Jugdaohsingh et al. 2002; Bisse et 
al. 2005). As foods have varying levels of silicon, it is clear to see how the different diets around the 
world affect dietary silicon intake. Table 1.2.1 is taken from a study (Jugdaohsingh et al 2002) showing 
the top 10 food sources contributing to total silicon intake within the population. 
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Table 1.2.1 Major (top 10) food sources that contribute to total silicon intake in the population 
(Jugdaohsingh 2002) 
 
 
2Total percentage contribution of the foods listed: 54.6% and 45.1% for men and women, respectively. 
3Total percentage contribution of the foods listed: 55.3% and 51.2% for men and women, respectively 
 
 High fibre diets are linked to being more silicon rich, therefore due to their traditional plant based 
diet, eastern communities are shown to have higher silicon intake (Chen et al. 1994; Anasuya et al. 
1996).  The concentration of silicic acid in drinking water and beer falls below the 2mM saturation, 
therefore containing a form of Si that is highly bioavailable and absorbable (Sripanyakorn et al. 2004). 
The geographic location at which the water is sourced has a large effect on the silicic acid 
concentration of the water, with water sourced from more volcanic environments containing the 
greatest concentrations. Silicon in hard waters is also noted to be at a higher concentration than that 
of soft waters (Sripanyakorn et al. 2004). 
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 As previously discussed, the amount of Si leached from rocks and minerals is variable due to the 
weathering taking place. Table 1.2.2 shows a variety of different tap and mineral waters, as well as 
their source and corresponding silicon contents to represent the differences found in water. 
Table 1.2.2: The silicon content of mineral waters and tap waters from different sources. 
Author  Country  Source  Silicon content  
Dobie, 1982 cited by 
Birchall, 1991  
U.K.  Tap water (n = 23)  7 – 256 μmol L-1  
Giammarioli et al. 2005  Italy  Mineral waters  
(n = 207)  
77% <10 mg L-1  
>25 mg L-1 sourced from 
volcanic areas  
Gillette-Guyonnet et al. 
2005  
France  Tap water (n = 7)  
Mineral water (n = 8)  
4 – 11.2 mg L-1  
8.6 – 36.4 mg L-1  
Powell et al. 2005  U.K.  Tap water (n = 4)  
Mineral water (n = 3)  
0.25 ± 0.11 mg 100g-1  
0.54 ± 0.49 mg 100g-1  
Robberecht et al. 2009  Belgium  Mineral water (n = 24)  0.76 – 19.13 mg kg- 
 
1.3 Absorption and excretion of silicon 
 
As the essentiality of silicon in humans is yet to be confirmed, what can be looked at is the manner in 
which silicon is absorbed in the body. Studies have shown that the concentration of silicon excreted 
in the urine is directly proportional to that consumed in a controlled diet, with a very small amount 
being lost in the faeces (Reffitt 1999). Despite this, it must be understood that the degree of 
gastrointestinal absorption is relatable to the polymerisation involved (Yokoi & Enomoto, 1979; Reffitt 
et al. 1999; Jugdaohsingh et al. 2000; Sripanyakorn et al. 2009). For instance, smaller molecules of 
silica or orthosilicic acid are readily absorbed by the gastrointestinal tract, whereas the larger are 
broken down using hydrolysis into soluble monomeric repeating units, which can be readily absorbed. 
From this, it is understood that the absorption of silicon from plant material is low, whereas of silicon 
in drinking water and beer, in the form of SiOH4, shows high bioavailability and is therefore the most 
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efficient form of silicon for absorption through the gastrointestinal wall (Bellia et al. 1994a). This also 
provides evidence that the movement of silicic acid follows the water pool. 
As silicon is more soluble in near neutral environments than acidic, the majority of the absorption 
occurs via the intestinal wall, rather than the gastric one, allowing more time for higher silicon 
complexes to be broken down.  
The main excretory organ for silicon is the kidney (Dobbie & Smith, 1982a; Reffitt et al. 1999; van Dyck 
et al. 1999b; Sripanyakorn et al. 2004). Once absorbed, silicon is then filterable by the kidney. It is 
worth noting however that there is a very small occurrence of renal reabsorption within the nephron. 
There is currently no known mechanism behind silicon reabsorption in the kidney (Adler & Berlyne, 
1986), however, a significant amount of silicon is seen to be retained in the kidneys of rats after 
intravenous silicon injections (Mehard & Volcani, 1975; Berlyne et al. 1986b; Adler et al. 1986). Studies 
have seen an increase in the blood plasma concentrations of silicon in uremic patients, once again 
highlighting that the kidney is the main excretory point for silicon.  
The excretion value for the renal clearance of Si is reported to be 28.9±13.3 mg L-1 (Dhaese et al. 1995), 
which is a value that relates well to the expected dietary intake lying at 20-50mg d-1. This high 
excretory value further indicates that silicic acid is readily absorbed across the intestinal wall and then 
swiftly excreted in the urine (Bellia et al. 1994b; Popplewell et al. 1998), furthermore, peaks in the 
silicon values were recorded in the urine as little as 4 hours after ingestion (Reffitt et al. 1999). Renal 
clearance is estimated to be between 80 – 100 mL Si min-1 (Adler & Berlyne, 1986; Reffitt et al. 1999) 
with a half-life of 2.7 hours (Popplewell et al. 1998) further highlighting that urinary excretion is a 
preferred route for the removal of Si from the body (Reffitt et al. 1999; Sripanyakorn et al. 2004). 
 
There is a lot of evidence suggesting that the gastrointestinal absorption of silicon is directly 
proportional to urinary excretion of the element. This absorption is facilitated by aquaporins, protein 
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channels in the gastrointestinal wall that aid the transfer of water and smaller ions through to the 
bloodstream. There has been increased attention on this element and its pathway through the body, 
through strong associations with the beneficial elements, copper and zinc (Henk-Maarten 2007). 
Silicon is also related to an increase in calcium absorption, again, suggesting a positive effect on bone 
health (Jugdaohsingh 2007).  
 
1.4 Mechanisms of silicon essentiality 
 
In spite of the fact that silicon is widely regarded as an essential element in lower organisms and is 
reported to be beneficial to mammals, the biochemistry to explain its requirement in biota remains 
undefined. Silicic acid is not bound to proteins and exhibits no activity towards organic species at 
physiological pH (D’Haese et al. 1995). Indeed, there is no evidence to support the presence of organic 
structures of Si-C or Si-O-C bonds in bio-systems and no stable binding of silicic acid in biological 
molecules has been witnessed (Birchall, 1990). 
The only known biological mechanism of silicon is in the interaction with aluminium which is basic at 
physiological pH (Birchall et al. 1996). It has been proposed that the bioinorganic interaction between 
silicon and aluminium is the reason behind silicon’s essentiality (Exley, 1998). 
 
1.5 Toxicity of aluminium 
 
Aluminium (Al) is a trivalent cation found in its ionic form in most kinds of animal and plant tissues 
and in natural waters everywhere (Jiang et al 2008). Despite being the third most abundant element 
in the Earth’s crust, and being located right next to silicon in the periodic table, aluminium is not 
tolerated by living organisms. In fact, reports documenting aluminium toxicity in plants, fish and higher 
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animals have been accumulating. Cases on aluminium toxicity in mammals have been well reported, 
and many conditions are now associated with the accumulation of this element, specifically 
neurological conditions. The severity of these conditions seems linked with the route, the quantity 
introduced, absorption rates, the tissue distribution and the excretion rate (Riihimaki et al. 2008; 
Lemire et al. 2009; Hernandez et al. 2008). 
In contrast to Si, no biological requirements have been attributed to aluminium, more importantly, 
aluminium is not tolerated by living organisms. Exploration of aluminium toxicity is vast in plants, fish 
and higher animals. Accounts of aluminium toxicity in mammals and humans include osteomalacia, 
anemia (Kaiser et al. 1984) and a myriad of neurological disorders (discussed later in this section).  
 
1.6 Exposure to aluminium 
 
 
Aluminium has become particularly isolated from biological systems and generally requires another 
element to ‘deliver’ it into the human body, therefore increasing its bioavailability.  
Throughout the history, humankind have lived through various ‘metal ages’ including the Iron Age and 
the Bronze Age. The world has now entered the ‘Aluminium Age’, and aluminium is accumulating in 
the natural world due to recent anthropogenic factors; increased use in industry and deposition of 
aluminium in soils. This is resulting in elevated aluminium throughout the biosphere (Kawahara et al. 
2007; Gomez et al. 2008; Exley, 2009). 
 
There are a variety of routes from which aluminium can end up entering the body. Dermally it can be 
absorbed through using anti-persperants (Flarend et al. 2001), where aluminium chloride is a 
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significant component. It can be delivered intravenously, through vaccines containing aluminium 
adjuvants (Keith et al. 2002) and inhaled from dust in an occupational environment (Rifat et al. 1990; 
McLachlan et al. 1995). Oral introduction is also a significant contribution to the overall burden of 
aluminium, foods such as spinach, potatoes and tea are high in Al (Pennington & Jones, 1989), while 
the worst culprits are chemicals involved in food additives, water purifiers and medicinal products. 
(Harris et al. 1996; World Health Organization, 1998). 
 
1.7 Aluminium in the body 
 
Once aluminium has found its way into the body, where does it go?  
Aluminium presents low solubility in neutral solutions. This hydrolytic chemistry has meant that this 
omnipresent element exists in a form of low biological availability and has therefore remained mostly 
sequestered from biological systems (Exley, 2009). However, recent anthropogenic dynamics, 
including acid deposition of soils and increased use in industry are increasing the availability of 
aluminium within the biosphere (Kawahara et al. 2007; Gomez et al. 2008; Exley, 2009) and resulting 
in the initiation of aluminium accumulation within living organisms. 
Fortunately, only around 0.1% of total aluminium ingested is absorbed through the gastrointestinal 
tract (Day et al. 1991), of which the majority is excreted rapidly through the kidneys. This fact may 
signify that aluminium has little benefit to human health. The aluminium that does remain in the body, 
which is around 5% of that absorbed into the bloodstream, slowly accumulates in various tissues 
(Priest et al. 1997). Over time, this could lead to morbidity and mortality due to various mechanisms, 
which is an important implication to consider when studying human disease (Denton et al. 1984; Alfrey 
et al. 1986; Wilhelm et al. 1990; Day et al. 1991; Yokel, 2006; Verstraeten et al. 2008).  
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Aluminium is rarely in its free state, however, it can be seen forming biological complexes in the 
bloodstream, of which the most common reaction is that with the iron transporter ferrin, accounting 
for around 90% of all aluminium interaction in the blood (Harris & Sheldon, 1990; Wrobel et al. 1995; 
Milacic et al. 2009). The movement of aluminium to binding sites in the tissue is facilitated by these 
weak interactions (Priest, 2004).  
On average, a healthy individual would contain a total measured body burden of around 60mg 
aluminium within their bones and tissues (Yokel, 2013). Although research states that aluminium can 
be found in all tissues in the body, it is very unevenly distributed, showing the greatest accumulation 
in bone tissue (Ganrot, 1986; Zafar et al. 1997). Other favourable spots for aluminium deposition are 
the skin, kidneys, liver, heart and brain (Alfrey, 1980; Exley, 2001; Xu et al. 1990; Hellstrom et al. 2008; 
Gonzales et al. 2009). On a cellular level, Al accumulation is mostly associated with lysosome, 
chromatin and cell nucleus (Galle, 1987; Lukiw et al. 1992; Karlik et al. 1980).  
Elimination rate of aluminium is dependents of the location of aluminium in the tissues, as aluminium 
can move throughout cellular compartments (Exley et al. 1996). When analysing the accumulation of 
aluminium in bone, it is possible to determine a half-life for aluminium in the body of around 50 years 
(Yokel, 2013). This ‘pool’ of aluminium allows to increase accumulation under prolonged exposure 
(Krewski et al. 2007). 
Many studies have set about to investigate the mechanism surrounding aluminium’s movement 
across the blood brain barrier. Aluminium is associated with many neurological conditions and can be 
viewed in the brain tissue histochemically. Modified haemotoxylin or lumigallion are the gold standard 
for aluminium staining in tissues. A common condition associated with increased brain aluminium 
pathology is Alzheimers disease, which is usually characterised by the presence of senile plaques, 
composed of Beta-Amyloid (Jones et al 2011). This study highlighted the relationship between 
aluminium and AB-42. Staining methods were combined to show a clear association between amyloid 
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protein, stained with Highman’s congo red and thioflavin t, and aluminium, stained with modified 
haemotoxylin, see Figure 1.7.1. 
 
 
Figure 1.7.1: Brain tissue of Alzheimer’s disease patients stained for aluminium and amyloid using modified 
haemotoxyln, congo red and thioflavin T. Tissue section (20 "m thickness) from occipital lobe (A–D) stained with 
modified haematoxylin and Highman’s Congo red and showing (arrow and insert) a spherulite (ca 20 "m diameter 
under, A) optical light; B) partially polarized light; C) crossed polarizers; D) fluorescence. Scale bar in A–D is 100 
"m. Tissue section (20 "m thickness) from frontal lobe (E–G) stained with modified haematoxylin and thioflavin T 
and showing (arrows and inserts) numerous spherulites (ca. 5–25 "m diameter) under, E) optical light; F) crossed 
polarizers; G) fluorescence. Scale bar inE–G is 200 "m. Tissue section (20 "m thickness) from frontal lobe (H–L) 
stained with Perl’s stain for Fe(III) and showing, H) under optical light no obvious spherulites but some ‘green’ 
stainingfor Fe(III) (arrow); I) numerous spherulites in the same section under crossed polarizers. Counter staining 
of the same section with thioflavin T shows numerous spherulites appearing, J) yellowunder optical light; K) as 
‘green’ Maltese crosses under polarized light; L) fluorescent green under fluorescent light. Scale bar in H–I is 200 
"m. (Jones et al. 2011) 
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The mechanism behind the uptake of aluminium into the brain is much more efficient than its release, 
this indicates that the amount of aluminium residing in our brain tissues increases with age (Exley and 
House 2011).  
1.8 Sources of Al exposure 
 
 
In this ‘Aluminium Age’ there are myriad sources responsible for this level of Al exposure. Al can be 
absorbed dermally through use of antiperspirants (Flarend et al. 2001), injected as vaccine adjuvants 
(Keith et al. 2002) or inhaled as dust in an occupational hazard risk (Rifat et al. 1990; McLachlan et al. 
1995). 
As explored during this thesis, oral introduction is also a significant source of Al exposure, one that 
with efforts could be minimised. Plant based foods, such as spinach, potatoes and teas are naturally 
abundant in Al (Pennington & Jones, 1989); in addition the application of Al in medicines, food 
additives and as a flocculent in water treatment further increases this oral exposure (Harris et al. 1996; 
World Health Organization, 1998). Typical diets in the western world contain about 20mg d-1 
(Pennington & Jones, 1989); although Al intake has been noted at up to 5g d-1 through the ingestion 
of antacids (World Health Organization, 1998). 
The presence of Al in tap water is relatively small in comparison with the amount contained within the 
food we eat (Priest et al. 1998); a mere 3-8 % of dietary Al comes from municipal water; the guideline 
for this is given by WHO (1998) and should not exceed 0.2mg L-1. However, it has been proposed that 
Al may be more bioavailable in water compared to food (Flaten, 2001). 
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The bioavailability of Al is highly affected by other dietary mechanisms; Al absorption is increased by 
fatty acids (Aspenstrom-Fagerlund et al. 2009) and affiliated with the ingestion of organic acids found 
in fruits and juices, particularly citrate (Slanina et al. 1986; Weberg & Berstad, 1986; Molitoris et al. 
1989; Walker et al. 1990; Day et al. 1991; Domingo et al. 1991; Taylor et al. 1992a; 1998). In direct 
contrast, silicic acid can reduce the bioavailability of aluminium (discussed later in this section), even 
in the presence of citrate (Birchall et al. 1989; Birchall & Chappell, 1989; Edwardson et al. 1993; 
Birchall, 1995). 
 
1.9 Al distribution around the human body 
 
 
Despite a number of studies highlighting the danger of large concentrations of Al on our diets, only a 
fraction (0.1%) of Al ingested by healthy individuals is actually absorbed through the gastrointestinal 
tract (Day et al. 1991) and the bulk of this is readily excreted through the kidneys (Ganrot, 1986; Exley 
et al. 1996; Popplewell et al. 1998; Powell et al. 1999b). This adds to the hypothesis that Al is of little 
significance to human health. However, about 5% of this absorbed amount of bioavailable Al is 
retained in the body (Priest et al. 1997), and over time, this accumulates in various tissues; potentially 
resulting in morbidity and mortality through a variety of mechanisms. This is an important implication 
for copious human diseases. (Denton et al. 1984; Alfrey et al. 1986; Wilhelm et al. 1990; Day et al. 
1991; Yokel, 2006; Verstraeten et al. 2008). 
Once in the blood, Al can complex with biological molecules (Harris, 1992; Priest, 2004), of which 
approximately 90% involves the iron transporter transferrin (Harris & Sheldon, 1990; Wrobel et al. 
1995; Milacic et al. 2009). These complexes are bound weakly and therefore the transport of Al to 
binding sites in our tissues is readily facilitated (Priest, 2004). 
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Al has been confirmed to accumulate in all tissues in mammals (Gonzales et al. 2009); however, the 
distribution of Al between tissue group is variable, with the highest levels seen in bone (Ganrot, 1986; 
Zafar et al. 1997). Other primary locations of notable Al deposition include the skin, kidneys, liver, 
heart and brain (Alfrey, 1980; Exley, 2001; Xu et al. 1990; Hellstrom et al. 2008; Gonzales et al. 2009). 
Al distributions also shows varied distribution within cell organelles, accumulating predominantly in 
the lysosome (Galle, 1987), cell nucleus (Lukiw et al. 1992) and chromatin (Karlik et al. 1980). 
Total body aluminium has been shown to transfer between different systemic compartments (Exley 
et al. 1996). This is highly dependent on the elimination rate of the tissue (Yokel & McNamara, 1989). 
The terminal half-life of Al in humans is estimated to be up to 50 years, a value calculated from Al in 
bone (Yokel, 2013); in addition, this notable high deposition of aluminium within the bone may allow 
it to serve as a reservoir for prolonged exposure (Krewski et al. 2007). 
As associations between Al and neurological disease continue, many studies have highlighted that Al 
may increase the permeability of the blood brain barrier. Uptake of aluminium into the brain is at least 
an order of magnitude more efficient than its release, which has a half-life of 7 years (Yokel et al. 
2006). In conclusion, aluminium within the brain increases with age; a review by Exley & House (2011) 
concluded that ‘normal’ human brains contain between 0.1 – 4.5 μg g-1 dry weight, with typically <2 
μg g-1 dry weight being associated with non-demented elderly. 
 
Gray matter appears to be the primary site for aluminium deposition in the brain (McDermott et al. 
1978), a region with a high density of transferrin receptors, such as the cerebral cortex and 
hippocampus (Edwardson et al. 1992). Specific compartments for brain aluminium are identified in 
Table 1.9.1. 
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Table 1.9.1: Major sinks/sources of aluminium within the brain (reviewed in Exley & House 2011). 
 
Despite the limited knowledge of the aluminium distribution throughout the tissues, it is known 
through histochemistry and quantitative analysis that it is present and has a strong association with 
neurodegenerative disease, specifically; Alzheimer’s disease, Parkinsons disease and multiple 
sclerosis. 
1.10 Role of metals: essential or neurotoxic? 
 
 
A number of metals are involved in the normal functioning and maintenance of the central nervous 
system. To mention a small number of examples, iron is critically required in the synthesis of 
neurotransmitters and plays a leading role in oxygen transport and electron transfer (Takeda, 2004); 
copper is a vital precursor in the electron transport chain involved in adenosine triphosphate 
synthesis, and finally, copper and zinc biochemistry is connected to messaging events within the 
synaptic cleft (Duce & Bush, 2010) and are components of superoxide dismutase (SOD). 
However, a level of neurotoxicity can result from a deviation in the natural balance of these essential 
metals (Olanow & Arendash, 1994; Bush, 2000; Sayre et al. 2005; Proudfoot, 2009). To measure 
Astrocytes, oligodendrocytes, microglia, mononuclear migratory cells.
Senile plaques, neurofibrillary tangels, Lewy bodies, lipofuscin.
Brain interstitial fluid
Pathological features
Non-neuronal cells
Neurons
Blood-brain barrier Endothelia, choroid epithelia, cerebrospinal fluid, pericytes, basal laminas.
Proteins (transferrin, albumin), neurotransmitters (glutamate, gamma amino butyric acid, 
acetylcholine, dopamine), nucleotides (ATP, ADP, AMP), amino acids (aspartate, serine, 
Sink/Source for Al Including
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toxicity, the underlying mechanisms are examined. These mechanisms of toxicity include alterations 
in cell membrane permeability, changes in nucleic acid function, and inhibition of protein synthesis 
resulting in variable enzyme activity. 
In multiple sclerosis, the levels of urinary aluminium excretion have been noted as similar to those 
seen in aluminium intoxication suggested that aluminium may be a hitherto unrecognized 
environmental factor associated with the aetiology of MS (Exley et al 2006).The cellular accumulation 
of lead and mercury has been associated with the development of autoantibodies against neuronal 
cytoskeletal proteins, neurofilaments, and myelin basic protein in humans and animals. Overexposure 
to lead and mercury ions is known to be neurotoxic, particularly to motor neurons. Low-to-moderate 
levels of lead exposure can cause functional alterations in T-lymphocytes and macrophages that lead 
to increased hypersensitivity and can alter cytokine production, which increases risk of inflammation-
associated tissue damage (Napier et al. 2016).  
The relationship between these essential trace metals and neurological disease is thought to be 
directly linked to a disruption in homeostatic mechanisms, leading to significant changes in their 
distribution and regulation (Duce & Bush, 2010). Evidence advocates that aluminium toxicity 
promotes the disruption of essential metal homeostasis (Exley, 2001; Kawahara et al. 2007; Wu 
et al. 2012). 
This has led to the idea that there is a connection between these metals and that their 
involvement in neurological disease may actually be a result of aluminium toxicity. 
 
1.11 Potential mechanisms of aluminium toxicity 
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Chemical properties, including charge and size, of aluminium are similar to many elements that the 
human body sees as essential, this enables it to act as a competitive inhibitor with other metals for 
target sites on specific enzymes, receptors and signalling molecules, resulting in a manipulation in 
activity (Exley, 2009). 
Magnesium and calcium play a leading role in neuronal reactions, being involved in neurotransmitter 
release and neuronal growth. Aluminium has been observed to replace magnesium at phosphate at 
binding sites on cell membranes, ATP, and DNA (Exley, 1992; Harris et al. 1996; Kawahara & Kato-
Negishi, 2011), and even demonstrated to replace calcium ions within bone, which results in an 
interference between calcium-based signaling events. This can trigger apoptosis within the tissue 
(Platt, 1994; Exley, 2001; Kawahara et al. 2007; Nday et al. 2010). 
Biological processes dependent on iron are considered to be a main target of aluminium toxicity. By 
disturbing iron homeostasis, the presence of aluminium subsequently leads to the production of 
reactive oxygen species (ROS) (Bondy & Kirstein, 1996; Exley, 2004; Wu et al. 2012), contributing to 
any toxicological effects. An increase in oxidative events have been noticed with interactions between 
aluminium and copper (Bondy et al. 1998; Becaria et al. 2003). 
In addition to this exploration about aluminium’s ability to affect homeostasis of essential metals in 
the body, other mechanisms for aluminium induced neurotoxicity have been proposed, mainly 
focussing on multiple sclerosis. 
The most commonly discussed suggestions include: 
a) Aluminium enhanced oxidative stress caused by lipid peroxidation of nervous tissue 
phospholipids, which affects the integrity of cell membranes (Sarin et al. 1997; Nayak & 
Chatterjee, 1999; Drago et al. 2008; Dua et al. 2010). 
b) Aluminium promotes neuro-inflammatory events (Platt et al. 2001: see also Bondy, 2010). 
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As it is believed that the occurrence of MS is liked to both genomic and environmental factors, the 
idea that Al may interact directly with the genomic structure (Nayak & Chatterjee, 1999) further 
supports this theory. Al is attracted to negative binding sites on nucleic acids (Lukiw et al. 1998). This 
could have detrimental effects on neuronal activity and could be linked to the several genetic 
mutations identified in multiple sclerosis. A possible mutation found, in a gene called NR1H3, is a 
missense mutation that causes loss of function of its gene product, LXRA protein. LXRA controls 
transcriptional regulation of genes involved in lipid homeostasis, inflammation, and innate immunity. 
Mice with this gene knocked out are known to have neurological problems, including a decrease in 
myelin production (Wand et al, 2016).  A detailed review on the potential mechanisms of Al toxicity 
can be found in Tomljenovic (2011). 
By considering of the variety of biological molecules able to bind to Al and the evidence that Al is 
able to displace essential metals from their binding sites, the idea can be consulted that Al toxicity 
could potentially affect any metabolic pathway (Exley, 2009) and may arise from a number of 
different interactions with the nervous system. 
1.12 Evidence for a role of aluminium in neurotoxicity 
 
 
The first report connecting aluminium and neurotoxicity in animals was reported by Dollken in 1897. 
However, the first evidential report confirming the connection was provided by Klatzo et al. (1965), 
who noted that rabbits injected with aluminium containing salts over time, formed neurofibrilary 
tangles in the brain. 
Evidence of aluminium neurotoxicity in humans was not presented until almost a century after this 
first connection (possibly because aluminium wasn’t as widely available during this time) when 
neurotoxicity was observed in individuals receiving dialysis treatment (Alfrey et al. 1976), confirming 
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the primary route of aluminium excretion is the kidney. Individuals with renal insufficiency are 
unable to effectively excrete aluminium (Flaten et al. 1996); dialysis encephalopathy occurred 
from notably high levels of aluminium in dialysis solutions (Wills & Savory, 1983); stemming from 
this, brain aluminium was revealed to be 10-fold in dialysis patients (Alfrey et al. 1976) compared 
to normal ranges < 2 μg g-1 (Andrasi et al. 2005). By treating the water used for dialysis, aluminium 
levels were decreased and aluminium related conditions were concededly reduced in these 
uremic individuals (Arenas et al. 2008). 
 
Since these investigations, aluminium toxicity has been linked to numerous neurological disorders, 
including amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease and Parkinson’s 
disease (Harris et al. 1996; Jeffery et al. 1996; van Landeghem et al. 1997; Altmann et al. 1999; 
Van der Voet et al. 1999; Jaffe, 2005; Peto, 2010; Bondy, 2010). However, the elements 
involvement in these conditions remains controversial as the specific role has not yet been 
concluded, despite increasing research being performed in this area (a full review of this is shown 
by Kawahara, 2005). 
It is thought that a common occupational exposure to aluminium is in dust and is suggested that 
this may contribute to cognitive impairment (Longstreth et al. 1985; Sjogren et al. 1990; 1996; 
White et al. 1992; Meyer-Baron et al. 2007) and Alzheimer’s disease (Kobayashi et al. 1987). As a 
lower urinary aluminium concentration may suggest a higher body burden, studies have related a 
urinary aluminium concentration below 135μg/L to a reduction in cognitive performance (Meyer-
Baron et al. 2007). In the mining industry, workers given McIntyre powder, an aluminium rich 
powder, as a prophylactic treatment against pneumoconiosis, saw a connotation between the on-
set of cognitive impairment with the length of their treatment (Rifat et al. 1990). However, to 
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refer back to the controversy surrounding this link, some authors state that there is little or no 
evidence to relate neurotoxicity to the occupational exposure of aluminium (Graves et al. 1998). 
 
The Camelford incident, in July 1988, twenty tonnes of aluminium sulphate was discharged by the 
South West Water Authority into the drinking water supplied to a large region of North Cornwall, 
raising the concentration to over three thousand times the admissible amount. Up to 20 000 people 
were exposed to concentrations of aluminium which were 500–3000 times the acceptable limit under 
European Union legislation (0.200 mg/l). When the first neuropathological examination of a person 
who was exposed and died of an unspecified neurological condition was carried out (Exley & Esiri, 
2006), a rare form of sporadic early-onset β-amyloid angiopathy in cerebral cortical and 
leptomeningeal vessels, and in leptomeningeal vessels over the cerebellum was identified. In addition, 
high concentrations of aluminium were found coincident with the severely affected regions of the 
cortex. Since then, there have been reports from individuals affected by this event who have 
developed long-term cerebral impairment (Altmann et al. 1999) and severe cerebral congophilic 
angiopathy (Exley & Esiri, 2006). 
 
A wealth of research has explored the use of aluminium adjuvants in vaccines. Adjuvants are included 
in vaccines as immunopotentiators (i.e. in order to stimulate the body's immune response to the small 
amount of coadministered antigen). 
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Figure 1.12.1, taken from Exley, Siesjö & Eriksson (2010). The aluminium adjuvant armoury and innate and 
adaptive immunity. (a) Dilution of the vaccine preparation into the muscle interstitial fluid (MIF) results in an array 
of potential agonists of the immune cascade, including: (1) Al3+(aq); (2) free antigen (AG); (3) particulate adjuvant 
(ADJ); (4) ADJ with associated AG; (5) AG-Al complex; (6) MIF ligand-Al complex; (7) ADJ with associated MIF 
ligand; (8) MIF ligand-AG complex; (9) particulate iron (as contaminant of adjuvant) either free or with adsorbed 
Al/AG and resultant reactive oxygen species (ROS); (10) ADJ with associated MIF ligand-AG complex; (11) ADJ 
with associated MIF ligand-Al complex. MIF ligands might include biomolecules such as; ATP, albumin, transferrin, 
citrate, fibrinogen. (b) The array of agonists act upon a number of cell types including, the resident muscle tissue 
(potentially causing necrotic and/or apoptotic cell death) and infiltrating innate cells such as, monocytes (potential 
for AlADJ-induced differentiation to dendritic cells), granulocytes (potential for AlADJ-induced eosinophilia acting 
directly on B cells), macrophages (are known to persist for long periods close to the injection site and may be 
characterised by inclusions of AlADJ) and dendritic cells (DC). The latter may be the major antigen presenting cell 
(APC). (c) There are myriad possible modes of interaction between agonists and innate cells including; (i) toll-like 
receptor (TLR) binding of AG2, AG-Al complex5, MIF ligand-AG complex8, Al3+(aq)1; (ii) multiple TLR binding of AG-
ADJ4; (iii) phagocytosis of ADJ3, AG-ADJ4, MIF ligand-ADJ7, MIF ligand-Al complex-ADJ11, MIF ligand-AG 
complex-ADJ10; (iv) direct1 or indirect6 binding of Al3+(aq) by membrane receptors and extracellular (lipid membrane) 
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or intracellular (nucleus) activity of ROS9. (d) APCs activate adaptive immunity through; (a) Nalp3 inflammasome 
dependent or independent release of chemokines and cytokines (green saucers) including IL-1β and IL-18; (b) AG 
presentation by MHC to T cell receptor combined with co-stimulatory molecules; (c) direct action of ADJ and/or 
Al3+(aq) on B/T cells. The superscripts refer to the numbers in parentheses in the figure. 
 
 
 Neurotoxity has been associated with this use and allied with chronic cognitive dysfunction in 
macrophagic myofascitis (Couette et al. 2009). In one study it was documented that Gulf war veterans 
who were offered aluminium hydroxide injections as protective measure against anthrax, saw an 
increase in occurance of motor neuron disease (Shaw & Petrik, 2009). Individual case reports and 
supporting animal studies in rats have highlighted associations between the use of oral Al-containing 
antacids during pregnancy and abnormal fetal neurologic development (Gilbert-Barness et al. 1998; 
Shuchang et al. 2008). 
 
 
 
1.13 The monster inside me: Multiple Sclerosis  
 
 
 
Multiple sclerosis (MS)  is a potentially debilitating disease of the brain and spinal cord (central nervous 
system) affecting 2.5 million people worldwide (Fox 2014). MS is an acquired, inflammatory, 
demyelinating, neurodegenerative disease of the central nervous system (CNS) (Fulgenzi et al 2011). 
MS is referred to as an auto-immune disease. The protective fatty myelin sheath that surrounds the 
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nerve cells, to increase efficiency of a nerve impulse, is attacked by local immune cells, because it is 
mistaken for a foreign body, much like an immune reaction (Mcfarlin 1982), see figure 1.13.1. This 
damage disrupts the conductivity of the nerve cell, delaying and distorting messages, or simply 
stopping message transmission altogether (Perry 2014). The disease tends to progress in adults at 
young age (between 20 and 40 years), variably progressing in severity of symptoms for the entirety of 
life, for which there is no cure (Reiber et al 2009; Ibrahim and Gold 2005). The neurological 
impairments (attacks) that characterise multiple sclerosis, can be followed by asymptomatic periods, 
e.g., the pathology can present a relapsing-remitting course. Progression of the disease is generally 
accompanied by presence in the central nervous system of focal inflammatory lesions which are 
visualised using magnetic resonance imaging (MRI) (Fulgenzi et al 2011). Although the mechanisms 
involved in the pathogenesis of multiple sclerosis an autoimmune reaction against a myelin-related 
antigen have been identified, the aetiology of the disease is yet unknown (Exley et al 2009). A 
consensus leads to the opinion that the disorder is the result of a relationship between environmental 
factors and susceptibility genes. A number of studies propose the association of neurodegenerative 
diseases with toxic metal (especially aluminium) exposition and accumulation in the CNS (Kumar and 
Gill 2009; Zahran et al. 2009; Taber and Hurley 2008). 
 
 
Figure 1.13.1 A normal nerve cell compared to a typical damaged nerve cell of an MS patient 
(RelayHealth 2009) 
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 1.14 The role of aluminium in MS 
 
In MS, the immune system attacks the protective myelin sheath that coats the nerve fibres. The 
damaged myelin forms scar tissue (sclerosis), giving the disease its name. The damage to myelin 
sheath results in nerve impulses traveling to and from the brain and spinal cord becoming distorted 
or interrupted, producing a wide variety of symptoms (Goldenberg, 2012). The aetiology and 
pathogenesis of MS has not yet been established although at autopsy, multiple, discrete pink or 
gray areas that have a hard, rubbery texture are identified within the white matter. The lesions are 
composed of areas of myelin and oligodendrocyte loss along with infiltrates of inflammatory cells, 
including lymphocytes and macrophages. The relative preservation of axons and neurons within these 
lesions helps to differentiate MS from other destructive pathological processes that are accompanied 
by focal inflammation (Goldenberg, 2012). 
More than 30% of MS patients have moderate-to-severe spasticity, mostly in the legs. Initial clinical 
findings in MS patients are often sensory disturbances, the most common of which are paresthesias 
(numbness and tingling), dysesthesias (burning and “pins and needles”), diplopia, ataxia, vertigo, and 
bladder (urinary sphincter) disturbances. A common manifestation of MS is unilateral numbness 
affecting one leg that spreads to involve the other leg and rises to the pelvis, abdomen, or thorax 
(Goldenberg, 2012). Sensory disturbances usually resolve but sometimes evolve into chronic 
neuropathic pain. Another common presenting sign of MS is optic neuritis, highlighted by complete or 
partial loss of vision. Bladder dysfunction occurs in more than 90% of MS patients and results in weekly 
or more frequent episodes of incontinence in one-third of patients. At least 30% of patients experience 
constipation. Fatigue occurs in 90% of patients and is the most common work-related disability 
associated with MS (Goldenberg, 2012). Sexual problems are often experienced as well. 
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Both mortality and morbidity data confirm that multiple sclerosis is a geographically-related disease, 
and thus MS can be thought of as an acquired exogenous illness (Kurtzke, 1977). MS occurrence is 
high in America, medium in Europe, and low in Asia. Processed foods which are high in aluminium are 
common in the diets in individuals residing in the western world, and make up a lower proportion of 
a traditional Asian diet (Pingali, 2007) In addition, an Asian diet is traditionally high in silicon rich foods 
(Jugdaohsingh, 2002), including rice, further highlighting the importance of the relationship between 
silicon and aluminium and how there may be a direct link between the prevalence of MS and body 
bioburden of aluminium. 
 
Several risk factors, including age, genetic disposition and environmental agents, have been 
connected with MS. Aluminium is a commonly discussed factor and has been associated with a 
multitude of neurophysiological processes responsible for the characteristic degeneration 
associated with MS; however, its actual role remains controversial (Exley, 2006). Dietary intake of 
aluminium from food and chemicals added may also be a noteworthy risk of MS (Rogers & Simon, 
1999). Tea, a significant part of the British diet, is estimated to contribute up to 50% of daily intake 
due to the high levels of aluminium it contains (Yokel, 2013). When greater than four cups of tea 
were consumed per day, aluminium in the urine was elevated, although not significantly (Forster 
et al. 1995). As aluminium is bound to organic complexes within tea, this may lead to it being 
poorly absorbed (French et al. 1989; Flaten, 2002). 
 
The level of aluminium found in the urine of MS patients is similar to that of aluminium intoxication, 
ranging from 0.22-0.66 µM (Exley et al 2006). There are no previous data on aluminium in MS, 
however a large incidence of MS was reported in macrophagic myofascitis (Authier et al 2001), an 
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inflammatory myopathy, linked to intramuscular injections of aluminium adjuvant containing vaccines 
(Gherardi et al 2001). Animal studies have shown that the favoured target of aluminium neurotoxicity 
was via accumulation in the myelin (Verstraeten et al 1998; Verstraeten et al 1997). Several reports 
exploring aluminium intoxication demonstrate a significant thinning of the myelin sheath, in both the 
spinal cord and hippocampus (Golub et al 1999; Deloncle et al 2001; Miu et al 2004). Aluminium has 
also been seen to increase kinase activity, responsible for the phosphorolation of myelin basic protein 
and decrease the activity of the myelin specific enzyme, 2’3’-cyclic nucleotide phosphohydrolase 
(Arroyo-Serralta et al 2005; Sarin et al 1997). This research indicates clear precedents that in animal 
research, if not yet in humans, the role of aluminium in MS is important. Those persons with a higher 
body burden of aluminium may accumulate the metal in oligodendrocytes and myelin, where it can 
disrupt the chemical pathways and facilitate iron-mediated oxidative damage (Exley 2004). The levels 
of urinary aluminium that are seen in relapse remissive MS may represent an association with myelin 
and demyelination, the breakdown of myelin may release aluminium that has accumulated in the 
protein, this may even mirror with the reactions involved with a relapse (Whitaker et al 2001). These 
neurotoxic results are mirrored in Alzheimer’s disease (Bartzokis 2004). 
 
1.15 Treating Al toxicity 
 
Evidence is compiling against aluminium and suggesting that it is a contributory factor in neurological 
disease. If this indeed is the case, if aluminium is a casual or at least contributory factor, it could be 
theorised that if the aluminium body burden was reduced and maintained at a lower level, the 
occurrence of the disease would decrease (Crapper McLachlan et al. 1991; Exley et al. 2006). We can 
also assume that a lowering of aluminium levels in the body would relieve symptoms of a disease in 
those previously diagnosed. 
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If aluminium is contributing so prolifically to neurodegeneration, it is crucial to educate the general 
population to understand the risks and symptoms surrounding the toxicity of the element. This may 
result in the population actively avoiding aluminium rich products (anti-persperant) and foodstuffs 
(tea). Accompanying this with current metal chelation techniques will produce a double whammy 
effect on aluminium levels in the body, as research has demonstrated chelation therapy as having 
positive effects on aluminium removal from body stores ((Nakamura et al. 2000). 
Desferrioxamine (DFO), a common chelating agent typically used as a treatment for ion toxicity, has 
also shown effectiveness when removing aluminium from the bone and brain (Nakamura et al. 2000; 
Yokel et al. 2001). DFO is linked to an increase in the urinary excretion of aluminium as well as reducing 
the rate of decline in Alzheimer’s disease patients suffering with a lowered performance of daily skills 
(Crapper McLachlan et al. 1991). Despite these positive findings, treatments involving the use of DFO 
is limited due to noticed side effects (Cronin & Henrich, 2006). Despite this, recent studies have 
suggested that a lower dose may still be effective, while lowering the occurrence of nasty side effects 
(Kan et al. 2010). There are other compounds which are seen to act as aluminium chelators, for 
example, ascorbate and feralex-G are commonly used in research (Kruck et al. 2004). Research into 
the synthesis of new ligands for aluminium is also increasing (Santos, 2008; Crisponi et al. 2012).  
In recent research, silicon has been deduced as an active antagonist towards aluminium. By 
supplementing the diet with silicon, as bioavailable silicic acid, a reduction in the bioburden of 
aluminium has been demonstrated, suggesting removal from tissue compartments such as the brain 
and surrounding nervous tissue (Exley 2009). 
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1.16 Silicon and its possible protection against aluminium toxicity. 
 
There is a wealth of evidence supporting the effect of silicon on aluminium accumulation in the body. 
It is also thought that silicon may have an influence on the oral absorption of aluminium (Belle’s et al 
1998).  
Once aluminium has found its way into the bloodstream, it is seen to co-localise with silicon, especially 
in aluminium rich regions such as the plaques characterising Alzheimer’s disease (Candy et al. 1986). 
This suggests that perhaps like aluminium, silicon, in its biological form of silicic acid, can cross the 
blood brain barrier (Yokel 2006). It may in fact be added that silicon in the brain could possess 
neuroprotective properties, being able to quench aluminium from the brain, hereby relieving the 
symptoms of AD and other neurodegenerative conditions. 
When introducing a silicon rich dietary source to rats, aluminium levels were significantly reduced in 
all tissues compared to that of the control group. Furthermore, urinary excretion levels of Al were also 
substantially lower (Belles et al 1998). This focuses primarily on the potential role of silicon in 
preventing oral aluminium absorption and retention in mammals. The results of a number of studies 
suggest that dietary silicon supplementation could be of therapeutic value for preventing chronic 
aluminium accumulation in the nervous system, and hence, be a potential therapy for 
neurodegenerative disease, such as MS (Domongo et al 2011).  
When processing all of the positive associations of silicon in drinking water, it can be suggested that 
the further addition of silicon to the diet in this manner, through silicon-rich mineral waters, can 
provide a non-invasive means to reduce aluminium body burden. The aluminium and silicon research 
group at Keele University (Exley et al 2006) was the leading pioneer in testing this suggestion. The 
initial study, investigating a potential non-invasive solution of reducing aluminium body burden in 
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Alzheimer’s disease patients, involved the consumption of up to 1L of silicon rich mineral water daily. 
An association between aluminium and MS has been established, so suggesting an increased silicon 
uptake, through consuming mineral water naturally high in silicon, is a viable method to reduce the 
aluminium bioburden in MS patients. The current results corroborate that silicon effectively prevents 
gastrointestinal aluminium absorption, which may be of concern in protecting against the neurotoxic 
effects of aluminium.  
1.17 Mechanisms behind the chelating effect of silicon. 
 
It was first proposed by Birchall et al (1989) that silicon could offer an ameliorating effect. When 
looking at salmon fry in acidic water, it was shown that acute toxicity of aluminium was eliminated in 
the presence of silicic acid. This mechanism was believed to involve hydroxyaluminosilicates (HAS) 
(Birchall et al. 1989; Birchall, 1990) and two discrete forms of HAS, called HASA and HASB. The 
structures of HASA and HASB have been determined are shown in Figure 1.17.1. It was theorised that 
similar mechanisms would apply to humans (Birchall et al 1989) and that interactions with human 
renal tubing may affect aluminium elimination by reducing reabsorption (Birchall, 1992).  
 
Figure 1.17.1 Hydroxyaluminosilicate structures (left); biological availability and solid phase, HASA 
and HASB self-aggregation (right) (Birchall et al 1989) 
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Investigating these two subspecies of HAS molecules, HASA and HASB may shine further light onto the 
protective mechanism of silicon against aluminium (Doucet et al 2003). Fig 1.17.2, a schematic 
showing pH-dependent formation and stability of Al(OH)3(s), HASA and HASB with particular 
reference to their abilities to carry charge, their pH of minimum solubility and their aggregation 
towards filterable sizes. (Exley 2012). 
 
Figure 1.17.2: Schematic showing pH-dependent formation and stability of 1 - Al(OH)3(s), 2 - HASA 
and 3 - HASB with particular reference to their abilities to carry charge, their pH of minimum solubility 
and their aggregation towards filterable sizes. From Exley (2012). 
Although it is believed that silicic acid is involved in the homeostasis of aluminium by reducing 
gastrointestinal absorption and facilitating the renal excretion of aluminium though the inhibition of 
reabsorption of systemic aluminium (King et al 1997), even in the presence of citrate, a natural 
aluminium binding agent (Birchall and Chappell 1989). Despite these positive findings, some studies 
show that there is no evidence that the ingestion of silicic acid promotes aluminium excretion (Reffitt 
et al 1999), and the presence of HAS in the body has yet to be proven (Exley, 1998). What is known is 
that the administration of silicic acid causes a peak in aluminium excretion, followed by a steady 
1 
2 
3 
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reduction, indicating that aluminium body burden is being reduced (Birchall et al 1989; Birchall, 1990; 
Bellia et al. 1996). Work stemming from this, carried out by Birchall and Exley (1992,1993) 
demonstrated that silicic acid inhibits the growth and nucleation of aluminium hydroxide at 
physiological levels when the pH is above 4.5, through the formation of filterable molecules of HAS. 
These studies suggest a minimum silicon concentration of 0.1 mmol L-1 is required to deliver this effect 
(Birchall 1992). 
Desouky and colleagues (2003) attempted to clarify the mechanisms behind the chelating effect of 
silicon on aluminium and how uptake of aluminium is in turn prevented in the water pathway, hereby 
reducing aluminium in the tissues. These studies involved the pond snail (Lymnaea stagnalis) and 
signified that instead of orthosilicic acid preventing the accumulation of aluminium within the tissues, 
the protective effect is in fact due to the formation of HAS, either in the water column or in the 
digestive tract. This idea correlated with notions theorised by Birchall and his colleages (1989). 
The Exley group reviewed the role of HAS(s) in controlling the biological availability of aluminium and 
considered the protective effects of HAS(s), which is known to extend to humans and human 
physiology, but is very poorly understood.  
What did Louis Pasteur have in mind when he said “Effects of silicic acid are destined to play a great 
and major role in therapy” (Pasteur 1878). 
Whatever it was that heightened Pasteur’s interest in the mid-nineteenth regarding the therapeutic 
properties of Si(OH)4 has remained largely unexplained, although the therapeutic potential of Si(OH)4 
still holds significant interest (Martin 2007). 
With increasing attention and focus on health, it is a hot topic to explore any method that causes 
significant health improvements, for such little invasiveness and cost. The fascination with Si(OH)4 and 
health possibly originates from the reputed health benefits of bathing in spa waters rich in Si(OH)4 
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(Domino and Gomez, 2011). Nutritional essentiality of silicon has been demonstrated in laboratory 
animals, using experiments which have given scientific support to theories of silicon essentiality in 
humans. Another study demonstrated that a higher level of urinary and faecal silicon was present in 
mice exposed to aluminium, while being administered silicic acid. These excretion levels were higher 
in those mice dosed with aluminium, suggesting that silicon and aluminium interact and combine to 
form a species, not taken up by the digestive tract (González-Muñoz et al. 2008a). Although, low blood 
serum correlated with high urinary silicon levels divulge that silicon-aluminium interactions limit 
reabsorption in the kidney (Bellia et al. 1996). 
The case for the importance of silicon is strengthened further by evidence that proves that living things 
grow better and healthier when they are grown in silicon rich environments (Epstein, 1994; 
Sripanyakorn et al 2009). Silicon is recognised as an essential trace element (Carlisle 1982). 
1.18 Concluding remarks 
 
The therapeutic mechanism of silicon when coupled with the toxicity of aluminium remains 
controversial, despite numerous studies supporting these claims. There is a wealth of evidence 
exploring the protective effects of silicon on the accumulation of aluminium. If biological systems have 
in fact evolved a protective mechanism, through interactions between silicon and aluminium, 
heightened also due to the increase in biospheric levels of aluminium (Birchall, 1990), it is understood 
that sufficient silicon (>0.1 mmol L-1 Birchall, 1992) is required to prevent the adverse effect correlated 
with aluminium intoxication. .  
 
Therefore, silicic acid-rich mineral water may be applied as a prophylactic means of diminishing the 
accumulation of aluminium within the body, providing an inexpensive and non-invasive method of 
reducing the risk of aluminium toxicity. 
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Chapter 2 -  Materials and methods 
 
Each study that included sweat and urinary measurements of aluminium and silicon were performed 
using TH GFAAS. Creatinine concentrations of urine were determined by UV-Vis spectroscopy. Further 
details of the study protocols are discussed in their relevant chapters.   
2.1.0 Background 
 
Techniques involving analysis at the atomic and molecular level are common when determining 
accurate concentrations of elements.  
Atomic techniques involve flame spectroscopy, inductively coupled plasma – optical emission 
spectroscopy (ICP-OES) and graphite furnace atomic absorption spectroscopy (GFAAS). Molecular 
techniques involve UV-visible spectroscopy (UV-Vis), infrared (IR) and nuclear resonance spectroscopy 
(NMR). 
This study involves the use of TH GFAAS to determine the concentration of aluminium and silicon in 
samples of human urine and sweat, these were complemented by creatinine concentrations 
determined by colourimetric analysis involving UV-Vis. 
2.1.1 Spectroscopy 
 
Spectroscopy is a branch of science concerned with the investigation and measurement of the 
interaction of electromagnetic radiation within matter. Electromagnetic radiation has wave and 
particle properties. This includes wavelength, frequency and amplitude, while light is composed of 
photons which possess certain characteristic energies.  
There is a relationship between these quantities and it can be represented by the following equation 
(Eq 2.1.1): 
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E = hv = hc/λ    Eq 2.1.1 
 
In this equation, E denotes energy (J), c represents the celerity of light (2.99792x108 m s-1) h is the 
Planck’s constant (6.62608x10-34 J s), v and λ denote frequency (s-1) and wavelength (m) respectively.  
The electromagnetic spectrum (Fig. 2.1.1) is composed of a wide array of wavelengths, ranging from 
gamma rays (<5nm) to radio waves (>300mm). In this study, only a small part of this spectrum is 
incorporated: UV-Vis spectroscopy is limited to the range of 190nm-750nm whilst atomic absorption 
spectroscopy occupies a range of 180nm-900nm. These techniques cover the range of the ultraviolet, 
visible and near infrared portions of the spectrum. 
 
Fig. 2.1.1 The wavelengths of the electromagnetic spectrum (NASA-imagine the universe, 2013). 
When light passes through a sample, the energy from the photons promotes a transition within the 
atoms in the sample. This transition results in the transfer of electrons in the molecule, atom or ion to 
be relocated to a different energy state.  
When an electron is promoted to a higher energy state from a lower energy state, this is known as 
absorption of energy. When an electron drops from a higher energy state to a lower energy state, this 
is known as emission of energy.  
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The Bohr frequency condition shows that the energy absorbed or emitted is equal to that of the energy 
difference between these levels and as each atom is unique, these values are characteristic to the 
atom involved and so the amount of radiation needed for these transitions is also characteristic of the 
element (Fig 2.1.2). 
 
Fig 2.1.2 Transition from a ground state (GS) to an excited state (ES) results in 
absorption, transitions from an excited state to the ground state results in emission. Energy 
absorbed or emitted is equal to the energy difference (ΔE) between energy levels. 
 
The two main methods used in this thesis involve types of absorption spectroscopy, therefore 
promoting electrons from a ground state to an excited state.  
These techniques involve a monochromatic light source of intensity (Io) passing through a cell of 
analyte (gaseous for GFAAS and liquid for UV-Vis). The analyte in the cell absorbs a quantity of this 
light which is directly proportional to the concentration of the analyte. The transmitting light (I) is 
turned into an electrical signal at the detector which is processed to indicate the amount of analyte 
present in the cell (Fig 2.1.3). 
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Fig 2.1.3 Schematic diagram of the atomic absorption of analyte in a cell. I0 is the incident 
intensity, I is the transmitted intensity and l is the path length. 
 
Transmittance, τ (no units), is the fraction of light that passes through the cell of analyte and is the 
ratio of intensity transmitted, I, and incident intensity, I0 (Eq2.1.2). 
τ = I/I0            (Eq 2.1.2) 
If a high concentration of analyte is present, very little light will be able to pass through the cell, this 
will result in a transmittance value close to zero; when no analyte is present in the cell, all of the light 
will pass through and a transmittance value of one occurs. Percentage transmittance can also be used 
to determine the amount of analyte in a cell. 
As there is no linear relationship between transmittance and concentration, quantitative 
measurements are presented in absorbance, A (no units). Absorbance can be related to transmittance 
using the following equation (Eq 2.1.3). 
A = -log τ = -log I/I0 = log I0/I       (Eq 2.1.3) 
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As concentration of the analyte increases, absorption value increases in consequence. There is a 
quantitative relationship here between absorbance and concentration and is governed by the Beer 
Lambert law. 
A = εCl      (Eq 2.1.4) 
Where ε is the molar absorptivity coefficient (m2 mol-1); l is the path length of the cell (m) and C is the 
concentration of the analyte (mol m-3). In AAS, sensitivity is increased by using long illuminated beam 
paths for the atom cells. This is due to the direct proportionality between path length and absorbance. 
 
As previously discussed, the Beer Lambert law states that there is a linear relationship between 
absorbance and concentration. However, when investigating larger concentrations, interactions 
between neighbouring atoms can cause non-linearity by affecting the absorbing ability at the given 
wavelength. As no light source is truly monochromatic, there are limits to the Beer Lambert law 
although these can be improved using background correction methods. 
 
2.1.1.1 Atomic absorption spectrometry (AAS) 
 
The principle of AAS is that atoms of different elements absorb characteristic wavelengths of light. To 
analyse a sample to determine whether it contains a particular element means using light from that 
element. For example with aluminium, a lamp containing aluminium will emit light from excited 
aluminium ions, producing the right wavelengths to be absorbed by aluminium ions in the sample. As 
this light is absorbed, electrons are promoted to an excited state. During the process of AAS, the 
sample is initially atomised then a beam of electromagnetic radiation which is emitted from the 
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excited aluminium ions is passed through the vaporised sample. The greater the number of aluminium 
atoms in the sample, the more radiation is absorbed; therefore, the amount of light absorbed is 
proportional to the number of aluminium atoms. A unique spectrum is achieved for each element due 
to a unique set of energy levels. 
Kirchhoft’s experiment can be used to demonstrate that gases absorb the same radiation they emit, 
which is a good illustration of atomic absorption. When white light projected through a split is 
dispersed by a prism, its constituent linear spectrum is observed. If this radiation source were to be 
replaced by a Bunsen burner, sprinkled with sodium chloride (NaCl) crystals, an emission of sodium is 
obtained presenting a yellow glow at 589nm and producing faded zones in its emission spectrum. This 
is the result of a high concentration of Na atoms in the flame which absorb these characteristic 
frequencies. This phenomenon is a manifestation of atomic absorption. 
An AAS requires three components; a light source, a cell compartment to produce gaseous atoms and 
a method of analysing the specific wavelengths absorbed. The most common light source is a hollow 
cathode lamp containing a tungsten anode and cylindrical hollow cathode, composed of the element 
to be quantified. These are sealed in a glass tube, containing an inert gas such as argon.  
During normal conditions, atoms are in their ground states (M) and upon light energy exposure are 
promoted to their excited state (M*). (Eq 2.1.1.1) 
M(g) + hv → M*(g) (Eq2.1.1.1) 
The ratio between these ground state (No) and excited state (N1) is given by the Boltzmann 
distribution equation (Eq2.1.1.2). 
 
 (Eq 2.1.1.2)                    
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In this equation, k represents the Boltzmann constant (1.381x10-23 J K-1). Temperature is noted as T (K) 
and g1/g0 represent the statistical weight of these states, showing each number of degenerative states 
contributing to the make-up of that level. 
 
Skoog et al (1998) shows that the energy difference between the ground (3s) state and the excited 
(3p) state for sodium is 3.37x10-19 J. Within these, there are 2 quantum levels in the 3s state and 6 
quantum levels contained by this 3p state. 
 
 
When values are submitted into the Boltzmann constant equation, it is shown that at 2500K more 
than 99.98% of sodium atoms exist in their ground state 
 
 
 
 
When the effect of temperature is examined, even with an increase of 10K, a value of N1/N0 = 1.79 x 
10-4 is given. This temperature change hardly affects the ground state population and therefore has 
very little effect on atomic absorption. The temperatures produced in a graphite furnace atomiser 
coupled to an AAS, ensure maximum sensitivity.  
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2.1.1.2 Graphite furnace atomic absorption spectrometry (GFAAS) 
 
Using a graphite atomiser is particularly useful when dealing with low analyte concentrations (ppb and 
ng/mL). 
A few millilitres of sample is injected into a graphite tube through a dosing hole (~1-3mm). The tube 
is heated electronically in several temperature ramping cycles, the highest being up to 3000oC, this is 
the atomisation step and is required to convert the sample into gaseous atoms.  
The entirety of this atomisation protocol consists of four stages: drying, pyrolysis, atomising and 
cleaning (Fig 2.1.1.2.1).The drying stage and pyrolysis stage involve the evaporation of solvent and 
removal of volatile matrix respectively. During atomisation, an atomic vapour of the analyte is formed 
during the decomposition of the prepared sample. The final stage concludes a cleaning process 
between each sample. 
 
 
Fig 2.1.1.2.1: Schematic of the temperature cycle employed in GFAAS. 1 = sample introduction, 2 = 
drying, 3 = pyrolysis, 4 = cooling, 5 = atomisation and 6 = cleansing. Adapted from Butcher and 
Sneddon (1998). 
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Throughout the entirety of this step, argon gas is passed through each side of the tube to channel out 
vaporised sample through the injection site. The gas flow is only ceased for the atomisation step, 
purely to ensure maximum sample residence time and maintain a higher temperature which coupled, 
will provide thorough sensitivity. 
 
The specific light energy emitted from the hollow cathode lamp is split and directed along two 
different paths; one beam is channelled throughout the atomised gaseous analyte, promoting the 
valence electrons to the higher energy level, while the other beam acts as a reference. These beams 
then pass through a monochromator which separate the multiple wavelengths receives from those 
from the analytical line. The detector then coverts the photons of light received at this wavelength 
into an electrical signal. The ratio of signal detected from the incident beam and transmitted beam 
respectively is logged and from these values, the absorbance, is recorded over the total analysis time. 
Following this step, the atoms are removed from the graphite tube. The absorbance value will increase 
in consequence to more atoms being formed. The concentration can then be accurately determined 
by using a range of calibration standards of known analyte concentration and compared using fit 
analysis.  
GFAAS offers many advantages over other instruments used for elemental analysis. Very low sample 
volumes can be used offering a high level of sensitivity therefore lower limits of detection. Despite 
this, analysis using GFAAS is very slow compared to other conventional methods of elemental 
detection; one replicate can take up to three minutes for a complete step cycle. The technique may 
also give a poor quality analysis result on a sample with many interfering matrices. More accurate 
absorption values may be obtained through a specific temperature design ramping protocol, removing 
this interfering matrix prior to the atomisation step. This measurement quality may also be improved 
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if the vaporisation of the analyte is prevented until the wall of the tube reaches a constant 
temperature. A L’vov platform may improve the efficiency of this step (Fig 2.1.1.2.2). 
 
 
 
 
 
 
 
Fig 2.1.1.2.2:  L’ov platform inside a graphite furnace 
The L’vov platform has minimal connections to the wall of the graphite tube which means that it heats 
at a steadier rate allowing a more constant temperature to be accomplished prior to the sample 
becoming atomised, giving a more accurate recording of absorbance. The furnace reaching this 
uniform temperature reduces any memory effects between readings.  
Analyte measurements may also be improved through the incorporation of matrix modifiers. A matrix 
modifier will increase the volatility of the matrix, thermally stabilising it, therefore reducing any 
chemical interferences. This is particularly useful when measuring elemental concentration in 
biological samples, for example silicon in urine; nickel chloride was used as a matrix modifier for the 
determination of silicon in urine, enhancing sensitivity and reducing background absorption 
(Kobayashi et al. 1997a; Matsusaki et al. 1996). 
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As previously discussed, the Zeeman background correction is used for those spectral interferences. 
This involved the addition of a 0.8T magnetic field. Measurements are made with and without a 
magnetic field; upon the addition of a magnetic field, only background readings are measured, whilst 
when the magnetic field is turned off, background and sample measurements are taken into account. 
The difference between these two readings equate to the measurement of the sample. The problem 
here is the interference of the magnetic field, the Zeeman background correction fails to take this into 
account.  
 
The carbon of the graphite tube can cause refractory carbides to form coupled with a loss of silicon 
dioxide from the atomisation process, causing a loss of sensitivity and reproducibility.  These 
limitations can be overcome by coating the graphite tube with titanium carbide and as previously 
discussed, incorporating a matrix modifier into the atomisation step. Matsusaki et al. (1996) carried 
out experiments involving a 0.04 mol L-1 cobalt nitrate and 0.01 mol L-1 boric acid mixture. The 
detection limit here was noted to be 0.0006mg L-1, providing high analytical sensitivity. 
The graphite tube is pyrolytically coated to minimise analyte diffusion into the material, reduce 
memory effect and reduce production of carbides (reducing chemical reactivity). This tube is enclosed 
by a blanket of argon to prevent combustion at the elevated temperatures witness in the graphite 
tube. The temperatures in this analysis chamber can be controlled up to 2700oC, with ramped heating 
up to 1500oC/s. 
This technique is not suitable for multi element simultaneous sample analysis due to the need for 
separate cathode lamp and furnace parameters per element. High dilution factors are required for the 
high sensitivity and limited calibration range of AAS. 
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2.1.1.3 UV-Vis Spectroscopy 
 
UV-Vis spectroscopy also involves the investigation of the absorption of photons as a principle. All 
compounds of different colours will absorb different wavelengths of radiation. UV-Vis makes use of 
this fact and can detect light absorption in the range of 190-900nm, covering ultraviolet, visible and 
near infra-red portions of the electromagnetic spectrum. The technique can be routinely used to 
quantify organic compounds by measuring this degree of absorption and the wavelengths at which 
this absorption occurs. The readings of absorption typically seen using UV-Vis measure between 0 (no 
absorption) and 2 (99% absorption). 
Energy is required to promote an electron to its excited state. When light passes through a ‘coloured’ 
complex, this energy corresponds to that particular wavelength and is sufficient to promote or excite 
a molecular electron to a higher energy orbital. As a rule, energetically favoured electron promotion 
will be from the highest occupied molecular orbital (HOMO) to the lowest unoccupied molecular 
orbital (LUMO). The resulting species referred to as existing in its excited state. 
The light transmitted adopts the complementary colour to that of the absorbed wavelength. In the 
case of the creatinine complex, an absorbance of 500-520nm is observed.  
 
 
 
Fig 2.1.1.3.1 Colour wheel representing absorbed colour and their complementary colours 
The absorbance value witness corresponds directly to the number of absorbing molecules in the 
sample. These absorbing molecules are known as chromophores. Chromophore are molecular 
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identities able to absorb light in the visible region of the spectrum and display colour. Chromophores 
possess a conjugated system of pi electrons or a lone pair of non-bonding valence electrons.  
Conjugation is an important concept when analysing chromophores. Conjugation can cause an 
absorption maximum at a longer wavelength, known as a bathochromic shift phenomenon. During 
this study, picrate was added to creatinine to form a larger conjugated compound, shifting the 
absorption to a longer wavelength, inducing a colour change of yellow to orange/red. This 
phenomenon was also noticed when quantifying silicic acid in water samples, when a colour change 
was observed from yellow to blue. 
 
2.1.2 Quantification of compounds using UV-VIS Spectroscopy 
 
 
UV-VIS spectroscopy was used to quantify amounts of creatinine in urine using the Jaffe reaction, 
and silicic acid concentration in water samples using the molybdenum blue reaction, details of which 
are provided in the following sections. 
 
2.1.2.1 Creatinine 
 
 
Creatinine (structure shown in Fig 2.1.2.1.1), is the major breakdown product of creatine. Creatine is 
a component of muscle of which its main role is to facilitate recycling of adenosine triphosphate (ATP), 
the energy currency of the cell.  
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Fig 2.1.2.1.1 Molecular structure of creatinine 
 
Creatinine however, has no known function and is readily excreted from the body in urine at a 
reasonably consistent rate (Rodriguez et al. 2004). Detecting levels of creatinine is an important 
diagnostic medical tool to monitor glomerular filtration rate (GFR), which has clinical importance in 
measuring kidney function as well as muscular function (Costa et al. 2007; Spierto et al. 1997). In this 
study however, creatinine will be measured to account for dilution factors in the sampling protocol.  
The concentration of creatinine observed is sensitive to age and lean body mass, it can naturally range 
between 500-2000mg/day (Dugdale, 2009). Individuals that regularly carry out a lot of sport will 
naturally have a higher proportion of lean body mass, therefore excreting a larger amount of 
creatinine per day. Vegetarians however, will on average excrete less creatinine per day as they will 
consume less creatinine in their diets (Smith-Palmer, 2002).  
Creatinine excretion remains quite linear for each individual, ranging only slightly from any variations 
in diet and exercise. Creatinine values can fluctuate throughout the day, corresponding to dietary 
intake, work load and volumes of liquids consumed (Clarke, 1961). 
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2.1.2.2 Jaffe reaction for the quantification of creatinine 
 
The Jaffe reaction was used for the colourmetric measurement of creatinine in urine. In 1886, Max 
Jaffe (1841–1911) wrote about the basic principles of the paper ‘Über den Niederschlag, welchen 
Pikrinsäure in normalem Harn erzeugt und über eine neue Reaction des Kreatinins’ (1886) in which he 
described the properties of creatinine and picric acid in an alkaline solution. The colour change that is 
observed is directly proportional to the concentration of creatinine 
The method using in the investigations presented in this thesis was adapted from Gentaur (2004) and 
Accura Diagnostics Inc. (2009) although other current methods can include; capillary electrophoresis 
(CE), biosensors and HPLC. 
In this Jaffe reaction, an alkaline picric reagent is added to a prepared sample, producing a red 
coloured complex when combined with structures of creatinine. The intensity of this red colouring 
formed in the reaction mixture directly correlates with the concentration of creatinine and can be 
accurately quantified using UV-Vis spectroscopy, measured at 520nm (Clarke, 1961; Cambridge 
Biomedical Research Group, 2009). 
 
 
 
Fig 2.1.2.2.1 Possible interactions of the creatinine – picrate complex (Vasiliades, 1976) 
The Jaffe reaction is a reproducible and reliable method of quantifying creatinine in urine samples, as 
interferences from picrate interactions with glucose and proteins are not as high in urine as they are 
in serum.  
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2.1.2.1.1 Stability of creatinine 
 
During the urine collection protocol, patients were asked to keep urine samples in a cool place, such 
as a fridge. Once the samples had been collected and transported to the University they were stored 
in the appropriately labelled laboratory refrigerator until removed for analysis. It was imperative to 
investigate the stability of creatinine in urine and consider how long the sample could be kept for and 
what conditions must be maintained. Readings of creatinine may be lower in older samples, if 
creatinine were to be unstable. 
A study looking into the decomposition of creatinine in sheep urine by Van Niekerk et al. (1963), 
showed a rapid decay when urine is stored above room temperature, however, when he stored his 
samples below 4oC there was no notable change in the concentration of creatinine over a 5 month 
period.  
 
 
Fig 2.1.2.1.1 The percentage reduction in creatinine concentration over time in sheep urine stored 
between 27-30ºC (Van Niekerk et al. 1963). 
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It is worth noting that the pH of sheep urine is higher than that of humans, ranging from 8.4-8.7, 
therefore being slightly alkaline (Van Niekerk et al, 1963). Human urine has a larger range, due to a 
more varied diet, of 4.6-8, although is typically around 6.5 (Smith-Palmer 2002). More reliable 
methods of analysis can be obtained without treating the urine with acid, therefore creatinine 
concentration is acquired prior to acid digestion. 
As with sheep’s urine, when human urine is maintained at a higher temperature, the creatinine value 
depletes at a faster rate. When human urine is kept at <4oC, it is much more stable over that same 
period of time (Fig 2.1.2.1.2). In fact, at room temperature, a creatinine reduction of 0.5% was witness 
compared with a 3% reduction at 55oC (Spierto et al. 1997). 
 
 
 
 
 
Fig  
2.1.2.1.2 Creatinine levels (% of initial values) in human urine stored at 4, 25 and 55˚C for 1hour to 30 
days (Spierto et al. 1997) 
 
In summary, literature indicates that the manner in which urine is stored leaves creatinine 
concentration virtually affected. The urine should also be left untreated prior to analysis ((Miki & Sudo 
1998; Ng et al. 1984). The National Committee for Clinical Laboratory Standards (Lockitch et al. 1997) 
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advise that sample analysis should take place no more than 2 hours after sample collection, and if this 
cannot be accomplished, the sample must be kept refrigerated. 
 
2.1.2.3 Quantification of silicic acid by molybdenum blue 
 
The molybdenum blue method is generally used to determine the concentration of soluble silica in 
water samples due to its high degree of sensitivity, allowing for the determination of trace 
concentrations of silicon (Karge Weitkamp, 2002). The determination of silicon is an example of the 
use of heteropoly-molybdenum blue in analytical chemistry. Silicic acid (SiOH4) combined with an 
acidic solution of MoVI, in this case ammonium molybdate, produces the yellow complex SiMo12O403−, 
which has an α-Keggin structure (Eq 2.1.2.3.1). 
 
7Si(OH)4 + 12H6Mo7O24·4H2O + 17H2O ⇔ 7H4SiMo12O40·29H2O (Eq 2.1.2.3.1) 
 
 The reaction could be stopped here and transferred to a UV-Vis cell for analysis, with readings taken 
at 568nm but a further step and colour change is often used to observe increased sensitivity and 
accuracy. The SiMo12O403− anion can be then reduced by ascorbic acid to form the blue coloured β-
keggin ion, SiMo12O407−, a silicomolybdic acid cluster (Fig 2.1.2.3.1). The amount of the blue coloured 
ion produced is proportional to the amount of Si(OH)4 present. The blue analyte can then be measured 
using UV-VIS Spectroscopy, set at 700nm, to determine the concentration of Si(OH)4. 
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Fig.2.1.2.3.2 Structure of the silicomolybdic acid cluster. The silicon atom (in grey) is caged by twelve 
MoO6 octahedra (oxygen atoms in white). (Coradin et al. 2004) 
 
2.1.3 TH GFAAS analysis 
 
 
 
2.1.3.1 Reagents  
 
Laboratory reagent grade HCl (12.4M, Fisher Scientific, UK) was used in solutions for rinsing and 
storing of polyethylene equipment and storage containers. An analytical grade HNO3 (15.9M, Fisher 
Scientific, UK) was used for all acid digests and acidification of samples. Ultrapure water from and Elga 
option R 7/15 (conductivity ≤ 6.8 x 10-6 S m-1) was used throughout. 
 
2.1.3.2 Treatment of microwave vessels  
 
In an effort to limit contamination, microwave vessels (PFA Teflon©) were stored in 5% HCl and rinsed 
3 times with UPW then allowed to dry before use. In the case of urinary analysis, 5mL of urine samples 
(20% v/v HNO3) and 1.25mL sweat samples (20% v/v HNO3 / 30% w/v H2O2) were added to the 
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microwave vessels which were weighed before and after the digest to check for any loss of sample. 
One method blank acidified to 20% v/v HNO3 was also added for approximately every 10 samples for 
quality assurance. Used vessels were cleaned well with detergent (Decon 90) and rinsed 3 times with 
UPW. Each vessel was then put through the microwave digest programme with 1mL of HNO3, rinsing 
a final 3 times with UPW before being transferred back into the 5% HCl acid bath.  
 
 
 
2.1.3.6 Microwave digest programme 
 
The above described digestions of sweat and urine samples were carried out using the Microwave 
Accelerated Reaction System, Model MARSXpress (CEM Mircowave Technology Ltd, UK). Prepared 
samples were heated from room temperature to 180ºC over a 10minute period; they were then held 
at 180ºC for 15minutes (1600W) before a final cooling period over 30minutes (0W). Vessels were then 
removed from the system and left on the work top to cool to room temperature. 
 
2.1.3.7 Instrumentation 
 
Concentrations of total Si and Al were measured using an AAnalylist 600 atomic absorption 
spectrometer with a Transversely Heated Graphite Atomiser (THGA). This was equipped with a 
longitudinal Zeeman effect background corrector and an AS-800 autosampler (Perkin-Elmer UK). 
Standard THGA pyrolytic-coated graphite tubes with an integrated L’vov platform were used (Perkin 
Elmer UK). 
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2.0mL acrylic TH GFAAS sample cups (Gradco International Ltd) were used and were rinsed with the 
sample before use. Each measurement was performed using lumina hollow cathode lamps and the 
software employed by the system was Winlab 32 (Perkin Elmer, UK). The TH GFAAS instrument 
parameters are shown in Table 2.1.3.7.1 and the temperature programmes are shown in Table 
2.1.3.7.2The Zeeman background corrected peak area of the atomic absorption signal was used for 
the determination of each experimental reading was the mean of three injections with relative 
standard deviation <10% accepted for each sample. 
 
 
Table 2.1.3.7.1 TH GFAAS instrument parameters for the measurement of aluminium and silicon in 
human urine and sweat samples. 
Instrument Parameters Aluminium Silicon 
Lamp current (mA) 25 30 
Wavelength (nm) 309.3 251.6 
Bandwidth (nm) 0.7 0.2 
Injection Volume (µL) 30 30 
Injection Temperature (oC) 20 20 
Pipette speed (%) 100 100 
Read Time (s) 2 3 
Delay Time (s) 0 0 
BOC Time (s) 0 0 
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Table 2.1.3.7.2: TH GFAAS atomisation programme for aluminium and silicon. 
Stage Temperature Ramp Time Hold Time Internal Flow 
 (oC) (oC /s-1) (s) (Lmin-1) 
Aluminium 
Drying 110 10 40 250 
Drying 130 15 40 250 
Pyrolysis 500 10 10 250 
Pyrolysis 1200 10 15 250 
Atomisation 2300 0 5 0 
Cleansing 2300 1 5 250 
 
Stage Temperature Ramp Time Hold Time Internal Flow 
 (oC) (oC /s-1) (s) (Lmin-1) 
Silicon 
Drying 110 10 40 250 
Drying 130 15 40 250 
Pyrolysis 1200 10 20 250 
Atomisation 2350 0 5 0 
Cleansing 2450 1 5 250 
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2.1.3.8 TH GFAAS calibration standards 
 
TH GFAAS was calibrated by automated serial dilution from 300, 60, 100, 40 ppb (w/v) standard 
solutions of Si, Al, Fe and Cu respectively, with 1% HNO3 to give the standards outlined in Table 2.1.3.8. 
Solutions were prepared by the dilution of 10 ppm (w/v) stock solutions with 1% HNO3 in 10 mL 
borosilicate volumetric flasks. The 10 ppm (w/v) stock solutions were prepared by dilution of 1000 
ppm (w/v) (2% HNO3) pure atomic spectrometry certified standards (Perkin Elmer, UK) with 1% HNO3 
in 100mL polyethylene volumetric flasks. 
 
Table 2.1.3.8: TH GFAAS calibration standard concentrations 
 
 
 
 
 
 
 
Blank correction was performed using 1% HNO3. Non-Linear through zero WinLab 32 generated 
calibration fits were applied (Perkin Elmer, UK). 
 
2.1.3.9 Dilutions of urine samples  
 
Urine samples were diluted to achieve concentrations within the calibration range. Analysis for Al, Fe 
and Cu were made using a 1:1 dilution (digested sample: 1% HNO3); silicon required higher dilutions 
of: 1:50, 1:100 and 1:200. Therefore, dilution effects were investigated for silicon. 
Silicon
Aluminium
50, 100, 200, 300
10, 20, 40, 60
Analyte Concentration of calibration standards (ppb w/v)
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2.1.3.9 Dilution effects on silicon determination  
 
 
24-hour treatment samples from three participants were used to investigate the effects of dilution on 
the Si readings. These samples were chosen because the lowest dilution (1:50) was within the 
calibration range. The results of these measurements are shown in Table 2.1.3.9.1.1. 
 
Table 2.1.3.9.1.1: The effect of dilution on the measured mean (n = 3) silicon concentrations 
 
 
 
 
As the Si samples are highly diluted in order to obtain an absorbance reading in the middle of the 
calibration range, it was not considered necessary to use matrix modifiers as high dilutions will reduce 
matrix effects. 
 
2.1.3.10 Quality control for TH GFAAS  
 
As some error is inherent to all analytical techniques, it is important to quantify this error and ensure 
that it does not exceed a tolerable level.  
 
 
 
1:50 1:100 1:200 1:50 1:100 1:200
299.72 153.04 71.15 0.00 -2.10 5.18
301.52 152.71 76.27 0.00 -1.29 -1.17
272.5 134.49 65.36 0.00 1.30 4.14
Percentage Difference from 
the 1:50 Dilution
24F8W1-3
24F1W12-1
24M4W1-4
Sample ID
Measured Means (ppb w/v)
for dilutions of
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2.1.3.10.1 Limit of detection (LoD)  
 
The LoD is the smallest quantity of analyte which is significantly different from the blank. TH GFAAS 
LoD for Si and Al were determined from three times the standard deviation (n = 3) of the absorbance 
of the 1% HNO3 calibration blank divided by the slope of the calibration fit. Means and SD of the LoD 
for each element are provided in Table 2.1.3.10.1.1. 
 
Table 2.1.3.10.1.1: Mean (SD) limit of detection of silicon and aluminium 
 
 
 
 
 
2.1.3.10.2 Limit of quantification (LoQ) 
 
 
LoQ is the amount of analyte which carries a reasonable degree of statistical certainty. TH GFAAS LoQ 
for Si and Al were determined from ten times the standard deviation (n = 3) of the absorbance of the 
1% HNO3 calibration blank divided by the slope of the calibration curve. Means and SD of the LoQ for 
each element are provided in Table 2.1.3.10.2.1 
 
 
 
SD 3.5 0.71
n 77 84
TH GFAAS Limit of Detection μg L-1
Element Silicon Aluminium
Mean 4.53 0.43
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Table 2.1.3.10.2.1: Mean (SD) limit of quantification of silicon and aluminium 
 
 
 
 
2.1.3.11 Method blanks  
 
Method blanks were used to determine the level of contamination which occurs from the procedure; 
the blanks were treated in exactly the same way as the samples, i.e. acidified to 20% v/v HNO3 and 
digested, they were then diluted with 1% HNO3 before analyses in relation to the element being 
determined. Frequency distributions are given for the method blanks after dilution factors were taken 
into account (Figure 2.1.3.11.1). The mean was taken from measured values as a source of 
contamination. 
 
Figure 2.1.3.11.1: Frequency distributions of method blanks for a) Si at dilutions 50, 100 and 200, b) 
Al. 
SD 11.66 2.35
n 77 84
TH GFAAS Limit of Quantification μg L-1
Element Silicon Aluminium
Mean 15.1 1.42
72 | P a g e  
 
2.1.3.12 Routine calibration standards 
 
Throughout analysis, standards of known concentrations are analysed to determine any changes in 
signal. A reading is considered adequate when it is within 10% of the known concentration value and 
subsequent measurements fall within 15% of the initial reading. Frequency distributions have been 
expressed for the initial calibration standards (CS1) and the continuing calibration standards (CS2, CS3 
and CS4) (Fig 2.1.3.12.1). Percentage differences from these initial calibration values are given in Table 
2.1.3.12.1.  
 
  
 
 
 
Figure 2.1.3.12.1: Frequency distribution of calibration standards for a) Si and b) Al. This figure 
represents CS1 as the initial calibration standard and CS2, CS3 and CS4 are the continuing calibration 
standards. 
  
Table 2.1.3.12.1: Mean concentrations (μg L-1) of calibration standards (M) with standard deviations 
(SD) and percentage difference (%D) from initial concentration standard (CS1). 
 
 
 
 
 
 
M SD %D M SD %D
CS1 157 8 N/A 30.9 1.91 N/A
CS2 162 8.89 3.23 31 2.22 0.29
CS3 167 9.06 6.41 30.1 2.17 2.84
CS4 169 9.39 5.42 29.7 2.4 3.27
Silicon Aluminium
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2.1.3.13 Replicate samples 
 
Replicates of the same sample were also measured to evaluate the precision of the equipment. The 
precision of the instrument was accepted if the replicate samples were within a percentage difference 
of 5. Examples are given in Appendix 1. 
 
2.1.3.14 Duplicate samples 
 
Duplicates of samples were independently analysed to determine the precision of the preparation 
methods. The precision of the preparation methods was accepted if the duplicate samples were within 
a percentage difference of 5. Examples are given in Appendix 2. 
 
2.1.3.15 Spike recovery 
 
A known concentration of analyte was added to a sample as a spike, the recovery of which allowed 
determination of the amount of analyte lost and may suggest the occurrence of any interferences. 
Spikes were added to selected urine samples and method blanks (reagent spikes). The quantity of 
spike added were selected to gain a concentration at the mid-point of the calibration curves at 100% 
recovery (Table 2.1.3.15.1). 
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Table 2.1.3.15.1: Spike recovery from reagents and urine samples 
 
  Reagent Spike Urine Sample Spike 
Element 
Mean 
recovery % 
(n = 10) 
SD Mean 
recovery % 
(n = 10) 
SD 
Silicon 99.73 3.42 103.00 2.39 
Aluminium 98.23 2.68 100.52 2.29 
 
 
On summary of this data, a high reliability of the analytical methods is shown through approximately 
100 % of the reagent and sample spikes being recovered; in this instance the need to account for 
interferences is not required. 
 
2.1.3.16 Contamination control 
 
Treatment of samples was performed in the clean room. Blank samples (UPW) were stored in plastic 
vessels and analysed in order to test for contamination. All plastic ware was washed and stored in acid 
bins to reduce adsorption of metals. 
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2.2.0 Materials and methods for the determination of creatinine by UV-Vis 
spectroscopy 
 
 
2.2.1. Reagents 
 
Reagent grade sodium hydroxide (2M, Fisher-Scientific, UK) and reagent grade picric acid (1%, Sigma-
Aldrich, UK) were used in the determination of creatinine concentration in urine. Anhydrous creatinine 
(Sigma-Aldrich, UK) was used in the calibration. UPW was used throughout. 
 
2.2.2 Treatment of samples 
 
Urine samples were diluted by 10 fold with UPW and mixed (1:10) with a freshly prepared reactant 
comprising of equal amounts of 1% picric acid and 0.75M NaOH; these were then agitated and left to 
react for 20 minutes before analysis by UV-Vis spectroscopy. Each sample was analysed three times 
and an average was taken. 
 
2.2.3 Instrumentation 
 
Creatinine concentration was determined using a Lambda 14 UV-Vis spectrometer (Perkin Elmer, UK), 
set to read wavelengths between 400–600 nm; maximum absorbance was at 520 nm. 
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2.2.4 Determination of creatinine concentration 
 
An 8 mM stock solution of creatinine was prepared by addition of anhydrous creatinine to UPW. This 
stock solution was serially diluted to give calibration standards containing 0.2, 0.4, 0.8, 1.6, 3.2, 6.4 
and 8 mM creatinine in UPW. The absorption of each calibration standard at 520 nm (25°C, cuvette 
path length 1 cm) was recorded. An example of a typical Beer Lambert calibration curve is shown in 
Figure 2.2.4.1. 
 
 
 
 
 
 
 
 
Figure 2.2.4.1: A standard Beer Lambert calibration curve for the creatinine-picrate complex: the 
absorbance of aqueous solutions containing creatinine concentrations between 0.2 and 8 mM 
measured using UV-Vis at 520nm. 
 
The Beer-Lambert calibration curve (Fig. 2.2.1.3.1)  was linear (R2=1) up to and including the highest 
concentration (8mM) indicating that its application is suitable for the determination of creatinine 
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concentration. However, the standards 6.4 and 8 mM gave absorbance readings > 1.0 and so 3.2 mM 
was chosen as the highest calibration standard during testing. 
 
2.2.5 Quality control for the determination of creatinine 
 
 
2.2.5.1The limit of detection 
 
The LoD was determined to be 0.00324 ± 0.00168 A. 
2.2.1.5.2 The limit of quantification 
 
The LoQ was determined to be 0.0108 ± 0.00559 A. 
 
2.2.1.5.3 Precision 
 
Precision was determined by sampling five replicates of 5 separate samples (Table 2.2.1.5.3.1). Each 
sample was diluted by 1:10, removing matrix interference and ensuring that they were within this 
measured detectable range of calibration. The reproducibility of each sample, highlighted by the low 
standard deviations, indicates that the precision of the technique is acceptable. 
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Table 2.2.1.5.3.1: sampling of five replicates of 5 separate samples to determine precision in the 
quantification of creatinine using the Jaffe reaction and UV-Vis Spectroscopy. 
 
 
2.2.1.5.4 Spike recovery  
 
A known concentration of creatinine was added to selected urine samples as a spike and the recovery 
determined (Table 2.2.1.5.4.1). 
Table 2.2.1.5.4.1 Spike recovery in creatinine analysis. 
 
Recovery was within the 10% acceptable limit, indicating the reliability of the analytical methods 
without the need to account for interferences. 
2.3.0 Detection of elements within mineral waters 
 
2.25 2.27 2.32 2.34 2.29 2.3 0.004
6.24 6.19 6.27 6.25 6.19 6.2 0.036
4.32 4.35 4.31 4.36 4.28 4.3 0.032
4.22 4.26 4.17 4.25 4.19 4.2 0.038
3.98 3.92 3.95 3.97 4.05 4 0.048
Measured Creatinine Concentration mM
Mean SD
Rep 1 Rep 2 Rep 3 Rep 4 Rep 5
Sample
F001-24-1
M004-24-3
F009-24-3
F013-24-4
M007-24-1
92.77
102.64
101.85
14.1 14.44
22.1 22.48
Spike 
Concentration 
(mM) Expected
Total Creatinine Concentration (mM)
Measured
4.00
8.00F015-24-1
16.00
10.1 9.92
Sample
Recovery 
(%) 
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The brand of mineral water used within the healthy volunteer study and MS study was provided by 
the Malaysian company Spritzer. This mineral water, Spritzer, is commercially available within 
Malaysia, but was not available within the U.K during the time of the study. It is now commercially 
available under the name ACILIS. 
The amount of Si and Al within a variety of mineral waters was determined by TH GFAAS (Table 2.3.1). 
 
Table 2.3.1: Mean and SD of the amount of Si and Al detected in the mineral waters (n = 10). 
 
 
 
 
 
 
2.4.0 Study Protocols 
 
These studies aimed to investigate if silicic acid-rich mineral waters could be used as a completely non-
invasive tool of ‘everyday’ diets to lower the body burden of aluminium. For this reason all volunteers, 
for each procedure, were asked to continue as normal with their daily routine and were not requested 
to avoid any products other than mineral waters not provided for the study. Specific aims for each 
study are provided at the beginning of the relevant results section. 
The technique of measuring the urinary excretion of Al has been used as a non-invasive indicator of 
the body burden of Al (Bellia et al. 1996; Exley et al. 1996; Roberts et al. 1998; Exley et al., 2006). 
Spritzer
Volvic
Evian
Silicon (µmol) Aluminium (nmol)
84 ± 6
81 ± 4
Amount in 1L of the water
Buxton
1053 ± 16
576 ± 17
24 ± 7
124 ± 6
Brand of Water
Island Chill
31 ± 4
1879 ± 32
768 ± 18
69 ± 5
127 ± 6
131 ± 8
Fiji
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Control measurements were always used to obtain estimates of volunteer’s ‘normal’ urinary excretion 
of Al. Comparisons of the urinary excretion of aluminium, before and after consumption of Si-rich 
mineral water, enabled accurate determination of the influence of the mineral water on the body 
burden of Al (see for example, Exley et al. 2009). Witnessing an initial increase in aluminium excretion 
would propose the removal of systemic aluminium from body stores. A reduction in aluminium 
excretion over time would suggest that aluminium body burden has been reduced (see Exley, 2012). 
Details of methods used here are provided in the relevant chapters. 
 
2.4.1 Silicic acid-rich mineral water as a non-invasive method of reducing the 
aluminium body burden in healthy individuals 
 
Nineteen healthy volunteers, comprising of 9 males and 10 females, with a mean age of 24 years 
(range 18-34 years), were recruited through Keele University. This was attained by personal invitations 
to volunteer via email, and through oral communication. All volunteers provided written consent prior 
to participation. Ethical approval for the study was obtained from Keele University Research Ethics 
Committee (favourable outcome is included in the appendix). 
The inclusion criteria for participation consisted of individuals between the ages of 18-35 years, who 
were considered to be in good health, could carry out a mild exercise regime and would not suffer any 
practical difficulties from the ingestion of up to 1.5L mineral water over a short time period. 
The exclusion criteria removed any individuals with any medical conditions or reoccurring ailments 
(e.g. bladder infections) which may lead to discomfort and/or influence results of the study. Those 
taking any medications containing the examined elements in the study, such as antacids, were 
excluded from the study as this may affect the results. 
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The project protocol was divided into two objectives (detailed below); each volunteer was requested 
to participate in both parts of the study. Therefore the same group is used for both of the following 
procedures. 
2.4.1.1 Record Sheets 
 
It was a crucial aspect of the study to ensure that participants did not change their diets or lifestyles 
in any way for the study. They were asked to complete a Life Style Questionnaire which was devised 
to give an approximate value of their daily exposures to Al. Dietary record sheets were also completed 
for the duration of each 24 hour urine collection procedure to observe the amount and type of 
beverages consumed within these periods, this information is provided for each volunteer in the 
appendix of this thesis. It was decided too much to ask for a full dietary analysis (as silicic acid will be 
released from food during digestion); the most bioavailable form of silicon is in the form of silicic acid 
found in the water. Therefore a general diet analysis and beverage record sheets were decided to give 
ample information. 
Volunteers were asked to consume the full amount of mineral water suggested, 1.5L per protocol. 
Although if this wasn’t possible, they were asked to record the volume that they could comfortably 
manage to consume within the given time period. 
 
2.4.1.2 Objectives 
 
Each of these protocols involved a time period in which the participant consumed the silicon rich 
mineral water and provided the urine sample for analysis. 
Sweat samples were collected at the time of the study.  
a) 24 hour trial (Chapter 3) 
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Investigation of total urinary excretion of Si and Al in 24h samples.  
Nineteen participants, 9 male and 10 female (age range 18–34) were recruited from the student 
population at Keele University and ethical approval was obtained from the University’s Life Sciences 
Ethical Review Body (Details of which are provided in the appendix). All participants were self-assessed 
as healthy and agreed to partake in a mild exercise program as part of the procedure for collecting the 
urine samples 
Participants provided a 24h urine sample before and following the consumption of up to 1.5L of 
mineral water, these before and after periods are hereafter referred to as control and treatment 
periods.  
The treatment period involved two different aspects, a loading and dosing mechanism. Following the 
first urinary excretion after waking, the volunteers were requested to collect all subsequent urinary 
excretions up to and including the first sample the following morning. This is a standard procedure for 
the collection of a 24-hour urine sample (CLS, 2007). For the loading treatment period, participants 
were asked to consume as much of the 1.5L of mineral water as they could manage between their first 
and second urinary excretion of the day. For the second part, referred to as the dosing protocol, the 
participants were instructed to consume approximately 150mL of the water each hour for 10 hours of 
the day. This way, the most effective measure of silicon delivery could be established.  
Differences in the urinary excretions of Si and Al between control and treatment periods were 
determined using the paired t-test, in addition comparisons between males and females were 
performed using the 2-sample t-test. 
Results for the 24 hour studies are displayed as being corrected for total amount excreted in the 24 
hours. These results display the total excretion of the elements in the urine sample. These results 
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provide the most effective information on the urinary excretions of the elements and are regularly 
used in similar studies (CLS 2007). 
Both creatinine-corrected data and 24 hour corrected data were collected for each individual. 
 
b) 30 – minute exercise trial (Chapter 4) 
Investigation of sweat excretion of Si and Al collected after 30 minutes of mild exercise 
Nineteen participants, 9 male and 10 female (age range 18–34) were recruited from the student 
population at Keele University and ethical approval was obtained from the University’s Life Sciences 
Ethical Review Body (Details of which are provided in the appendix). All participants were self-
assessed as healthy and agreed to partake in a mild exercise program as part of the procedure for 
collecting the sweat samples.  
 
An appropriate material was selected for the absorption of sweat, details of this analysis is 
presented in Chapter 4.3.1. This material, cut into 5 x 5cm sections, were soaked in 5% HCl for 2 
hours, UPW for 24 hours, and then placed in a drying oven overnight before use. Prior to the 
exercise protocol, the upper back was cleaned using a pad immersed in 100% ethanol, then six 
pieces of this prepared material was transferred to the upper back of each individual, covered with a 
plastic film and secured with an adhesive medical tape to prevent any allergic reaction to adhesives. 
The individual was then instructed to complete a total of thirty minutes cycling on an exercise bike, 
including five minutes initial fast paced cycling, twenty minutes moderate paced cycling and a final 
five minutes fast paced cycling. Once this program was completed, the sweat soaked material was 
transferred to 7mL centrifuge tubes and span down at 6000RPM for 6 minutes to extract the volume 
of sweat collected in the material to the bottom of the tube, this series of steps is shown in Figure 
2.4.1.2.1. 
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Figure 2.4.1.2.1: Sweat collection apparatus and exercise protocol 
 
Differences in the excretions of Si and Al in sweat between control and treatment periods were 
determined using the paired t-test, in addition comparisons between males and females were 
performed using the 2-sample t-test. 
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2.5.0 Silicic acid-rich mineral water as a non-invasive method of reducing the aluminium body 
burden in multiple sclerosis participants 
 
Fifteen multiple sclerosis patients were recruited through the University Hospital of North 
Staffordshire (UHNS, now Royal Stoke) through the MS department by a qualified clinician following 
the inclusion and exclusion criteria. Ethical approval was attained by myself, from the national 
research ethics committee (North Staffordshire NREC). All volunteers provided written consent prior 
to participation, which was obtained by a qualified clinician. 
All SPMS patients attending the Neurology clinics were screened for possible inclusion in the study. 
Suitable and interested patients will be posted a participant information pack, including the PIS and 
coversheet, explaining the outline of the study. This was followed up via telephone calls/postal letters 
by a study clinical to confirm their interest and participation. Those who were interested were asked 
to be come back to a research clinic where a screening assessment was carried out by a study clinician 
and eligible patients were asked to sign the consent form. A standard time period of 24 hours was 
given between the receipt of the study information sheet and taking informed consent. 
The inclusion criteria included: All patients must have a confirmed diagnosis, by a study clinician, of 
secondary progressive multiple sclerosis (SPMS) according to the McDonald inclusion criteria. Patients 
must be willing and able to give informed consent in line with the Mental Capacity Act. Patients had a 
carer to help ensure that the protocol was followed accordingly. Carer was willing and able to give 
informed consent. Patient would not suffer any ill effects or practical difficulties on the consumption 
of up to 1L of mineral water and had no restriction on fluid ingestion. As well as any patients not 
satisfying the above inclusion criteria, a potential study participant would be excluded; those patients 
on disease modification treatment, patients with current urinary infections and patients with a history 
of impaired renal function. The patient could be initiated onto the study once an infection free urine 
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sample had been provided. During recruitment, a Kurtjze EDSS score was given to each patient. This 
was followed up at the end of the study to look for improvements in mobility, as well as a 
questionnaire querying general wellness. 
One patient (008) had to be withdrawn from the study due to a series of urine infections. The mean 
age of the remaining 15 MS patients who completed the study, was 72 (range 56 - 81) and 8 were 
female. 
 
2.5.1 Protocol 
 
 
The project protocol was divided into two objectives; the primary objective was to measure the 
urinary excretions of Si and Al over a 24 week period during which patients consumed up to 1.5L of 
silicon-rich mineral water each day. The first 12 weeks of the study, referred to as the control, required 
each participant to provide urine samples following their normal diets, thus acting as their own control 
to determine individual changes. The secondary objective was to observe changes in mobility using 
EDSS scores at the beginning and end of the study. 
 
 
 
2.5.2 Urinary excretions 
 
This study examined the effects of long-term consumption of mineral water on the urinary excretion 
of Si and Al. The study duration was split up into two parts, the first 12 weeks (W1-W12), known as 
the control period and the second 12 weeks (W13-W24) referred to as the treatment period. 
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Participants collected all of their urine (24 hour samples) for the 5 days in W1, W12, W13 and W24 
into 3L sterile containers. During the rest of the study weeks, the first morning sample of the day on 
the same day of each week was collected into sterile 50mL containers. These collections were made 
for the baseline (W1 to W12 - no mineral water consumption) and treatment periods (W13 to W24 - 
including consumption of up to 1.5L of mineral water each day).  
Differences in the urinary excretions of Si and Al between control and treatment weeks 1, 2, 13 and 
24 for each individual were determined using one-way ANOVA and Tukey’s paired comparison tests. 
Differences for control and treatment data were measured using repeated measures ANOVA and 
Wilcoxon signed-rank tests. 
 
Results were displayed as creatinine-corrected data in order to account for the deviations in urine 
volumes of spot samples. Volunteers were requested to consume as much as the 1.5L of the provided 
mineral water as they could comfortably manage. This volume is the same as the healthy individual 
urine study because the consumption of 1.5L every day for a period of 12 weeks seemed acceptable 
to the patients, although, unlike the loading treatment in the healthy volunteer study, patients in this 
study were able to make up their normal drinks with the water, essentially replacing other water 
consumed in their daily diets with the Spritzer. 
It was thought to be inconvenient for the patients to provide record sheets as in the health volunteer 
study. Instead, the patients were provided with a tick sheet to recognise their water consumption and 
sample collection.  
 
As in the healthy volunteer study, results are recorded both before and following correction for 
creatinine concentrations, and 24 hour samples were expressed in both formats. 
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The requirements for this study were maintained at a minimum so not to make participation too 
complexed for individuals suffering from MS. Therefore, dietary record sheets, as collected in the 
healthy individual, study were not required during this study. The length of the control period satisfied 
this as it meant that a thorough indication of normal Si and Al excretion could be deduced. 
 
 
Differences in the urinary excretions between the control and treatment periods were determined 
using the paired t-test, and comparisons between males and females were performed using the 2-
sample t-test. An aged matched healthy control group was not sought after for this study, but instead 
data available from other studies was used (Minshull et al 2014). 
 
 
2.5.3 EDSS Score 
 
 
The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple 
sclerosis. The scale has been developed by John F. Kurtzke (1983). 
Each individual completed the EDSS test prior to and following the treatment of the mineral water, 
this was performed by the qualified clinician. Comparisons between the initial and final score were 
used to determine whether the consumption of the mineral water had any influence on their mobility. 
It is accepted that an EDSS score reduced by 0.5 or more points (Kurtjze 1983) indicates an 
improvement in mobility performance. 
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Overall scores of the EDSS tests were provided by the clinical nurse on the completion of the urinary 
analysis and are noted in the appendix of this thesis, referenced by patient ID. Detailed reports of the 
performance of the tests (i.e. scores of each section) were not made available for this thesis due to 
patient confidentiality. Patient questionnaires were collected post study to determine any 
improvements in health, wellbeing and general feedback. 
 
 
2.6.0 Biostatistical analysis 
 
 
As discussed within the study protocols, the purpose of these analyses were to assess the use of silicic 
acid-rich mineral waters as a potential non-invasive therapy to reduce aluminium body burden. The 
primary null hypothesis was that the consumption of silicic acid-rich mineral waters would have no 
effect on the urinary excretion of aluminium, thereby, would have no effect on aluminium body 
burden. 
Analysis of the biological data has been statistically examined using the software Minitab ® 15. This 
section includes a description of the general statistical tests that were conducted to identify changes 
in urinary excretions of Si and Al. Details on the statistical tests used within this thesis can be found in 
(Zar, 1996). 
The results are ordered by study (HV U, HV S and MS) and within each study are ordered by element 
(Si andAl). Comparisons are made between control and treatment periods, male and female 
populations using the appropriate tests. 
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2.6.1 Power analysis 
 
Power analysis with values of 80% and 90% were calculated using Minitab’s Power and Sample Size 
calculation for a single sample. This was in order to provide an indication of the sample size needed 
for each study to conduct a statistically reliable experiment (Table 2.6.1.1). Expected differences (SD) 
were derived from Exley et al. (2006) and used to calculate the effect size (Difference/SD). 
 
Table 2.6.1.1: Sample size needed for each study. 
 
 
 
2.6.1 P-value 
 
The P-value was accepted as statistically significant when it was below P = 0.05. All confidence intervals 
were set to 95%. P-values were noted to 3 decimal places and a P-value less than 0.001 was reported 
as < 0.001. 
 
2.6.2 Normality and transformations 
 
Parametric tests assume that the data has a normal distribution; these were always attempted before 
the non-parametric tests. They are more powerful and offer increased accuracy in determining 
statistical significance. However, if the data wasn’t to follow a normal distribution, these parametric 
tests may not provide reliable results. 
Power 80% Power 90%
10 13
SD Effect size
Sample size
24 1
Expected difference
24
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Anderson-Darling normality checks were performed on the residual data for each data set; P > 0.05 
directed that the data followed a Gaussian distribution and could therefore be considered as being 
normally distributed. Data sets which did not follow a normal distribution were rendered normal using 
logarithmic transformations.  
If the transformation of the data didn’t normalise the distribution, non-parametric tests were used as 
these are distribution free, reducing the influence that outlying data points have on the overall data 
set. 
Minitab highlighted outliers in the data but these points were only removed from the data set if there 
was reason to assume that the results were unreliable (i.e. contamination); it’s possible to suggest 
that some outliers represented natural biological variability. Where a direct comparison was made 
between data sets and at least one set was not normally distributed the selection of non-parametric 
tests were used. 
 
2.6.3 Study variables 
 
Independent variable = urinary/sweat excretion under control conditions (i.e. before consumption of 
the mineral water). 
Dependent variable = urinary/sweat excretion under treatment conditions (i.e. after consumption of 
the mineral water). 
Confounding variables = differences in dietary intake, including the amount of mineral water the 
individual managed to consume. 
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2.6.4 Statistical tests used 
 
The different parametric tests used within this study are highlighted in Table 2.6.10.1. Details of the 
test and their non-parametric equivalents are described below. 
 
2.6.5 Pearson’s correlation coefficient and linear regression 
 
Purpose - Test for relationships between two variables 
Rational - Simple linear regression and correlations performed to determine a relationship between 
variables and to describe this particular witnessed relationship. The best fit was determined by 
Minitab using the available method of least squares. 
The Pearson’s correlation coefficient (r) measures the strength of linear relationships. Values are 
between -1, which indicates a perfect negative relationship and 1, which indicates a perfect positive 
relationship. The non-parametric analogue used was the Spearman’s rank correlation. 
 
2.6.6. Paired t-test 
 
Purpose - Compare the means of two measurements within a single group. 
Rational - The paired t-test calculates the difference between two measurements for each individual 
member of a population and determines whether the mean difference is different from zero. This test 
was used to compare urinary excretions before and after the treatment of mineral water. Wilcoxon 
signed rank is the non-parametric equivalent to the paired t-test. This test compares the medians of 
the two groups. 
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2.6.7 One-way ANOVA 
 
Purpose – Compare the variance in the mean for more than two measurements between groups. 
Rational - One-way ANOVA uses the F-distribution to compare the variance between the means of 
three or more measurements and to determine whether or not there is a difference. The F-distribution 
is related to the F-crit value to determine significance of the data. This test was used to determine 
whether an individual showed a difference in their urinary excretions between the two control and 
treatment weeks. 
The F-distribution is calculated by dividing the sum of squares between each group (SSB) by the sum 
of squares within each group (SSW). 
 
F = 
Variance due to difference between means
Variance due to difference within means
 
 
 
Tukey’s paired comparison was used in conjunction with ANOVA to distinguish where the differences 
lie between specific pairs. Kruskal-Wallis test is the non-parametric equivalent to one-way ANOVA. 
 
2.6.8 Repeated measures ANOVA 
 
Purpose – Compare variance in the mean for more than two measurements for a single group. 
Rational – Repeated measures ANOVA uses the F-distribution (as described above) to compare the 
variance between the means of three or more measurements and to determine whether or not there 
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is a significant difference. This test was performed in Excel, and was used to determine whether the 
group showed a difference in their urinary excretions between the control weeks and treatment 
weeks. 
 
2.6.9 2-sample t-test 
 
Purpose - Compare the means of a single measurement between two different populations. 
Rational - The 2-sample t-test calculates the difference between the means of two populations which 
are independent of each other. The difference in means is compared with an approximation of the 
standard error calculated between the two populations. This test was used to compare the urinary 
excretion of the elements between different groups, i.e. between males and females, BMI data and 
relationships between age. Mann-Whitney U test is the non-parametric equivalent to the 2-sample t-
test. This compares the medians of the two groups. 
 
Table 2.6.10.1: Summary of the different parametric tests used within the statistical analyses 
 
 
 
 
 
 
 
Urine Sweat
 
 
 
Repeated measures ANOVA
Study
MS
HV





Statistical test
Pearson’s Correlation Coefficient
paired t- test
2 sample t- test
One way ANOVA
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Chapter 3. - Silicic acid mineral water as a non-invasive method of 
reducing aluminium body bioburden in healthy individuals. 
 
3.1.0 Aims 
 
The aim of this chapter is to investigate if regular drinking of a silicon-rich mineral water can 
facilitate the removal of Al from the body of healthy individuals. 
 
3.2.0 Introduction 
 
Previous studies have demonstrated that silicic acid reduces the gastrointestinal absorption of 
aluminium (Edwardson et al. 1993), facilitating the removal of systemic aluminium within the body 
(King et al. 1997; Exley et al. 2006). Certain commercial mineral waters, such as Volvic, provide a 
good source of silicic acid and could potentially be utilized as a preventative measure against the 
accumulation of aluminium within the body. This could be exploited in young, healthy individuals, 
which could in turn reduce the rate and slow the progression of aluminium-related disorders. 
However, the role of silicon in drinking water and how humans handle this silicon has not been 
widely studied, particularly with respect to healthy individuals. 
The purpose of this work was to elucidate the effect of drinking silicic acid-rich mineral waters on 
the urinary excretion of silicon in healthy individuals. The main aim of this research was to 
investigate the influence of a silicic acid-rich mineral water, as a non-invasive therapy, on the urinary 
excretion of aluminium. This was investigated following the objectives detailed in Chapter 2. Data for 
each individual are provided in Appendix 3. 
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3.3.0 Methodology 
 
Nineteen healthy volunteers, comprising of 9 males and 10 females, with a mean age of 24 years 
(range 18-34 years), were recruited through Keele University. This was attained by personal 
invitations to volunteer via email, and through oral communication. All volunteers provided 
written consent prior to participation. Ethical approval for the study was obtained from Keele 
University Research Ethics Committee (See Appendix for favourable outcome letter). 
The inclusion criteria for participation consisted of individuals between the ages of 18-35 years, 
who were considered to be in good health, could carry out a mild exercise regime and would not 
suffer any practical difficulties from the ingestion of up to 1.5L mineral water over a short time 
period. 
The exclusion criteria removed any individuals with any medical conditions or reoccurring 
ailments (e.g. bladder infections) which may lead to discomfort and/or influence results of the 
study. Those taking any medications containing the examined elements in the study, such as 
antacids, were excluded from the study as this may affect the results. 
The project protocol was divided into two objectives (detailed below); each volunteer was 
requested to participate in both parts of the study. Therefore the same group is used for both of 
the following procedures. 
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3.3.1 Treatment of urine samples 
 
Urine samples were collected and stored directly into pre-acid washed 3L polypropylene 
containers for each twenty four hour trial. The twenty four hour sample volumes were 
measured, vortex to ensure uniformity, and a portion transferred to a washed 50mL Falcon™ 
tube for storage in a clearly marked refrigerator. The remaining sample was disposed of down 
the toilet and the jug thoroughly cleaned with decon. An aliquot of un-acidified urine sample 
was taken and diluted to 10% with UPW for creatinine (Crt) analysis using the Jaffe method 
(Toora, 2002). The remaining urine was acidified using 15.8M HNO3 to 20% v/v and subjected to 
microwave digestion to prepare samples for measurement of total silicon and aluminium by 
THGFAAS.  
 
3.3.1 Record Sheets 
 
It was a crucial aspect of the study to ensure that participants did not change their diets or 
lifestyles in any way for the study. They were asked to complete a Life Style Questionnaire which 
was devised to give an approximate value of their daily exposures to Al (see Appendix). 
Dietary record sheets were also completed which indicated the amount and type of foods 
consumed by each participant in their average daily diet. It was decided that it was too much to 
ask for a full dietary analysis (as silicic acid will be released from food during digestion); the most 
bioavailable form of silicon is in the form of silicic acid found in the water. Full beverage record 
sheets were decided on to give the most appropriate information. 
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Volunteers were asked to consume the full amount of mineral water suggested during the loading 
protocol, 1.5L in 1 hour. Although if this wasn’t possible, they were asked to record the volume 
that they could comfortably manage to consume within the given time period. 
3.3.2 Investigation of total urinary excretion of Si and Al in 24h samples.  
 
Participants provided a 24h urine sample before and following the consumption of up to 1.5L of 
mineral water, these before and after periods are hereafter referred to as control and treatment 
periods.  
The treatment period involved two different aspects, a loading and dosing mechanism. Following 
the first urinary excretion after waking, the volunteers were requested to collect all subsequent 
urinary excretions up to and including the first sample the following morning. This is a standard 
procedure for the collection of a 24-hour urine sample (CLS, 2007). For the loading treatment 
period, participants were asked to consume as much of the 1.5L of mineral water as they could 
manage between their first and second urinary excretion of the day. For the second part, referred 
to as the dosing protocol, the participants were instructed to consume approximately 150mL of 
the water each hour for 10 hours of the day. This way, the most effective measure of silicon 
delivery could be established.  
Differences in the urinary excretions of Si and Al between control and treatment periods were 
determined using the paired t-test, in addition comparisons between males and females were 
performed using the 2-sample t-test. 
Results for the 24 hour studies are displayed as being corrected for total amount excreted in the 24 
hours. These results display the total excretion of the elements in the urine sample. These results 
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provide the most effective information on the urinary excretions of the elements and are regularly 
used in similar studies. 
 
Methods of analysis are detailed in Chapter 2. 
 
3.4.0 Results 
 
This chapter includes all the statistical comparisons between the control and treatment data for the 
24-hour trial. Comparisons were made for the overall group and for males and females separately; 
however, male and female data are only presented within the main text when showing a 
noteworthy difference from the overall group. 
Results are displayed as total amounts excreted and expressed as 24-hour data. 
The group size (n) is equal to 19, 9 male and 10 female. 
 
 
3.4.1 Urinary creatinine and sample volume 
 
Creatinine (Crt) concentrations were measured for each sample in order to correct for 
differences in renal functioning between individuals and to take any dilution effects of the 
urine into consideration. 
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Figure 3.4.1.1: Crt concentration (mM) against sample volume (mL) for control (●) and treatment 
samples, loading (●) and dosing (●) in a 24-hour urine sample. 
  
There was no significant difference between males and females in mean Crt concentrations 
within all protocols; the control protocol gave an average Crt measurement of 4.7mM for males 
and 7.7mM for females (t = 2.87: P = 0.012), the loading treatment gave an average Crt 
measurement of 5.3 mM for males and 4.9mM for females (t = 0.82: P = 0.424) and dosing 
treatment periods gave an average Crt measurement of 4.0 mM for males and 4.4mM for 
females (t = 1.09: P = 0.293). There was also no significant difference between males and 
females in the mean volumes collected within both treatment protocols; the loading protocol 
gave an average volume of 1866mL for males and 1708mL for females (t = -1.1: P = 0.29), and 
the dosing treatment gave an average volume of 1963mL for males and 1811mL for females (t = 
-2.38: P = 0.031) periods (Table 3.4.1.1). 
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Table 3.4.1.1 Mean (SD) Crt concentration (mM) and sample volume (mL) provided in a 24-hour urine 
sample for the control and loading/dosing treatment periods for males (n = 9) and females (n = 10). 
 
 
 
Females revealed a higher Crt in their urine, specifically for the control period, equating to an 
average of 7.7mM (1.7) compared with an average male Crt concentration of 4.7mM (2.7). 
In comparison, urinary volume collected for the 24 hour period was, on average, larger in males 
than females. This difference was significant during the baseline collection period (t = -3.97: P = 
0.001), when an average urine collection was measured at 1705mL in males and 968mL in 
females. During the treatment protocol, the amount of urine collected during the 24 hours was 
comparable, 1867mL (385) collected for males and 1709mL (SD=510) collected for females. 
 
 
 
 
 
 
1709 (509.5)
1810.5 (219.4)
4.9 (1.5)
4 (1.9)
7.7 (1.7)
5.3 (2.0)
4.4 (1.9)
1705 (336.8)
1866.7 (385)
1963.3 (357.9)
Male Female Male Female
4.7 (2.7) 968 (446.5)
Creatinine Concentration                                                                                                                                                    
(mM/24h)
Sample Volume
(mL/24h)
Control
Loading Treatment
Dosing Treatment
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3.4.2 Comparison between the urinary excretion of silicon with the 
volume of silicon rich mineral water consumed 
 
 
The mean amount of all beverages imbibed was significantly increased for the loading treatment 
period compared to the control period for the overall group, increasing from 1527mL (±501mL) 
to 2579mL (±139mL), (t = -5.84, P < 0.001). When considered separately (Table 3.4.2.1), this 
increase was less significant for males (t = -3.61, P = 0.006), presenting an increase of beverages 
consumed from 1918mL (±245) than for females (t = -4.47, P = 0.001), who in the control 
consumed 1175mL (±398mL) and in the loading treatment consumed 2592mL (±154mL). 
Consumption of the mineral water provided approximately half of the total volume of beverages 
consumed in the loading treatment period for the group, total beverages equalled 2579mL 
(±139mL) and each individual consumed on average 1357mL of the provided mineral water 
during this protocol. When completing the mineral water dosing protocol, the mineral water 
provided approximately three quarters of the total volume of beverages as total consumed 
equalled 2112mL (±177mL) and each individual consumed all 1500mL of mineral water during 
this protocol. 
 
3.4.2.1 Total mineral water excreted vs amount of urinary volume and 
silicon excreted 
 
 
Males consumed significantly more than females for both the control (t = 2.53, P = 0.020), and both 
loading and dosing treatment (t = 2.05, P = 0.060) periods, males consumed 1918mL (±245mL), 
2564mL (±128mL) and 2142mL (±229mL) respectively compared to females who consumed 1175mL 
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(±398mL), 2592mL (±154mL) and 2086mL (±119mL) respectively. In addition, males consumed a 
greater volume on average of the mineral water than females (t = 4.31, P = 0.001), 1447mL (±81mL) 
compared to 1437mL (±137mL). 
There was a significant relationship (Figure 3.4.2.1.1) between the urinary excretion of Si with the 
total urine collected for the loading treatment period (r = 0.48, P = 0.022) and dosing treatment 
period (r = 0.44, 0.036), suggesting that a higher urinary volume produces a larger Si excretion. The 
relationship was not significant for the control (r = 0.28, P = 0.200) where no additional Si was being 
added to the diet. 
 
When looking into the difference in Si excretion between the control and combined treatment 
periods (i.e. excretion of Si in the treatment group minus excretion of Si in the control group), this 
overall relationship was considered as insignificant (r = 0.26, P = 0.226) when considering the total 
amount of beverages consumed over the 24-hour periods (i.e. total volume of beverages consumed 
in the treatment group minus total volume of beverages consumed in the control portion of the 
study). 
The amount of Si measured in the provided mineral water was 865±17μmol L-1. There was no 
correlation (r = 0.35, P = 0.099) between the difference in Si excretion (i.e. Si excreted in either 
treatment period minus Si excreted in control period) and the amount of Si present in the 
imbibed mineral water.  
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Table 3.4.2.1.1: Total volume (mL) of all beverages consumed over the 24-hour period  
 
Total refers to the sum of all beverages consumed over the 24-hour period. MW is the volume 
of mineral water consumed; this counts towards the total in the treatment period.  
 
 
 
 
 
 
 
 
Figure 3.4.2.1.1: Amount of Si excreted (μg/24h) against total urine excreted during the 24 hours 
for the control (●) and loading treatment (●) and dose treatment (●) samples. 
 
 
Control
Total MW Total MW Total
1526 (501) 1442 (111) 2579 (139) 1500 2112 (177)
1917 (245) 1447 (81) 2564 (128) 1500 2142 (229)
1175 (398) 1437 (137) 2592 (155) 1500 2086 (119)
Group
Males
Females
Loading treatment Dosing treatment
Volume of beverages consumed (mL) 
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Table 3.4.2.1.2: Percentage of Si consumed as mineral water which equates to the difference in 
Si excretion between the control and treatment period.    
Ref 
Amount of 
silicon 
consumed as 
mineral water 
(μmol) 
Difference in 
silicon 
excretion 
(Loading 
treatment – 
Control, μmol) 
Difference in 
silicon 
excretion 
(Dose 
treatment – 
Control, μmol) 
Percentage of 
mineral water 
which equates to 
the difference in 
silicon - Loading 
Percentage of 
mineral water 
which equates to 
the difference in 
silicon - Dose 
M1 764 215 372 28 43 
M2 865 511 1154 59 133 
M3 865 634 939 73 109 
M4 865 621 882 72 102 
M5 865 665 800 77 93 
M6 865 612 993 71 115 
M7 865 711 993 82 115 
M8 793 223 803 28 93 
M9 761 363 782 48 90 
F1 865 533 751 62 87 
F2 865 91 597 10 69 
F3 865 447 720 52 83 
F4 865 322 607 37 70 
F5 643 499 761 78 88 
F6 724 1160 702 160 81 
F7 865 432 771 50 89 
F8 865 372 1197 43 138 
F9 865 382 1200 44 139 
F10 865 488 657 56 76 
ẍ 831 (64) 488 (232) 825 (215) 59 (31) 95 (25) 
  
ẍ represents the mean values. Pink represents females and blue represents males. 
 
The concentration of Si in the urine collected from the dosing treatment protocol was larger 
than that collected from the loading dosing protocol, equating to 951.1µmol/24hr (±245.8 
µmol/24hr) compared to 614.2 µmol/24hr (253.0 µmol/24hr). This equated to a difference in Si 
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excretion of between 59 ± 31% for the loading treatment and 95± 25% for the dosing period of the 
amount of Si consumed from the mineral water. An elevated Si excretion in the dosing protocol 
was seen for both male and female participants.  
Patient ID F6 was an anomaly to this trend who excreted a much larger amount of Si during the 
loading protocol compared to the dosing protocol, measuring 1160 µmol/24hr and 702 
µmol/24hr respectively, this individual was notably one of the two female patients who didn’t 
consume the suggested volume of mineral water. All remaining participants were shown to 
excrete more Si during the dosing protocol than the loading treatment protocol (Table 
3.4.2.1.2). 
 
3.4.3 Urinary excretion of silicon and aluminium in control and 
treatment periods 
 
 
24-hour collections provide the most reliable information on urinary excretions and were 
collected for 2 consecutive days. One week was allowed between protocols. Data from each 
individual is considered below and presented in concentrations of nmol/24 hr for Al excretion 
and μmol/24 hr for Si excretion. When examined as a group (patient F6 omitted), Al excretion 
correlates positively with Si excretion (r = 0.76) during the loading protocol. This relationship 
indicates statistical significance for the healthy treatment protocol for long term Si consumption as a 
method of removing bioavailable Al (P < 0.001). 
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Silicon 
 
There is a weak positive correlation between the urinary excretion of Si in the control and loading 
treatment data (r = 0.20, P = 0.015). When an individual presents a small urinary Si concentration 
during their baseline, a comparatively small concentration is noticed during the addition of a high 
dose of Si to the diet (Figure 3.4.3.1). This is true for all of the data except for one patient, ID F007 
presenting the largest concentration of Si in their loading treatment compared to a comparatively 
small Si concentration in the baseline quantification, equating to 1160µmol and 724 µmol 
respectively. Removing this outlier produced a stronger correlation between this data set (r = 0.76, P 
= 0.012). When considering the whole group data, correlation was stronger between the control and 
dosing treatment (r = 0.40, P = 0.011). 
The mean excretion of Si during both treatment protocols is significantly higher (t = -5.13, P < 0.001) 
than the control period (Table 3.4.3.1); no individuals excreted more Si prior to drinking the mineral 
water. 
Males excreted significantly more Si than females for the treatment period (t = 2.95, P = 0.008), but 
not for the control (t = 1.30, P = 0.208). 
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Table 3.4.3.1: Mean (SD) urinary excretion of Si (µmol/24hr) for the healthy volunteer study 
population for both loading and dosing treatment protocols (n=7) 
 
 
 
Data presented for the whole study population in figure 3.4.3.2 is a visual representation of the 
difference in Si excretion between the baseline and the loading protocol. This figure shows a 
similarity in this for fifteen out of the nineteen participants. Participant F7 presents a clear peak in 
this data, excreting more Si than other participants. Individuals F2, M2 and M8 excreted a smaller 
difference in Si between the control and treatment periods. 
 
Mean (SD) 125.8 (55.3) 614.2 (253.0) 951.1 (245.8)
140.5 1340.7
140.7 798.0
522.6
628.4
70.1 841.4
111.0 1307.7
502.0
483.2
80.9 841.7
80.0 781.9
580.1
1240.3
70.3 789.9
60.4 667.6
517.2
382.0
170.3 921.6
70.0 667.1
703.5
160.7
80.3 302.8 883.3
61.0 424.0 842.8
210.2 822.6 1202.8
210.7 921.4 1203.4
140.5 761.0 1022.6
140.9 806.1 941.1
F10
150.7 365.2 523.2
230.7 741.4 1384.4
170.2 804.4 1109.2
F4
F5
F6
F7
F8
F9
M7
M8
M9
F1
F2
F3
M1
M2
M3
M4
M5
M6
ID
Si Concentration - Control 
(µmol/24 Hr)
Si Concentration - Loading 
(µmol/24 Hr)
Si Concentration - Dose 
(µmol/24 Hr)
Healthy Volunteer Urine Study                                                                                                                                                                                            
Mean (SD) Si concentration (n=5)
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Figure 3.4.3.1: Urinary excretion comparison of Si (μmol/24h) during control and treatment 
periods. Control vs loading (●) and control vs dosing treatment (●) 
 
 
 
 
 
 
 
 
Fig 3.4.2.2 Difference in Si excretion (μmol/24h) between control and treatment data for each 
individual (loading treatment – control) (n=5). 
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Values collected for the difference in Si excretion between the dosing protocol and the baseline are 
consistently higher than the loading protocol in Figure 3.4.3.2. When visualising this data, it 
represents a similar pattern in that fifteen out of the nineteen participants present a similar 
difference in Si excretion. Patients F9, F10 and M13 excrete a notably higher amount of Si during this 
protocol, while patient M2 presents a much lower excretory value of Si, see Figure 3.4.3.3. 
 
 
 
 
 
 
Fig 3.4.3.3: Difference in Si excretion (μmoles/24h) between control and treatment data for each 
individual (dosing treatment – control) (n=5) 
 
Aluminium 
 
 
The mean excretion of Al during both treatment protocols is significantly higher (t = -4.87, P < 0.001) 
than the control period (Table 3.4.3.2); no individual excreted more Al prior to drinking the mineral 
water. Males excreted significantly more Al than females for the treatment period (t = 3.16, P = 
0.006), and the control (t = 3.84, P = 0.011).  
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Al excretion was highest during the loading protocol. Considering the whole study population, Al 
excretion rose from 934.4nmol/24 hr to 2889.1nmol/24 hr and 2049.6nmol/24 hr during the loading 
treatment and dosing treatment respectively.  
Patient M1 and F6 saw a large increase in Al excretion during the loading protocol, although 
presented a urinary Al excretion similar to that of the baseline amount during the dosing protocol. 
Patient M1 revealed a mean baseline Al urinary concentration of 645.3±34.1nmol/24hr, giving rise to 
a urinary Al concentration of 1602.6±143.7nmol/24hr during Si loading. This value falls back to 
741.6±28.5nmol/24hr during the dosing protocol. 
 
 
Table 3.4.3.2: Mean (SD) urinary excretion of Al (nmol/24hr) for the healthy volunteer study 
population for both loading and dosing treatment protocols (n=7) 
F10 342.8 4240.6 1407.6
Mean (SD) 934.4 (682.8) 2889.1 (1297.1) 2049.6 (1065.6)
F8 467.1 2781.7 2198.5
F9 546.9 3641.3 2000.1
F6 287.5 1684.2 551.5
F7 567.1 3111.4 2762.4
F4 622.5 2762.2 2408.2
F5 360.5 2003.1 1102.4
F2 661.5 1605.1 1271.5
F3 343.0 1647.6 1406.5
M9 392.9 1723.6 1208.6
F1 1047.3 1531.0 1144.4
M7 1944.8 5016.9 2643.5
M8 300.0 960.4 1004.8
M5 1367.6 4652.7 3144.6
M6 1842.0 3702.5 2961.0
M3 2021.6 4551.6 3726.4
M4 1949.1 4527.0 4216.6
645.3 1602.6 741.6
M2 2044.4 3147.4 3042.5
Healthy Volunteer Urine Study                                                                                                                                                                                            
Mean (SD) Al concentration (n=5)
ID
Al Concentration - Control 
(nmol/24 Hr)
Al Concentration - Loading 
(nmol/24 Hr)
Al Concentration - Dose 
(nmol/24 Hr)
M1
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There was a significant positive correlation between the urinary excretion of Al in the control and 
loading treatment (r = 0.5, P < 0.001) as well as control and dosing treatment (r = 0.6, P < 0.001), as 
shown in Figure 3.4.3.4. When an individual presents a small urinary Al concentration during their 
baseline, a comparatively small concentration is noticed during the addition of a high dose of Si to 
the diet. 
 
 
 
Figure 3.4.3.4: Urinary excretion comparison of Al (nmol/24hr) between the control and 
treatment periods. Control vs loading (●) and control vs dosing treatment (●) 
 
Urinary excretion of silicon and aluminium in control and treatment 
periods 
 
 
Urinary excretion of Al and Si differed greatly when a Si rich mineral water was added to the diet of 
nineteen healthy volunteers. The excretion of Si was higher during the dosing protocol, whereas the 
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concentration of Al in urine was higher during the loading protocol. These differences were more 
predominant in males than females. 
 
Table 3.4.3.3: Mean (SD) urinary excretion of Si (µmol/24hr) and Al (nmol/24hr) for the healthy 
volunteer study population for both loading and dosing treatment protocols  
 
 
 
Data for the three protocols are shown in Table 3.4.3.3 with means and deviations for the data 
population shown at the bottom of the table. Comparisons between male and female individual data 
are made later on in chapter 3.  
The variance between the data points is smaller for Si than Al. In the control period, standard 
deviation in Si concentration is 55.3, whereas the deviation between the same data points is 682.8 
Si Al Si Al Si Al
150.7 645.3 365.2 1602.6 523.2 741.6
230.7 2044.4 741.4 3147.4 1384.4 3042.5
170.2 2021.6 804.4 4551.6 1109.2 3726.4
140.5 1949.1 761.0 4527.0 1022.6 4216.6
140.9 1367.6 806.1 4652.7 941.1 3144.6
210.2 1842.0 822.6 3702.5 1202.8 2961.0
210.7 1944.8 921.4 5016.9 1203.4 2643.5
80.3 300.0 302.8 960.4 883.3 1004.8
61.0 392.9 424.0 1723.6 842.8 1208.6
170.3 1047.3 703.5 1531.0 921.6 1144.4
70.0 661.5 160.7 1605.1 667.1 1271.5
70.3 343.0 517.2 1647.6 789.9 1406.5
60.4 622.5 382.0 2762.2 667.6 2408.2
80.9 360.5 580.1 2003.1 841.7 1102.4
80.0 287.5 1240.3 1684.2 781.9 551.5
70.1 567.1 502.0 3111.4 841.4 2762.4
111.0 467.1 483.2 2781.7 1307.7 2198.5
140.5 546.9 522.6 3641.3 1340.7 2000.1
140.7 342.8 628.4 4240.6 798.0 1407.6
125.8 (55.3) 934.4 (682.8) 614.2 (253.0) 2889.1 (1297.1) 951.1 (245.8) 2049.6 (1065.6)
Healthy Volunteer Urine Study                                                                                                                                                                                            
Mean (SD) Si (µmol/24hr) and Al (nmol/24hr) concentration (n=5)
F9
F10
Mean (SD)
Control Loading Treatment Dose Treatment
F3
F4
F5
F6
F7
F8
M6
M7
M8
M9
F1
F2
ID
M1
M2
M3
M4
M5
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for Al. The differences between the standard deviation values for both treatment protocols remains 
similar for Si, at 253.0µmol/24hr and 245.8 µmol/24hr respectively, this variance represents the 
difference in Si handling between individuals. Despite a significantly larger excretion in Al during the 
loading protocol, variability between the data for both loading and dosing protocol does not vary 
largely, equating to 1297.1 nmol/24hr and 1065.5 nmol/24hr respectively. Baseline excretion of Si 
ranged from 60.4-230.7µmol/24hr, this range increases to 365.2-1240.3µmol/24hr during the 
loading protocol and 523.2-1384.4µmol/24hr. This range further highlights the difference in Si 
handling between individuals. This difference may promote a similar affect in Al excretion, which is 
seen in the range of data points seen in urinary Al concentration throughout the three protocols. 
Baseline Al excretion was large and ranged from 287.5-2044.4nmol/24hr, this range increased to 
960.4-5016.9nmol/24hr and 551.5-4216.6nmol/24hr for the loading and dosing treatment protocols 
respectively.  
 
The small variance between Si excretion data points and large deviation between Al excretion data 
points is shown in Figure 3.4.3.5. 
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Table 3.4.3.4: Mean (SD) excretion of Si (μmol/24h) and Al (nmol/24h) in control and treatment 
urine samples for the healthy volunteer group (n = 19). 
 
 
 
 
 
Figure 3.4.3.5 Mean  and standard deviation bars of excreted Si (μmol/24h) and Al 
(nmol/24h) in the control and treatment samples (n=19) 
 
 
 
 
 Urinary excretions in a 24-hour urine sample 
  
Silicon                                            
(μmol/24h) 
Aluminium                                    
(nmol/24h) 
Mean  SD Range Mean  SD Range 
Control 126 55 60-231 967 687 288-2044 
Loading treatment 614 253 161-1240 2814 1292 960-5017 
Dosing treatment 951 246 583-1384 2085 1085 552-4217 
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3.4.4 Gender comparisons 
 
 
When comparing male and female data, increases in Si and Al were significant for both treatment 
protocols. When comparing the amount of Si consumed, the p-value between genders for these 
weeks are below 0.04 (P = 0.038, Pearson) which is consistent with the idea that all patients are 
consuming the same amount of silicon during this time. The excretion of Al is more sporadic and 
p-value between each treatment protocol shows a clear difference and variation between the 
means for loading and dosing (P = 0.56 and P = 0.52, Wilcoxon signed ranked), showing a large 
variation between genders during this treatment period (Table 3.4.4.2). 
 
 Table 3.4.4.1: Mean (SD) excretion of Si (μmol/24h) and Al (nmol/24h) in control and 
treatment urine samples for males (n=9) and females (n=10) in the healthy volunteer group. 
 
 
Differences between gender elemental excretions are smaller for Si than Al. Although males 
consistently excrete more Si and Al in each of the protocols, this difference is more notable for Al 
excretion. During the control protocol, Si excretion was noted to average at 155µmol/24hr while 
Urinary excretions in a 24-hour urine sample 
  
Silicon                                            
(μmol/24h) 
Aluminium                                   
(nmol/24h) 
Male Female Male Female 
Control 155 (58) 99 (39) 1390 (741) 525 (225) 
Loading treatment 661 (230) 572 (277) 3321 (1536) 1501 (956) 
Dosing treatment 1013 (253) 896 (239) 2521 (1244) 1625 (687) 
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this value for females is 99µmol/24hr, this difference is comparably larger for Al excretion during 
the same time period, varying from 1390nmol/24hr for males and 525nmol/24hr for females. 
During the loading protocol, Males excrete more than double the amount of Al than females, 
3321nmol/24 hr compared with 1501nmol/24 hr, despite only showing a slight positive increase 
in Si excretion, 661µmol/24hr compared with 572 µmol/24hr for females. 
These relationships were confirmed with Wilcoxon signed-rank statistical testing. Differences 
between the means were smaller for Si than Al and data was considered statistically similar (P = 
0.08) between males and females for baseline Si excretion, indicating that there is no notable 
difference in the metabolism of Si between genders in a normal population. However, the large 
difference between the means between genders considering Al excretion suggests that there may 
be a difference in Al body burden in this pool of individuals. 
 
Table 3.4.4.2: Summary of Wilcoxon signed-rank - differences between pairs of means of 
excretion for male (n = 9) and female groups (n = 10). 
 
 
 
 
 
 
 
 
0.08 0.37
0.22 0.56
0.27 0.52
Control
Loading
Dosing
Male v Female Healthy Volunteers
Silicon Aluminium
P - Value P - Value
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3.4.5 Urine volume 
 
 
Urinary excretion of Si demonstrated a significant relationship, using Pearson correlation analysis, 
with sample volume for both the control (r = 0.56, P = 0.005), and treatment periods (r = 0.45, P = 
0.030); however, this correlation was not seen in the treatment period when males were examined 
separately (r = 0.04, P = 0.901). 
A significant relationship was highlighted between urinary excretion of Al and sample volume for both 
the control (r = 0.45, P = 0.030), and treatment periods (r = 0.46, P = 0.029); however, no correlation 
was seen when males (Control, r = 0.29, P = 0.414; Treatment, r = 0.43, P = 0.214) and females (Control, 
r = 0.48, P = 0.099; Treatment, r = 0.42, P = 0.156) were considered separately. 
Figure 3.4.5.1: Excretion of Si (μmol/24h) and Al (nmol/24h) in the control and the treatment 
periods, loading and dosing, against sample volume (mL). 
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3.4.5.1 Silicon 
 
Urine volume increased as Si excretion increased within the female population, however, three out of 
the nine males saw a decrease in urine volume correlated with an increase in Si during one of the 
treatment protocols. Patient ID M1 gave a baseline 24 hour urine sample of 1535mL which contained 
150.7µmol Si, while during the dosing treatment protocol the same patient passed 1150mL urine 
during this 24 hour period despite excreting 523.2µmol Si (see Table 3.4.5.1).   
 
Table 3.4.5.1: Mean (SD) urinary excretion of Si (µmol/24hr) total urine volume (mL) for the 
healthy volunteer study population for both loading and dosing treatment protocols  
 
Si Volume Si Volume Si Volume
150.7 1535 365.2 1550 523.2 1150
230.7 1850 741.4 1600 1384.4 2100
170.2 2020 804.4 2150 1109.2 2300
140.5 1950 761.0 2150 1022.6 2400
140.9 1835 806.1 2350 941.1 2050
210.2 1870 822.6 1850 1202.8 2050
210.7 1960 921.4 2300 1203.4 1900
80.3 1145 302.8 1280 883.3 1870
61.0 1180 424.0 1570 842.8 1850
170.3 1300 703.5 2140 921.6 1790
70.0 550 160.7 650 667.1 1600
70.3 1240 517.2 1500 789.9 1900
60.4 575 382.0 1200 667.6 1450
80.9 1490 580.1 2100 841.7 2150
80.0 1300 1240.3 1800 781.9 1760
70.1 610 502.0 1470 841.4 1700
111.0 520 483.2 1980 1307.7 2050
140.5 520 522.6 1900 1340.7 2025
140.7 1575 628.4 2340 798.0 1680
125.8 (55.3) 1317 (541) 614.2 (253.0) 1783 (450) 951.1 (245.8) 1883 (295)Mean (SD)
F5
F6
F7
F8
F9
F10
M8
M9
F1
F2
F3
F4
M2
M3
M4
M5
M6
M7
Healthy Volunteer Urine Study                                                                                                                                                                                            
Mean (SD) Si (µmol/24hr) and Volume (mL) (n=5)
ID
Control Loading Treatment Dose Treatment
M1
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Overall, an increase in urine volume was coupled with an increase in the excretion of Si. A mean 
increase in urine volume from 1317mL in the control period to 1783mL in the loading treatment 
period was twinned with an increase of silicon from 125.8µmol to 614.2 µmol. A larger increase 
still was seen during the dosing protocol, showing an increase in urine volume from 1317mL to 
1883mL correlating with an increase in Si from 125.8µmol to 951.1µmol. This increase was 
consistent between males and females. 
 
Aluminium 
 
Urine volume increased as Al excretion increased within the female population, however, three out 
of the nine males saw a decrease in urine volume correlated with an increase in Al in their urine during 
at least one of the treatment protocols. Patient ID M1 gave a baseline 24 hour urine sample of 1535mL 
which contained 645.3nmol Al, while during the dosing treatment protocol the same patient passed 
1150mL urine during this 24 hour period despite excreting 1602.6nmol Al (see Table 3.4.5.2).   
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Table 3.4.5.1: Mean (SD) urinary excretion of Al (nmol/24hr) total urine volume (mL) for the 
healthy volunteer study population for both loading and dosing treatment protocols 
 
 
 
Overall, an increase in urine volume was coupled with an increase in the excretion of Al. A mean 
increase in urine volume from 1317mL in the control period to 1883mL in the dosing treatment 
correlating with an increase in Al from 934.4nmol to 2049.6nmol. A larger increase still was seen 
during the loading protocol, showing an increase in urine volume from 1317mL to 1783mL, 
Al Volume Al Volume Al Volume
645.3 1535 1602.6 1550 741.6 1150
2044.4 1850 3147.4 1600 3042.5 2100
2021.6 2020 4551.6 2150 3726.4 2300
1949.1 1950 4527.0 2150 4216.6 2400
1367.6 1835 4652.7 2350 3144.6 2050
1842.0 1870 3702.5 1850 2961.0 2050
1944.8 1960 5016.9 2300 2643.5 1900
300.0 1145 960.4 1280 1004.8 1870
392.9 1180 1723.6 1570 1208.6 1850
1047.3 1300 1531.0 2140 1144.4 1790
661.5 550 1605.1 650 1271.5 1600
343.0 1240 1647.6 1500 1406.5 1900
622.5 575 2762.2 1200 2408.2 1450
360.5 1490 2003.1 2100 1102.4 2150
287.5 1300 1684.2 1800 551.5 1760
567.1 610 3111.4 1470 2762.4 1700
467.1 520 2781.7 1980 2198.5 2050
546.9 520 3641.3 1900 2000.1 2025
342.8 1575 4240.6 2340 1407.6 1680
934.4 (682.8) 1317 (541) 2889.1 (1297.1) 1783 (450) 2049.6 (1065.6) 1883 (295)
F8
F9
F10
Mean (SD)
F2
F3
F4
F5
F6
F7
M5
M6
M7
M8
M9
F1
Healthy Volunteer Urine Study                                                                                                                                                                                            
Mean (SD) Al (nmol/24hr) and Volume (mL) (n=5)
ID
Control Loading Treatment Dose Treatment
M1
M2
M3
M4
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twinned with an increase of silicon from 934.4nmol to 2889.1 nmol. This increase was consistent 
between males and females. 
3.4.6 Comparisons between the urinary excretions of silicon and 
aluminium 
Relationships between the excretions of Si with the metal Al was explored to determine variability 
in handling between individuals. Correlations between the compounds were also considered. The 
data showed that there was no significant correlation between Al excretion (Fig 3.4.6.1) with Si 
excretion for the control and both treatment periods. The strongest correlation was seen in the 
control period (r = 0.68), but as amounts of both elements increased, the strength of the relationship 
between them decreased. These differences highlight the variance in individual biochemistry. 
 
Figure 3.4.6.1: Comparative correlation of the excretion of Al (nmol/24h) against excretion of Si 
(μmol/24h) during the three study protocols 
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Table 3.4.6.1: Pearson correlation analysis between the urinary excretions of Al (nmol/24h) with 
the excretion of Si (μmol/24h). 
 
Relationship with silicon 
  
Aluminium 
r Value p Value 
Control 0.65 0.64 
Loading treatment 0.21 0.69 
Dose treatment 0.4 0.64 
 
 
 
3.4.7 Baseline aluminium excretion compared to metadata. 
 
 
The average consumption of beverages during the control period are presented in Figure 3.4.7.1 
Bottled water (neat or with cordial) and coffee make up the majority of beverages consumed (18% 
and 18% respectively). Thirteen out of nineteen individuals consumed tea during the control period. 
There was a very weak positive relationship (r = 0.02; P = 0.77) between the amount of tea consumed 
with Al excretion (Figure 3.4.7.2). Nine out of nineteen individuals consumed bottled water during the 
control period. Four out of nine males consumed beer during the control period, as discussed in 
chapter 1, beer and some bottled waters of which are potentially rich sources of Si.  
 
There was no significant relationship (r = 0.21; P = 0.605) between body mass index (BMI) with Al 
excretion (Figure 3.4.7.2). 
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Figure 3.4.7.1: Average consumption of beverages consumed during the control 24 hour period 
(n = 19) 
 
 
 
 
 
 
 
 
Figure 3.4.7.2 Excretion of Al at baseline against volume of tea consumed by each healthy volunteer 
(n=19) 
 
125 | P a g e  
 
Most of the healthy volunteers were of a normal BMI, ranging from 20-25. Figure 3.4.7.3 shows how 
the individuals with a larger BMI differ from the trend and excrete an Al concentration either side of 
the general trend. The majority of individuals with a normal BMI excrete a lower concentration of Al.  
 
 
 
 
 
 
 
 
 
 
Figure 3.4.7.3 Excretion of Al baseline compared with the body mass index score calculated for each 
participant. 
 
 
3.5 Summary of results for healthy individuals  
 
 
• Creatinine concentration was negatively correlated with sample volume (Section 3.4.2.).  
• The difference in Si excretion between the loading treatment and control periods corresponded 
to 59± 31% of the amount of Si consumed as the mineral water. (Section 3.4.2).  
•The difference in Si excretion between the loading treatment and control periods corresponded 
to 95± 25% of the amount of Si consumed as the mineral water. (Section 3.4.2). 
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• Urinary excretions of Si and Al are significantly increased following the consumption of the 
mineral water (Section 3.4.3).  
• Si and Al showed weak positive correlation with sample volume (Section 3.4.5).  
•Weak positive correlation was demonstrated between Si and Al excretion (Section 3.4.6) 
• No correlation was noted between BMI and urinary excretion of Al and Si during the control 
protocol (Section 3.4.7) 
 
3.6 Discussion of results 
 
This research was undertaken with the aim of elucidating the utilisation of a commercial silicic acid-
rich mineral water as a non-invasive method of reducing Al body burden, when used as part of an 
individual’s regular diet. The primary objectives were to investigate Si handling and the consequent 
effects on urinary Al excretion. 
Despite extensive evidence suggesting a beneficial role of Si in biota, there is very little reliable 
information on Si handling in humans, particularly regarding healthy individuals. In order to determine 
whether there is any change in Si handling in disease it is first important to elucidate Si handling in 
‘normal’ individuals. Thorough investigations concerning healthy individuals were therefore 
performed, using three different protocols. As Si is known to be rapidly absorbed and excreted 
(Popplewell et al. 1998), it was considered that a period of one week between each protocol would 
be sufficient to minimize any influence on Si excretion between each study. However, it is likely that 
Al body burden would have been influenced, if not lowered, after each protocol. 
Al intake in the diet is approximately 20 mg day-1 (Pennington & Jones, 1989); only 0.1% of this is 
absorbed (Day et al. 1991), meaning that around 140 μg of Al could be added to Al body burden from 
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dietary exposure each week. With this in mind, it is unlikely that the time periods between each 
different protocol were sufficient to replenish the Al body burden removed from the preceding Si 
dose. 
However, as each protocol consisted of a control and treatment period in which the urinary excretions 
were compared, the overall effect on Al excretion would not have been negated by the preceding 
protocols. 
 
Comparing urinary volume and creatinine concentration 
 
24-hour collections provide the most reliable information on urinary excretions; however, 
creatinine corrected measurements were also documented. The negative correlation between 
creatinine concentration and sample volume (Figure 3.4.1.1) verifies that creatinine 
concentration provides an acceptable indication of dilution effects. The mean creatinine 
concentration at baseline (5.2 ± 2.5 mM) and volume of urine produced (1687 ± 542 mL) 
correlates well with the literature values (Table 7.1), confirming that the healthy participants had 
normal kidney function. A high level may mean that the kidneys are not working as they should. 
The amount of creatinine in the blood depends partly on the amount of muscle tissue present in 
the body. Men generally have higher creatinine levels than women. Although, in this study, Crt 
values were higher throughout the study for females than males (Table 3.4.1.1).  
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Silicon handling was variable between individuals  
 
Urinary excretion of Si was variable between individuals, for example, the range of urinary Si at 
baseline was 60.4-230.7µmol/24hr (Table 3.4.5.1). As urinary Si is a good marker of absorbed Si, thus 
dietary differences between individuals would have contributed to these variations (Jugdaohsingh et 
al. 2002; Sripanyakorn et al. 2009).  
Overall, an increase in urine volume was coupled with an increase in the excretion of Si. A mean 
increase in urine volume in the control period to the loading treatment period was twinned with 
an increase of Si in the urine. This relationship was further strengthened during the dosing 
protocol, showing an even greater increase in urine volume correlating with an increase in Si 
excretion. An increase that was consistent throughout the study between males and females.  
It must be noted that overall fluid consumption increased for each volunteer between the control 
and either treatment protocol. To improve the outcome of this investigation, the amount of fluids 
consumed each day must be kept constant to minimise variability. 
 
The effect of the mineral water on urinary excretions 
 
Consumption of the mineral water significantly increased the amount of Si excreted in the urine (P < 
0.001, Section 3.4.3), this was coincident with increased Al excretion (P < 0.001). This signifies that 
the consumption of silicic acid-rich mineral water successfully enhanced the urinary excretion of 
Al in healthy individuals. 
The mean amount of Al excreted increased for all healthy volunteers after the addition of the Si 
rich mineral water. Furthermore, Al excretion was highest during the loading protocol than the 
dosing protocol, while Si excretion was consistently larger during the dosing protocol. Considering the 
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whole study population, Al excretion was larger in males, however females saw a notable increase in 
each treatment period (Table 3.4.3.3). Co-excretion of Si and Al was apparent in this data; the 
relationship between Si and Al along with the rapid excretion of Si demonstrates that Al is 
excreted as a bolus following the consumption of the mineral water. 
 
Conclusions 
 
To summarise the healthy individual study; consumption of the mineral water significantly increased 
the urinary excretions of Si and Al. Si and Al were rapidly excreted as a bolus and treatment over a 
long term period may result in reduced Al body burden. 
Baseline 24h urinary excretions of Si and Al were compared with literature values (Table 7.2). With 
the exceptions of the studies by Roberts et al. (1998) and Kazi et al. (2008), who used large study 
populations, the group sizes used in the other studies were considerably lower. These differences 
would have contributed to the high variations seen in urinary excretions between the literature 
sources. For instance, the urinary excretion of Al appears to be higher compared to other studies using 
a similar age range (Morie et al. 1996; Reffitt et al. 1999), however, these studies had population sizes 
of 6 and 5 respectively. In addition, the low excretion of Al in the study by Reffitt et al. (1999) could 
be attributed to participant fasting. 
The higher excretion of Al seen within the present study could also be a reflection of a university 
student’s diet, typically high in processed foods and alcohol (Devine et al. 2006), these food are 
generally high in Al (Pennington & Jones, 1989) and alcohol is noted to increase gut permeability 
(Barchfeld & Deamer, 1988), possibly enhancing Al uptake. Other dietary factors, such as citrate 
130 | P a g e  
 
(Taylor et al. 1998) also effects the absorption of Al, therefore, an individual who regularly 
consumes fruit juice may have an increased absorption of Al. 
The majority of individuals in the present study were also regular tea drinkers 13/19. Tea is a 
diuretic which contains high levels of Al (Forster et al. 1995). Even though the bioavailability of Al 
in tea is considered to be low (Powell et al. 1993; Gardner & Gunn, 1995), regular consumption 
could be linked to an increased absorption and to the high amount of Al present (Nieboer et al. 
1995).  
In the study by Reffitt et al. (1999), the participants fasted in order to investigate whether silicic 
acid promotes the urinary excretion of endogenous Al. Their results demonstrated no significant 
change in Al excretion; however, considering the young age of the group (and the small 
population size) it is unlikely that Al accumulation was particularly high and so any effects on 
removing Al from body stores would have been minimal. 
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Chapter 4 - Silicic acid rich mineral water accompanied by exercise to 
reduce body burden of aluminium via sweat excretion in healthy 
volunteers. 
 
 
This chapter includes all the statistical comparisons between the control and treatment data for 
the 30 minute exercise trial. Comparisons were made for the overall group and for males and 
females separately. 
4.1.0 Aims 
 
The aim of this chapter is to investigate if regular drinking of a silicon-rich mineral water can facilitate 
the removal of Al from the body of healthy individuals in sweat. 
 
4.2.0 Introduction 
 
There are few data to describe human excretion of systemic aluminium and almost no reliable data 
which relate to aluminium in sweat, although recent data has suggested that perspiration might be a 
significant route of excretion of systemic aluminium (Exley, 2014). 
Certain commercial mineral waters, provide a good source of silicic acid and could potentially be 
utilised as a preventative measure against the accumulation of aluminium within the body. This could 
be exploited in young, healthy individuals, which could in turn reduce the rate and slow the 
progression of aluminium related disorders, including multiple sclerosis, Alzheimer’s disease and 
Parkinson’s disease. However, the role of silicon in drinking water and how humans handle this silicon 
has not been widely studied, particularly with respect to healthy individuals. 
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The purpose of this work was to elucidate the effect of drinking silicic acid-rich mineral waters on the 
excretion of silicon in the sweat of healthy individuals. The main aim of this research was to investigate 
the influence of a silicic acid-rich mineral water, as a non-invasive therapy, on the excretion of 
aluminium in sweat. Data for each individual are provided in Appendix 3. 
 
4.3.0 Methodology 
 
Details are provided for the specific methods involved during the collection of sweat during a thirty 
minute exercise protocol. Further details regarding sample analysis of Al and Si are presented in 
Chapter 2. 
 
4.3.1 Method blank material analysis 
 
It was paramount to design a sweat collection apparatus that would be effective in absorbing as much 
sweat as possible during a 30 minute duration of exercise, would be comfortable for the healthy 
volunteers and that wouldn’t produce any contamination to the final eluate. 
In previous methods, sweat was collected using measured squares of Whatman’s 541 hardened 
ashless filter paper. When testing materials for their suitability to this study, it was seen that the filter 
paper resulted in a significant contamination of Si and therefore wasn’t suitable for this investigation, 
of which the accurate measurement of silicon was paramount. Other materials were tested with 
solutions of known Al and Si concentrations, to determine contamination level and leachability of 
these elements into the centrifuged eluate. A summary of these results are provided in Table 4.3.1.1. 
Images of the materials tested in addition to the filter paper are taken from Lennard Jones 
Laboratories at Keele University and shown in Figure 4.3.1.1. 
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Figure 4.3.1.1 Materials analysed for Al and Si contamination for use during the sweat collection 
program.1) Cotton wool, 2) Dressing 3) Foam armpit pad 
A 5mM solution of citric acid was used due to its known ability to bind Al and so potential to leach Al 
from the material being tested. Table 4.3.1.1 shows how larger amounts of Al were drawn out of the 
materials when immersed with citric acid; an example being filter paper where 6.2µg/L was quantified 
in the citric acid eluate compared with 1.2 µg/L being quantified in the eluate of the UPW test. This is 
important when considering the absorption of sweat, and how sweat may leach Al from the material. 
Al ‘hiding’ in the material may be drawn out with the eluate, giving a falsely strong signal. 1mL of each 
solution was added to the materials prior to centrifuging. The solutions drawn out of the material 
were diluted 1:1, although dilution corrections were made for this analysis. 
 
Table 4.3.1.1 Comparative summary of materials tested for elemental contamination (n=18) 
 
 
Al Si Al Si Al Si Al Si
Solutions Alone 0.0034 0.012 0.022 0.011 99.82 0.065 0.017 99.981
Filterpaper 1.321 4.533 6.2 4.889 104.53 4.341 1.209 103.618
Cotton wool 0.809 1.244 4.218 3.042 103.56 1.206 0.754 102.312
Foam 0.012 0.026 0.508 0.278 100.52 0.038 0.018 100.192
Dressing 0.112 0.098 0.708 0.498 101.27 0.174 0.154 101.78
UPW 5mM Citric Acid 100µg/L Al 100µg/L Si
 Neat contamination µg/L (SD)
ID
% % 
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The foam material, cut from an armpit sweat collection pad, provided the smallest contamination 
values, see Table 4.3.1.1, and this result was comparable to the control metadata (P = 0.011, R=0.96, 
Pearson) so was therefore selected for the investigation. Method blanks, using this foam material, 
were immersed in 1mL UPW alongside each experiment and treated in the same manner to the 
samples. This control was treated in the same manner as the samples and subjected to the microwave 
digestion program (details of this are given in Chapter 2) to establish the final level of contamination 
that should be considered when processing the experimental data. This value was calculated to be 
57ng/digest (n=50) for aluminium and 92ng/digest for silicon (n=50). These values were subtracted 
from each sweat sample before the aluminium and content of the sweat samples were analysed.  
 
3.4.2 Protocol 
 
Nineteen participants, 9 male and 10 female (age range 19–34) were recruited from the student 
population at Keele University and ethical approval was obtained from the University’s Life 
Sciences Ethical Review Body (details of which are provided in the appendix). All participants were 
self-assessed as healthy and agreed to partake in a mild exercise program as part of the procedure 
for collecting the sweat samples.  
 
Foam pads, taken from an armpit sweat collection apparatus were selected as they delivered a 
good absorbency and minimal aluminium and silicon contamination. Pads were soaked in 5% HCl 
for 2 hours, ultra-pure water for 24 hours, then placed in a drying oven overnight before use. Prior 
to the exercise protocol, the upper back was cleaned using a pad immersed in 100% ethanol, then 
six pads were transferred to the upper back of each individual, covered with a plastic film and 
secured with an adhesive medical tape to prevent any allergic reaction to adhesives. The 
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individual was then instructed to complete a total of thirty minutes cycling on an exercise bike, 
including five minutes initial fast pace cycling, twenty minutes moderate paced cycling and a final 
five minutes fast paced cycling. Once this program was completed, the pads were transferred to 
7mL centrifuge tubes and span down at 6000RPM for 6 minutes to extract the volume of sweat 
collected in the material to the bottom of the tube, this series of steps is shown in Figure 4.3.2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2.1 Sweat collection apparatus and exercise protocol 
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Figure 4.3.2.2: Removing sweat from the collection pad 
 
The only difference between the control and treatment protocols was the addition of the Si rich 
mineral water one hour prior to the exercise period. Each protocol was repeated three times for 
each healthy volunteer. 
 
Concentrations of aluminium and silicon in collected sweat were adjusted to take account of the 
volume of sweat produced by men (1342 mL/24 h) and women (712 mL/24 h) in this age range 
(Manz et al, 2012).  
 
The aluminium content of sweat was measured in 19 healthy volunteers (9 male and 10 female) 
following 30 minutes of mild exercise, with and without the addition of theSi rich mineral water, 
hereafter referred to as the control and treatment period. Research has strongly suggested that 
perspiration is the major route of excretion of systemic aluminium in humans (Exley et al 2013). 
The amount of Si in the Spritzer mineral water provided was determined to be 26.1mg/L 
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The mean aluminium content of method blanks equated to a contamination level of 57 ng/digest 
(mean±1.654 SD) and this value was subtracted from each sweat sample before the aluminium 
content of sweat samples were calculated.  
The volumes of sweat collected using this method ranged from 0.3 to 1.4 mL. Method blanks which 
consisted of the same squares of prepared foam material to which 1 mL of ultrapure water had been 
added were centrifuged and the solution extracted was collected in acid-washed centrifuge tubes and 
frozen prior to analysis. These method blanks were estimates of contamination by extraneous 
aluminium of the procedure used for collecting and processing the sweat.  
 
 
4.4.0 Results 
 
This chapter includes all the statistical comparisons between the control and treatment data for the 
controlled exercise experiments. Comparisons were made for the overall group and for males and 
females separately; however, male and female data are only presented within the main text when 
showing a noteworthy difference from the overall group. 
Results are displayed as amounts excreted per L-1 and extrapolated for literature values of sweat 
production for males and females per 24 hours (Manz et al, 2012). 
The group size (n) is equal to 19, 9 male and 10 female. 
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4.4.1 Sweat Volume 
 
 
The amount of sweat collected by the foam pad material is representative of the amount of sweat 
produced during the 30 minute exercise period. In general, Males excreted more sweat than females 
during this time. When comparing the data as a whole, the total sweat volume from men was around 
double that of females, for the control period gaining total volumes (n=6) of 8.82mL (±1.91mL) and 
3.96mL (±1.42mL) for the control and treatment period respectively.  
Sweat production was slightly higher in data collected post Si rich mineral water consumption than in 
the control. In the control period, females excreted an average total volume of 3.96mL, compared to 
a total volume of 4.5mL (±1.77mL) in the treatment period. This relationship was seen for male 
participants, during the control, a total volume of 8.82mL was collected, while in the treatment period, 
this value increased to 9.29mL (±1.81). 
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Table 4.4.1.1: Collection volume average (men and women) including individual sweat collection pad 
total as well as combining all six sweat collection pad volumes (n=3) 
 
 
 
Males had a higher variance in their data for sweat volume; in the control period, total volumes were 
6.04-11.36mL, resulting in a difference of 5.32mL, while for females, sweat volumes during the control 
period were measured of 1.99-6.24mL, a range of 4.25mL. Although, females had a greater variance 
in their sweat volume during the treatment protocol; measured at 2.64-8.44mL, a difference of 5.8mL, 
while for males, sweat volumes during the treatment period were measured of 6.42-11.59mL, a 
difference of 5.17mL. 
 
Mean total collected Mean Individual Volume Mean total collected Mean Individual Volume
F1 5.62 0.94 (0.07) 5.87 0.98 (0.11)
F2 2.63 0.44 (0.04) 3.02 0.5 (0.04)
F3 3.76 0.63 (0.03) 4.29 0.72 (0.06)
F4 2.66 0.44 (0.04) 3.40 0.57 (0.03)
F5 5.15 0.86 (0.05) 5.82 0.97 (0.06)
F6 3.31 0.55 (0.03) 3.32 0.5 (0.03)
F7 6.24 1.04 (0.04) 8.44 1.41 (0.04)
F8 1.99 0.33 (0.04) 2.64 0.44 (0.03)
F9 3.34 0.56 (0.03) 4.12 0.69 (0.05)
F10 4.85 0.81 (0.02) 5.42 0.9 (0.02)
Mean 3.96 (1.42) 0.66 (0.24) 4.5 (1.77) 0.77 (0.3)
M1 7.94 1.32 (0.09) 8.96 1.49 (0.06)
M2 11.01 1.84 (0.06) 11.35 1.89 (0.05)
M3 7.5 1.25 (0.06) 8.23 1.37 (0.03)
M4 6.04 1.01 (0.08) 6.42 1.07 (0.03)
M5 6.69 1.12 (0.04) 7.31 1.22 (0.03)
M6 11.36 1.89 (0.07) 11.59 1.93 (0.04)
M7 9.79 1.63 (0.04) 10.23 1.71 (0.05)
M8 8.69 1.45 (0.04) 8.77 1.46 (0.04)
M9 10.33 1.72 (0.06) 10.71 1.79 (0.04)
Mean 8.82 (1.91) 1.47 (0.32) 9.29 (1.81) 1.55 (0.3)
ID
Control Treatment
Volume of sweat collected mL (SD)
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4.4.2 The effect of a Si rich mineral water on Si excretion in sweat 
 
 
During the baseline, Si excretion equated to a mean of 748 µg/L (±140 µg/L) when considering the 
whole group, while during the treatment protocol, this mean increased to 1660 µg/L (±303 µg/L). In 
the control period, Si concentration in sweat varied from 576-1050µg/L between the study population, 
this value increased to 1110-2327µg/L during the treatment protocol. The smallest increase between 
control and treatment period was seen in individual M3, where the sweat Si content increased from 
874 µg/L to 1281µg/L after the consumption of the mineral water (Table 4.4.2.1). 
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Table 4.4.2.1 Mean (SD) content of Si (µg/L)  in sweat collected and measured after 30 minutes of 
mild exercise for both treatment and control patient data (n=6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mean amount of Si excreted in sweat is higher for all study participants during the treatment 
protocol than the baseline. Males excreted statistically similar amounts of Si to females during the 
control period (r = 0.81, P = 0.009 Pearson Correlation analysis used for comparing means), presenting 
mean sweat Si concentrations of 828 µg/L (±153 µg/L) and 676µg/L (±80 µg/L) respectively. 
ID [Si] Sweat control (µg/L) [Si] Sweat treatment (µg/L)
F1 812 (170) 1466 (172)
F2 647 (8) 1609 (23)
F3 601 (9) 1332 (72)
F4 626 (27) 1683 (113)
F5 576 (5) 1476 (22)
F6 668 (37) 1612 (56)
F7 616 (12) 1110 (17)
F8 732 (87) 1634 (323)
F9 787 (57) 1778 (18)
F10 691 (9) 1938 (17)
M1 944 (31) 1661 (18)
M2 1050 (10) 2167 (28)
M3 874 (22) 1281 (35)
M4 743 (34) 1870 (80)
M5 810 (25) 1348 (52)
M6 783 (20) 2327 (73)
M7 994 (15) 1941 (5)
M8 578 (31) 1588 (28)
M9 674 (17) 1726 (41)
Mean (SD) 748 (140) 1660 (303)
Excretion of Si in sweat 
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Concentrations of Si in sweat during the treatment protocol indicated little variance between males 
and females (r = 0.69, P = 0.013 Pearson Correlation analysis) equating to 1768 µg/L and 1564 µg/L 
respectively.  
 
Table 4.4.2.2: Mean (SD) content of Si(µg/L)  in sweat collected and measured after 30 minutes of 
mild exercise for males in both treatment and control patient data (n=6) 
 
 
 
 
 
 
 
The variance seen between male and females in regard to Si excretion in sweat was relatively small. 
Although, this variance was larger during the treatment period than the control period, for males, the 
range in concentrations was 1281 µg/L to 2327 µg/L, and for females, this range was noted at 1110 
µg/L to 1938 µg/L. The SD value increased for each gender during the treatment people, suggesting 
higher variability within the data, increasing from 153 to 333 in males (Table 4.4.2.2), and 80 to 232 in 
females (Table 4.4.2.3). This larger variation in treatment protocol Si excretion is consistent 
throughout the healthy volunteer studies and can be contributed to individual biochemistry. 
 
ID [Si] Sweat control (µg/L) [Si] Sweat treatment (µg/L)
M1 944 (31) 1661 (18)
M2 1050 (10) 2167 (28)
M3 874 (22) 1281 (35)
M4 743 (34) 1870 (80)
M5 810 (25) 1348 (52)
M6 783 (20) 2327 (73)
M7 994 (15) 1941 (5)
M8 578 (31) 1588 (28)
M9 674 (17) 1726 (41)
Mean (SD) 828 (153) 1768 (333)
Excretion of Si in sweat in males
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Table 4.4.2.3: Mean (SD) content of Si (µg/L)  in sweat collected and measured after 30 minutes of 
mild exercise for males in both treatment and control patient data (n=6) 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3 The effect of a Si rich mineral water on Al excretion in sweat 
 
The mean amount of Al excreted in sweat is higher for all study participants during the treatment 
protocol than the baseline. Males excreted significantly more Al than females for the treatment period 
(t = 3.26, P = 0.007), presenting mean sweat Al concentrations of 1208 µg/L (±433 µg/L) and 834 µg/L 
(±334 µg/L) respectively. Contrary to this, baseline sweat concentrations did not show large variance 
between males and female (t = 1.07, P = 0.46), equating to 341 µg/L and 353 µg/L respectively. 
An increase in sweat Al concentration was seen for all study participants during the treatment protocol 
however, this increase was more predominant in some members of the study population. The sweat 
of individual M2 contained 72 µg/L, the lowest concentration of Al of all study participants, although, 
ID [Si] Sweat control (µg/L) [Si] Sweat treatment (µg/L)
F1 812 (170) 1466 (172)
F2 647 (8) 1609 (23)
F3 601 (9) 1332 (72)
F4 626 (27) 1683 (113)
F5 576 (5) 1476 (22)
F6 668 (37) 1612 (56)
F7 616 (12) 1110 (17)
F8 732 (87) 1634 (323)
F9 787 (57) 1778 (18)
F10 691 (9) 1938 (17)
Mean (SD) 676 (80) 1564 (232)
Excretion of Si in sweat in females
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presented the largest increase in sweat Al content after consumption of a Si rich mineral water, 
increasing to 1030 µg/L. 
In the control period, Al concentration in sweat varied from 71-574 µg/L between the study 
population, this value increased to 381-1677 µg/L during the treatment protocol. The smallest 
increase between control and treatment period was seen in individual F2, where the seat Al content 
increased from 217 µg/L to 381µg/L after the consumption of the mineral water. 
 
Table 4.4.3.1 Mean (SD) content of Al (µg/L)  in sweat collected and measured after 30 minutes of 
mild exercise for both treatment and control patient data (n=6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ID [Al] Sweat control (µg/L) [Al] Sweat treatment (µg/L)
F1 467 (96) 1184 (169)
F2 217 (11) 381 (33)
F3 270 (10) 1081 (55)
F4 255 (17) 986 (20)
F5 187 (9) 619 (13)
F6 300 (16) 424 (42)
F7 266 (57 427 (29)
F8 520 (120) 1035 (131)
F9 585 (8) 994 (51)
F10 461 (9) 1215 (85)
M1 444 (88) 772 (15)
M2 71 (4) 1030 (42)
M3 526 (6) 1589 (113)
M4 574 (26) 1677 (28)
M5 464 (12) 1666 (33)
M6 183 (36) 1276 (87)
M7 152 (57) 1536 (88)
M8 400 (31) 690 (18)
M9 255 (34) 639 (25)
Mean (SD) 347 (156) 1012 (419)
Excretion of Al in sweat 
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As discussed earlier in this section, the excretion of Al in sweat is significantly higher in males than 
females throughout the treatment protocol.  
Table 4.4.3.2: Mean (SD) content of Al (µg/L)  in sweat collected and measured after 30 minutes of 
mild exercise for males in both treatment and control patient data (n=6) 
 
 
 
 
 
 
 
 
 
Table 4.4.3.3: Mean (SD) content of Al (µg/L)  in sweat collected and measured after 30 minutes of 
mild exercise for females in both treatment and control patient data (n=6) 
 
  
 
 
 
 
 
 
 
 
ID [Al] Sweat control (µg/L) [Al] Sweat treatment (µg/L)
F1 467 (96) 1184 (169)
F2 217 (11) 381 (33)
F3 270 (10) 1081 (55)
F4 255 (17) 986 (20)
F5 187 (9) 619 (13)
F6 300 (16) 424 (42)
F7 266 (57 427 (29)
F8 520 (120) 1035 (131)
F9 585 (8) 994 (51)
F10 461 (9) 1215 (85)
Mean (SD) 353 (141) 835 (334)
Excretion of Al in sweat in females
ID [Al] Sweat control (µg/L) [Al] Sweat treatment (µg/L)
M1 444 (88) 772 (15)
M2 71 (4) 1030 (42)
M3 526 (6) 1589 (113)
M4 574 (26) 1677 (28)
M5 464 (12) 1666 (33)
M6 183 (36) 1276 (87)
M7 152 (57) 1536 (88)
M8 400 (31) 690 (18)
M9 255 (34) 639 (25)
Mean (SD) 341 (245) 1208 (433)
Excretion of Al in sweat in males
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The variance in data is smaller for females than males, in both the control period at 141 µg/L and 245 
µg/L respectively, and the treatment period, at 334 µg/L and 433 µg/L . Al excretion doubled in 
participant F8, increasing from 520 µg/L to 1035 µg/L, while Al excretion quadrupled in participant F3, 
who had a baseline Al sweat excretion of 270 µg/L which rose to 1081 µg/L post Si rich mineral water 
consumption. 
 
Table 4.4.3.4 Mean (SD) content of Al (µg/L) and (µg/L) Si in sweat collected and measured after 30 
minutes of mild exercise for both treatment and control patient data (n=6) 
 
 
 
4.4.4 Comparing the study population 
 
Elemental sweat excretions were comparable within the group, with low variance between the 
collated data. Excretions of Si and Al during the control period were 748 μg/L (±140 μg/L) and 347 
ID Age [Al] Sweat control ( µg/L) [Si] Sweat control (µg/L) [Al] Sweat treatment ( µg/L) [Si] Sweat treatment (µg/L)
F1 24 467 (96) 812 (170) 1184 (169) 1466 (172)
F2 25 217 (11) 647 (8) 381 (33) 1609 (23)
F3 19 270 (10) 601 (9) 1081 (55) 1332 (72)
F4 20 255 (17) 626 (27) 986 (20) 1683 (113)
F5 24 187 (9) 576 (5) 619 (13) 1476 (22)
F6 23 300 (16) 668 (37) 424 (42) 1612 (56)
F7 18 266 (57 616 (12) 427 (29) 1110 (17)
F8 25 520 (120) 732 (87) 1035 (131) 1634 (323)
F9 20 585 (8) 787 (57) 994 (51) 1778 (18)
F10 22 461 (9) 691 (9) 1215 (85) 1938 (17)
M1 27 444 (88) 944 (31) 772 (15) 1661 (18)
M2 34 71 (4) 1050 (10) 1030 (42) 2167 (28)
M3 26 526 (6) 874 (22) 1589 (113) 1281 (35)
M4 24 574 (26) 743 (34) 1677 (28) 1870 (80)
M5 21 464 (12) 810 (25) 1666 (33) 1348 (52)
M6 28 183 (36) 783 (20) 1276 (87) 2327 (73)
M7 21 152 (57) 994 (15) 1536 (88) 1941 (5)
M8 29 400 (31) 578 (31) 690 (18) 1588 (28)
M9 25 255 (34) 674 (17) 639 (25) 1726 (41)
Excretion of Al and Si in sweat 
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μg/L (±156 μg/L) respectively, while during the treatment period, these values were shown to 
increase to 1660 μg/L (±103) and 1012 μg/L (±419) respectively (Table 4.4.4.1). 
 
Table 4.4.4.1: Mean (SD) and median sweat concentrations of Si (μg/L) and Al (μg/L) for patients 
(n = 19) 
 
 
 
 
When comparing the relevance of these means within the study population, a t-test was performed 
to establish the distribution of this data.  This test revealed that the means between the control were 
statistically different for Al (t = 1.52, p = 0.08) and Si (t = 1.22, p = 0.01), this difference was even more 
notable during the treatment period for Al (t = 2.45, p < 0.001) and Si (t = 3.75, p < 0.001) are 
statistically different, highlighting that Si and Al biochemistry varies significantly between individuals.   
 
 
 
 
 
 
Control Treatment Control Treatment
Silicon (µg/L) Aluminium (µg/L)
Group 747.6 (140.4) 1660.3 (303.2) 347.2 (156.0) 1011.5 (419.4)
Mean (SD) elemental sweat concentration
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Table 4.4.4.2: Summary of t-Test for paired means - differences in the urinary excretion of Al  
and Si in control and treatment protocols in the healthy volunteer population (n=19) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
The One-way ANOVA statistical testing (Table 4.4.4.3) revealed that data was significant (P < 
0.001) for all nineteen healthy volunteers for Al and Si between control exercise period and 
treatment exercise period for the study group.  
  
t-Test: Paired Two Sample for Means                  
Aluminium (n=19)   
  
Function Control Treatment 
t Stat 1.52 2.45 
P one-tail 0.08 3.65E-05 
t Crit one-tail  1.71 1.91 
P two-tail 0.15 7.29E-05 
t Crit two-tail 2.17 2.23 
Pearson Correlation 0.68 0.93 
      
  
t-Test: Paired Two Sample for Means                                    
Silicon (n=19)   
  
Function Control Treatment 
t Stat 1.22 3.79 
P one-tail 0.0100 0.00 
t Crit one-tail  0.97 2.14 
P two-tail 0.0200 0.00 
t Crit two-tail 1.07 3.45 
Pearson Correlation 0.78 0.96 
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Table 4.4.4.3 Summary of One-way ANOVA - differences in the urinary excretion of Si (μg/L) and 
Al (ug/L) between the control and treatment period of the volunteer group. 
 
 
Means within the data displayed significance when comparing the F crit and F values. F – crit was 
smaller than F for all study participants for Al and Si and when applying Tukey testing, the treatment 
period contained higher elemental excretion of Si and Al in sweat for all individuals. 
 
 
 
 
150 | P a g e  
 
 
4.4.5 Comparing gender within the study population 
 
 
Wilcoxon signed-rank was used to determine where any differences within the data lie. The 
differences between the mean sweat excretion of Al and Si for the study group are shown in Table 
4.4.5.1. Correlation between the treatment data was stronger than the control, presenting r-
values of 0.96 and 0.51 respectively, highlighting that these two independent variables were 
selected from populations with the same distribution. 
 
Table 4.4.5.1: Summary of Wilcoxon signed-rank - differences between pairs of means of 
excretion for male (n = 9) and female groups (n = 10). 
 
 
 
 
 
 
Males generally excreted more Si and Al, which was statistically significant during the entire study 
duration (P = 0.001). An example of a treatment study replicate showing a mean excretory Al 
value of 619μg/L was seen for female F5, compared to 1276 μg/L for male M5. A further example 
Relationship with Silicon 
  
Aluminium 
r-Value p-Value 
Control 0.51 <0.05 
Treatment 0.96 <0.05 
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for a mean excretory Si value of a treatment study replicate of 1476μg/L was seen for female F5, 
compared to 2327μg/L for male M5. 
 
Table 4.4.5.2 Summary of Wilcoxon signed-rank - differences between pairs of means of 
excretion for male (n = 9) and female groups (n = 10). 
 
 
 
 
 
The Mann-Whitney U test confirms a statistical significance (W=0, P < 0.05) for the study population 
when comparing amount of Al and Si sweat. Table 4.4.5.3 shows this statistical relationship and the 
difference in medians between the control and treatment period. 
 
 
 
 
 
Male v Female Patients 
  Silicon Aluminium 
  P-Value P-Value 
Control 0.018 0.962 
Treatment 0.268 0.039 
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Table 4.4.5.3: Significance of the differences in sweat excretions of Si (μg/L) and Al (μg/L) between 
control and treatment (Mann Whitney U test). 
 
 
 
 
Data (Table 4.4.5.4) showing the excretion of Si in sweat during the control phase was statistically 
similar for males and females (P=0.018) although data held less statistical relevance between the same 
pool of individuals for the treatment period (P = 0.268). In addition to this, the data showed similarities 
between males and females during the treatment period for Al, indicating that people show a similar 
relationship in Al excretion (P = 0.039), however, during the control, this relationship was statistically 
dissimilar different between males and females (P=0.962). 
 
 
Silicon (ug/L) 
Difference  
Male Female 
W-Value P-Value Median W-Value P-Value Median 
Control-Treatment 0 0.014 810-1726 0 0.009 657-1611 
Aluminium (ug/L) 
Difference  
Male Female 
W-Value P-Value Median W-Value P-Value Median 
Control-
Treatment 
0 0.014 400-1276 0 0.009 285-990 
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Table 4.4.5.4 Differences in the median excretions of Si (μg/L) and Al (μg/L) between males and 
females for the healthy volunteer group.(Mann-Whitney U test). 
 
 
 
 
 
 
 
 
 
 
When looking at the difference between amounts of Si and Al excreted in the sweat of the healthy 
volunteers (Table 4.4.5.5), seventeen out of the nineteen individuals excreted 50% more Si in their 
sweat after consuming the Si rich mineral water. Seventeen out of nineteen participants excreted 50% 
more Al in their sweat after the consumption of the mineral water, the two individuals (M3 and M5) 
presenting less than 50% were different for the lower percentage difference in Si excretion (F6 and 
F7). It is interesting to note that for Al these individuals were both male, while for Si these individuals 
were both female. 
 
Male                       
(n=9)
Female                            
(n=10)
P-value
ΣW 1298 1120 0.143
Control
Treatment
826 676 0.018
1767 1564 0.268
Silicon (μg/L)
Patient
0.039
ΣW 775 594 0.5
353 0.962
Aluminium (μg/L)
Patient
Male                       
(n=9)
Female                            
(n=10)
P-value
Treatment 1208
Control 341
835
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Table 4.4.5.5: Mean creatinine corrected urinary excretions of Si (μg/L) and Al (μg/L) for the 
control and treatment groups and the percentage difference between the groups. 
 
 
The correlation between aluminium and silicon excretion in sweat during the baseline and treatment 
period is shown in figure 4.4.5.1.  
 
 
 
 
 
Control Treatment % Difference Control Treatment % Difference
F1 812 1466 57.4 467 1184 86.9
F2 647 1609 85.3 217 381 54.8
F3 601 1332 75.6 270 1081 120.1
F4 626 1683 91.6 255 986 117.8
F5 576 1476 87.7 187 619 107.2
F6 668 1612 82.8 300 424 34.3
F7 616 1110 57.2 266 427 46.5
F8 732 1634 76.2 520 1035 66.2
F9 787 1778 77.3 585 994 51.8
F10 691 1938 94.9 461 1215 90
M1 944 1661 55 444 772 53.9
M2 1050 2167 69.4 71 1030 174.2
M3 874 1281 37.8 526 1589 100.5
M4 743 1870 86.3 574 1677 98
M5 810 1348 49.9 464 1666 112.9
M6 783 2327 99.3 183 1276 149.8
M7 994 1941 64.5 152 1536 164
M8 578 1588 93.3 400 690 53.2
M9 674 1726 87.7 255 639 85.9
Silicon Aluminium
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Figure 4.4.5.1 Sweat excretion of Al (µg/L) for the control (●) and treatment (●) periods against 
Si excretion (μg/L). 
 
4.4.6 Comparison between the excretion of silicon in sweat with the 
volume of silicon rich mineral water consumed 
 
All healthy volunteers were instructed to consume as much of the 1500mL bottle of Spritzer mineral 
water as possible 1 hour before the exercise programme was initiated. The final volumes consumed 
were noted for each control and treatment experimental replicate (n=6) and the amount of Si taken 
on board prior to the exercise was calculated (Table 4.4.2.1). This value was then compared to the 
difference between control and treatment Si excretion values so any influence of the water on Si 
excretion was established.  
156 | P a g e  
 
Despite the loading of the mineral water 1 hour before exercise, the difference in Si values represents 
a small proportion of the Si consumed in the water, with low variability between both male and female 
participants, 2.4 and 2.1% respectively.  
The concentration of silicon in sweat increased significantly during the treatment period, a trend seen 
for all volunteers (P < 0.005, ANOVA). Further to sweat volume being larger for male participants, on 
average, silicon excretion was larger in males than females, despite more males not consuming the 
entirety of the Spritzer water provided to them. Five out of the ten females and six out of the nine 
males failed to consume the suggested volume of 1500mL in 1 hour.  
The maximum amount of Si in 1500mL of the mineral water was calculated to be 44.26mg and eight 
out of the nineteen volunteers consumed this full amount. 
When the study population was considered as a group, sweat Si concentration increased after the 
consumption of the mineral water an hour before exercise. During the control, Si excretion was 
calculated at 748µg/L (±140 µg/L) and during the treatment protocol, this value increased to 1660 
µg/L (±303 µg/L). This increase was seen for both males and females (Table 4.4.6.1), although, the 
difference was more significant for the male subjects, when comparing the two means (P < 0.001 and 
P = 0.002 respectively, Pearson correlation analysis). Males excreted 828 µg/L (±153 µg/L) Si in their 
sweat as a baseline and 1767 µg/L (348 µg/L) during the treatment protocol, while females produced 
676 µg/L (±79 µg/L) of Si in the baseline period and 1564 µg/L (±244 µg/L). 
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Table 4.4.6.1: Comparison between the excretion of Si in sweat with the volume of silicon rich 
mineral water consumed (mL) and percentage of Si consumed as mineral water. 
 
 
 
During the healthy volunteer study in Chapter 3, a weak positive correlation was witnessed between 
the amount of Si taken into the body and the amount excreted. This is seen in sweat too. When more 
Si is consumed, more Si is excreted (R=0.39). Eight out of the nineteen volunteers consumed all 
1500mL silicon rich mineral water, but those that didn’t enabled us to see this relationship in Figure 
4.4.6.1. 
 
 
 
 
 
F1 1258 37091 654 1.8
F2 1460 43047 962 2.2
F3 1329 39184 731 1.9
F4 1500 44226 1057 2.4
F5 1376 40570 900 2.2
F6 1500 44226 944 2.1
F7 1247 36767 494 1.3
F8 1500 44226 902 2.0
F9 1500 44226 991 2.2
F10 1500 44226 1247 2.8
Mean 1417 41779 888 2.1
M1 1320 38919 717 1.8
M2 1500 44226 1117 2.5
M3 754 22231 407 1.8
M4 1343 39597 1127 2.8
M5 1022 30133 538 1.8
M6 1500 44226 1544 3.5
M7 1500 44226 947 2.1
M8 1429 42133 1010 2.4
M9 1300 38329 1052 2.7
Mean 1296 38224 940 2.4
ID
Difference in silicon excretion 
(Treatment – Control, μg/L)
Percentage of mineral water which 
equates to the difference in Si
Si consumed (µg)Spritzer consumed (mL)
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Figure 4.4.6.1 Comparing the amount of Si taken on by each participant in the form of Si rich mineral 
water in relation to the amount excreted by each study participant. 
 
4.4.7 Twenty-four hour data correction 
 
The data was corrected for 24 hour sweat excretion using literature values. Concentrations of 
aluminium and silicon in collected sweat were adjusted to take account of the volume of sweat 
produced by men (1342 mL/24 h) and women (712 mL/24 h), values established by Manz et al 
(2012). 
 
4.4.7.1 Silicon 
 
When corrected for 24 hour perspiration, Si excretion increased for males and reduced for females 
over this time (Table 4.4.7.1.1), making these differences more prominent than measurements 
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calculated per L-1. The amount of Si excreted in the sweat of males increased from 1110.9 µg (±205.8 
µg) during the control 24 hour period to 2372.1 µg (±467.7 µg). The variance in this male data was 
from 905 µg to 1409 µg during the control 24 hour period, and 1719.1 µg to 3123.2 µg during the 24 
hours for the treatment protocol. 
 
Table 4.4.7.1.1: 24-hour mean (SD) excretion of Si in the perspiration of males within the study 
population (n=9) 
 
 
 
 
 
 
 
The amount of Si excreted in the sweat of females increased from 486.3 µg (±57.2 µg) during the 
control 24 hour period to 1125.9 µg (±167.3 µg). The variance in this female data was from 414.9 µg 
to 584.6 µg during the control 24 hour period, and 799.2 µg to 1395.2 µg during the 24 hours during 
the treatment protocol (Table 4.4.7.1.2). 
 
 
ID [Si] Sweat control (µg/24hr) [Si] Sweat treatment (µg/24hr)
M1 1267.3 2228.5
M2 1409.0 2907.7
M3 1172.9 1719.1
M4 997.1 2509.7
M5 1086.3 1808.7
M6 1050.1 3123.1
M7 1334.5 2605.0
M8 776.2 2131.0
M9 905.0 2316.6
Mean (SD) 1110.9 (205.8) 2372.1 (467.7)
[Si] in 24 hr sweat excretion in males
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Table 4.4.7.1.2: 24-hour mean (SD) excretion of Si in the perspiration of females within the study 
population (n=9) 
 
 
 
 
 
 
 
After 24-hour correction, a larger difference can be seen between elemental excretion in sweat 
between males and females within the healthy volunteer study (Table 4.4.7.1.3).  When considering 
Si excretion, the baseline Si concentration in sweat for males equated to 1110.0µg/L, while for 
females, less than half of this amount was recorded at 486.3µg/L. This ratio was consistent to the 
treatment protocol, as for males, an average sweat Si content was 2372.1 µg/L, while for females, this 
value equated to 1125.9 µg/L. 
Table 4.4.7.1.3: 24-hour mean (SD) excretion of Si in the perspiration of healthy volunteers within the 
study population (n=19) 
 
 
 
 
ID [Si] Sweat control (µg/24hr) [Si] Sweat treatment (µg/24hr)
F1 584.6 1055.4
F2 465.5 1158.6
F3 432.6 959.1
F4 450.4 1211.6
F5 414.9 1062.9
F6 480.7 1160.6
F7 443.4 799.2
F8 527.1 1176.5
F9 566.6 1279.8
F10 497.5 1395.2
Mean (SD) 486.3 (57.2) 1125.9 (167.3)
[Si] in 24 hr sweat excretion in females
[Si] in 24 hr sweat excretion in healthy volunteers
Gender
[Si] Sweat control (µg/24hr) [Si] Sweat treatment (µg/24hr)
Male
Female 486.3 (57.2) 1125.9 (167.3)
1110.9 (205.8) 2372.1 (467.7)
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4.4.7.2 Aluminium 
 
When corrected for 24 hour perspiration, Si excretion increased for males and reduced for females 
over this time, making these differences more prominent than measurements calculated per L-1. Data 
in Table 4.4.7.2.1 shows how the amount of Al excreted in the sweat of males increased from 457.6 
µg (±241.1 µg) during the control 24 hour period to 1621.5 µg (±581.4 µg). The variance in this male 
data was from 95.8 µg to 769.8 µg during the control 24 hour period, and 857.1 µg to 2250.0 µg during 
the 24 hours for the treatment protocol. 
 
Table 4.4.7.2.1: 24-hour mean (SD) excretion of Al in the perspiration of males within the study 
population (n=9) 
 
 
 
 
 
 
 
The amount of Al excreted in the sweat of females increased from 254 µg (±101.6 µg) during the 
control 24 hour period to 600.8 µg (±240.4 µg). Table 4.4.7.2.2 shows the variance in this female data, 
ranging from 191.2 µg to 421.1 µg during the control 24 hour period, and 305.1 µg to 874.7 µg during 
the 24 hours during the treatment protocol. 
ID [Al] Sweat control (µg/24hr) [Al] Sweat treatment (µg/24hr)
M1 595.8 1036.0
M2 95.8 1382.5
M3 705.2 2132.3
M4 769.8 2250.0
M5 623.0 2236.0
M6 245.9 1712.0
M7 203.7 2061.8
M8 536.5 925.7
M9 342.5 857.1
Mean (SD) 457.6 (241.1) 1621.5 (581.4)
[Al] in 24 hr sweat excretion in males
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Table 4.4.7.2.2: 24-hour mean (SD) excretion of Al in the perspiration of females within the study 
population (n=9) 
 
 
 
 
 
 
 
 
After 24-hour correction, a larger difference can be seen between elemental excretion in sweat 
between males and females within the healthy volunteer study (Table 4.4.7.2.3).  When considering 
Al excretion, the baseline Al concentration in sweat for males equated to 457.6µg/L, while for females, 
just more than half of this amount was recorded at 254.0µg/L. This ratio was consistent to the 
treatment protocol, as for males, an average sweat Al content was 1621.5 µg/L, while for females, this 
value equated to 600.8 µg/L, less than half of the amount calculated for males. 
 
 
 
 
ID [Al] Sweat control (µg/24hr) [Al] Sweat treatment (µg/24hr)
F1 336.5 852.3
F2 156.4 274.1
F3 194.3 778.5
F4 183.6 709.6
F5 134.9 445.8
F6 215.8 305.1
F7 191.2 307.4
F8 374.5 745.1
F9 421.1 715.9
F10 331.6 874.7
Mean (SD) 254.0 (101.6) 600.8 (240.4)
[Al] in 24 hr sweat excretion in females
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Table 4.4.7.2.3: 24-hour mean (SD) excretion of Si in the perspiration of healthy volunteers within the 
study population (n=19) 
 
 
 
 
 
 
Once corrected, weak positive correlation was noticed between Si and Al excretion in sweat during 
both control (r = 0.4) and treatment (r = 0.5) protocols (Figure 4.4.7.2.1). 
 
 
 
 
 
 
 
 
Figure 4.4.7.2.1: Corrected 24 hour sweat excretion concentrations of Al (µg/L) for the control (●) 
and treatment (●) periods against Si excretion (μg/L). 
[Al] in 24 hr sweat excretion in healthy volunteers
Gender
[Al] Sweat control (µg/24hr) [Al] Sweat treatment (µg/24hr)
Male
254.0 (101.6) 600.8 (240.4)Female
457.6 (241.1) 1621.5 (581.4)
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Pearson correlation analysis (Table 4.4.6.7) indicated that this weak positive correlation between Si 
and Al excretion in sweat was significant for both control and treatment protocols (P < 0.005). 
Table 4.4.6.7: Correlation analysis between the 24hr corrected excretion of Al (μg/24hr) with the 
excretion of Si (μg/24hr). 
 
 
 
 
All data analysis highlights that consuming the Si rich mineral water had a positive effect on the 
excretion of Si and Al in sweat, supporting the observation that levels of Si and Al in sweat 
approximately doubled after the incorporation of 1500mL of mineral water 1 hour before exercise. 
This is visually represented in Figure 4.4.6.2. 
 
 
 
 
 
 
 
Control
Treatment
0.4
0.5
<0.05
<0.05
Relationship with silicon
Aluminium
r-Value p-Value
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Figure 4.4.6.2: 24 hour corrected excretion of Al (μg/24hr) for the control (Si ● Al ●) and 
treatment period (Si ● Al ●) compared to Si excretion (μg/24hr) for the study group (n=19) 
4.4.7 Age and BMI comparisons within the study group 
 
After 24-hour correction, the elemental sweat excretions were compared with age. Healthy volunteers 
in this study ranged from 18-34 years and despite low significant correlation between age and Si 
excretion in sweat (P > 0.3), correlation between Al excretion in sweat and age were more significantly 
correlated ( P <0.05), using Pearson correlation analysis (Table 4.4.7.1). 
Table 4.4.7.1: Correlation analysis between age and excretion of Si and Al (µg/L) between the 
control and treatment periods 
 
 
 
p- value
Age v 24hr corrected sweat excretion
Silicon Aluminium
Control 0.4 0.007
Treatment 0.3 0.004
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Excretion of Si and Al were plotted against age in Figure 4.4.7.1. The mean age for the study was 24 
years and only one individual over 30 years of age took part in the study. Weak positive correlation 
can be seen for all relationships, although, the relationship between elemental excretion and age is 
stronger during the control period. 
 
 
 
 
 
 
 
Figure 4.4.7.1: 24 hour corrected excretion of Al (μg/24hr) against age for the control (Si ● Al ●) 
and treatment period (Si ● Al ●) compared to Si excretion (μg/24hr) against age for the study 
group (n=19) 
 
Pearson correlation analysis, shown in Table 4.4.7.2 confirms the relationship between age and 
elemental excretion in sweat. Stronger correlation and higher r – values were seen during the 
control protocol for both Si and Al, at 0.59 and 0.79 respectively. This correlation decreases 
during the treatment protocol, signifying a unique relationship between each individual and 
their handling of Si at high doses. 
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Table 4.4.7.2: 24-hour corrected comparison between elemental excretion in sweat and subject 
age (n=19) 
 
After 24-hour correction, the elemental sweat excretions were compared with BMI. Healthy 
volunteers in this study ranged BMI values from 20-41.5, although most of the healthy volunteers 
were of a normal BMI, ranging from 20-25. When analysed, the data followed a similar trend to age 
comparisons. The statistical significance between elemental excretion was larger for the control 
protocol than the treatment protocol, Pearson correlation analysis revealed a p- value of 0.022 and 
0.17 for these populations respectively. 
Despite low significant correlation between BMI and Si excretion in sweat (P > 0.2), correlation 
between Al excretion in sweat and BMI were significantly correlated ( P <0.05) in the control period, 
using Pearson correlation analysis (Table 4.4.7.3). 
 
 
 
 
 
Silicon Aluminium
Control
Treatment
Study
r - Value
Age v sweat elemental excretion (n=19)
0.59 0.79
0.44 0.26
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Table 4.4.7.3: Correlation analysis between BMI and excretion of Si and Al (µg/L) between the 
control and treatment periods  
 
 
 
 
Excretion of Si and Al were plotted against BMI in Figure 4.4.7.2. The mean BMI for the study was 
26.4 and only one individual with a BMI over 40 took part in the study. Weak positive correlation can 
be seen for all relationships, although, the relationship between elemental excretion and BMI is 
stronger during the control period. 
 
 
 
 
 
 
 
Figure 4.4.7.2: 24 hour corrected excretion of Al (μg/24hr) against BMI for the control (Si ● Al ●) 
and treatment period (Si ● Al ●) compared to Si excretion (μg/24hr) against age for the study 
group (n=19) 
BMI v 24hr corrected sweat excretion
Control
Treatment
Silicon Aluminium
p - value
0.022 0.018
0.17 0.13
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Pearson correlation analysis, shown in Table 4.4.7.4, confirms the relationship between BMI and 
elemental excretion in sweat. Stronger correlation and higher r – values were seen during the 
control protocol for both Si and Al, at 0.55 and 0.68 respectively. This correlation decreases 
during the treatment protocol, signifying a unique relationship between each individual and 
their handling of Si at high doses. 
 
Table 4.4.7.4: 24-hour corrected comparison between elemental excretion in sweat and subject 
BMI (n=19) 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Silicon Aluminium
BMI v sweat elemental excretion (n=19)
Study
r - Value
Control 0.55 0.68
Treatment 0.31 0.18
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4.5 Summary of results for healthy individuals  
 
 
• Sweat volume collected was larger for males than females (Section 4.4.1.).  
• The amount of Si from the Si rich mineral water was determined to be only around 2% of that 
consumed (4.4.2) 
• Excretions of Si and Al in sweat are significantly increased following the consumption of the 
mineral water (Section 4.4.3).  
•Weak positive correlation was demonstrated between Si and Al excretion (Section 4.4.5) 
• Si and Al showed weak positive correlation with age during the control period (Section 4.4.7).  
• Weak positive correlation was noted between BMI and urinary excretion of Al and Si during 
the control protocol (Section 4.4.7) 
 
4.6 Discussion of results 
 
The mean aluminium content in the control period was higher in females (341 ± 245 µg/L) than males 
(353 ± 141 µg/L) though the data for each group were not found to be significantly different from one 
another (P > 0.05). Contrary to this the mean aluminium content in the treatment protocol was higher 
in males (1208 ± 433µg/L) than females (835 ± 334µg/L) and the data for each group were found to 
be significantly different from one another (P < 0.05). The volume of sweat collected ranged from 0.66 
to 1.55 mL and corresponded well with literature values for perspiration rates (Chen et al. 2012). The 
method blanks demonstrated a very low level of possible contamination by aluminium and were 
within the range of a previous study (Exley et al 2014).The latter demonstrated a high degree of 
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confidence in the concentrations of aluminium measured herein which were towards the higher end 
of previous literature values (House et al 2012).  
When the concentrations of aluminium in collected sweat were adjusted to take account of the 
volume of sweat produced by men (1342 mL/24 h) and women (712 mL/24 h) in this age range (Manz 
et al 2012) and undergoing mild exercise the amount of aluminium excreted over 24 h ranged from 
135 to 421 µg/24 h for women to 96–770 µg/24 h for men during the control and from 274 to 875 
µg/24 h for women to 857–2250 µg/24 h for men (Table 4.4.7.2.1 and Table 4.4.7.2.2) with men 
excreting significantly more aluminium than women (P < 0.05). These data are significantly higher than 
those that describe the daily excretion of aluminium in urine, up to 100 µg/24 h (Exley, 2013) and 
therefore they heavily implicate sweating as the major route of excretion of systemic aluminium in 
humans, especially after the consumption of a Si rich mineral water. In doing so it may be that men, 
through perspiration, excrete aluminium from the body more effectively than women and it can be 
suggested that regular exercise might be a way to increase the excretion of aluminium from the body. 
If sweating is the major route for the removal of systemic aluminium from the body then this 
observation puts into question the practice of disrupting or blocking perspiration using 
antiperspirants, specifically, aluminium-based antiperspirants. 
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Chapter 5 - Silicic acid-rich mineral water as a non-invasive method of 
reducing the aluminium body burden in individuals diagnosed with 
multiple sclerosis. 
 
5.1.0 Aims 
 
The aim of this chapter is to investigate if regular drinking of a silicon-rich mineral water can help in 
the removal of Al from the body of individuals with a diagnosis of MS. Secondary aims were to 
determine if drinking silicic acid-rich mineral water had any effect on mobility index scores and 
general patient wellbeing. 
5.2.0 Introduction 
 
The link between aluminium and multiple sclerosis has been one of tremendous dispute for several 
decades. Despite a number of studies suggesting a potential involvement, the link still remains 
controversial (see section 1.1). By highlighting the effect of silicic acid in the removal of aluminium 
from the human body, unequivocal data can be obtained to support this link (Exley et al 2006). 
Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of the central nervous 
system of as yet unknown aetiology (see section 1.14). A consensus of opinion has suggested that the 
disorder is the result of an interplay between environmental factors and susceptibility genes. Exley et 
al (2006) used a battery of analytical techniques to determine if the urinary excretion of i) markers of 
oxidative damage and ii) the environmental toxin aluminium and its antagonist, silicon, were altered 
in secondary progressive MS (SPMS). Urinary concentrations of aluminium were significantly increased 
in SPMS (P<0.05) such that the levels of aluminium excretion in the former were similar to those 
observed in individuals undergoing metal chelation therapy. The excretion of silicon is lower in MS 
and significantly so in SPMS (P<0.05). Levels of urinary aluminium excretion were similar to those seen 
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in aluminium intoxication and suggested that aluminium may be a hitherto unrecognized 
environmental factor associated with the aetiology of MS. If aluminium is involved in MS then an 
increased dietary intake of its natural antagonist, silicon, might be a therapeutic option. 
 
 
In Chapter 3 of this thesis it was demonstrated that for healthy individuals (Chapter 3.0), silicic 
acid-rich mineral waters could be exploited as a non-invasive means of reducing burden of 
aluminium and long term treatment by regular consumption could maintain aluminium body 
burden at a reduced level. 
 
5.3.0 Methodology 
 
Fifteen multiple sclerosis patients were recruited through the University Hospital of North 
Staffordshire (UHNS, now Royal Stoke) through the MS department by a qualified clinician 
following the inclusion and exclusion criteria. Ethical approval was attained by myself, from the 
national research ethics committee (NREC reference 14/YH/1115). All volunteers provided 
written consent prior to participation, which was obtained by a qualified clinician. 
All SPMS patients attending the Neurology clinics were screened for possible inclusion in the 
study. Suitable and interested patients were posted a participant information pack, including the 
PIS and coversheet, explaining the outline of the study. This was followed up via telephone 
calls/postal letters by a study clinician to confirm their interest and participation. Those who were 
interested were asked to be come back to a research clinic where a screening assessment was 
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carried out by a study clinician and eligible patients were asked to sign the consent form. A 
standard time period of 24 hours was given between the receipt of the study information sheet 
and taking informed consent. 
The inclusion criteria included: All patients must have a confirmed diagnosis, by a study clinician, 
of secondary progressive multiple sclerosis (SPMS) according to the McDonald inclusion criteria. 
Patients must be willing and able to give informed consent in line with the Mental Capacity Act. 
Patients had a carer to help ensure that the protocol was followed accordingly. Carer was willing 
and able to give informed consent. Patient would not suffer any ill effects or practical difficulties 
on the consumption of up to 1.5L of mineral water and had no restriction on fluid ingestion. As 
well as any patients not satisfying the above inclusion criteria, a potential study participant would 
be excluded if those patients were on disease modification treatment, patients with current 
urinary infections and patients with a history of impaired renal function. The patient could be 
initiated onto the study once an infection free urine sample had been provided. During 
recruitment, a Kurtjze EDSS score (Kurtjze 1983) was given to each patient. This was followed up 
at the end of the study to look for improvements in mobility, as well as a questionnaire querying 
general wellness. 
One female patient (008) had to be withdrawn from the study due to a series of urine infections. 
The mean age of the remaining 15 MS patients who completed the study, was 72 (range 56 - 81) 
and 8 were female. 
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5.3.1 Protocol 
 
 
The project protocol was divided into two objectives; the primary objective was to measure the 
urinary excretions of Si and Al over a 24 week period during the second 12 week period of which 
patients consumed up to 1.5L of silicon-rich mineral water each day. The first 12 weeks of the 
study, referred to as the control, required each participant to provide urine samples following 
their normal diets, thus acting as their own control to determine individual changes. The 
secondary objective was to observe changes in mobility using EDSS scores at the beginning and 
end of the study. 
 
5.3.2 Urinary excretions 
 
This study examined the effects of long-term consumption of mineral water on the urinary 
excretion of Si and Al. The study duration was split up into two parts, the first 12 weeks (W1-
W12), known as the control period and the second 12 weeks (W13-W24) referred to as the 
treatment period. Participants collected all of their urine (24 hour samples) for the 5 days in W1, 
W12, W13 and W24 into 3L sterile containers. During the rest of the study weeks, the first morning 
sample of the day on the same day of each week was collected into sterile 50mL containers. These 
collections were made for the baseline (W1 to W12 - no mineral water consumption) and 
treatment periods (W13 to W24 - including consumption of up to 1.5L of mineral water each day).  
Differences in the urinary excretions of Si and Al between control and treatment weeks 1, 2, 13 
and 24 for each individual were determined using one-way ANOVA and Tukey’s paired 
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comparison tests. Differences for control and treatment data were measured using repeated 
measures ANOVA and Wilcoxon signed-rank tests. 
 
Results for the daily collections are presented as total amount excreted per 24 hours (µg/24 hr 
for Si and ng/24 hr for Al), however, these concentration are also displayed as creatinine-
corrected data in order to make comparisons with the spot samples, allowing for any deviations 
in urine volume. Volunteers were requested to consume as much as the 1.5L of the provided 
mineral water as they could comfortably manage. This volume is the same as the healthy 
individual urine study because the consumption of 1.5L every day for a period of 12 weeks seemed 
acceptable to the patients, although, unlike the loading treatment in the healthy volunteer study, 
participants in this study were able to make up their normal drinks with the water, essentially 
replacing other water consumed in their daily diets with the Si rich mineral water. 
It was thought to be inconvenient for the patients to provide record sheets as in the healthy 
volunteer study (see Chapter 3). Instead, the patients were provided with a tick sheet to record 
their water consumption and sample collection.  
 
As in the healthy volunteer study, results are recorded both before and following correction for 
creatinine concentrations, and 24 hour samples were expressed in both formats. 
 
The requirements for this study were maintained at a minimum so not to make participation too 
complexed for individuals suffering from MS. Therefore, dietary record sheets, as collected in the 
healthy individual, study were not required during this study. The length of the control period 
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satisfied this as it meant that a thorough indication of normal Si and Al excretion could be 
deduced. 
 
5.3.2.1 Treatment of urine samples 
 
Samples were collected and stored in pre acid-washed polypropylene containers (5% HCl), rinsed 
with UPW. Urine samples were collected directly into these pre-washed 3L containers for the 24 
hour trial. Pre-washed jugs were provided for the 24 hour-long term trials for the purpose of 
convenience. The 24 hour sample volumes were measured and a portion transferred to the 50mL 
container. The remaining sample was disposed of down the toilet and the jug rinsed with Decon. 
Samples were directly transferred to the trace element lab where there were stored in a clearly 
labelled refrigerator. Samples were vortexed to ensure uniformity and an aliquot of urine sample 
was taken and diluted to 10% with UPW for creatinine analysis using the Jaffe method (Toora, 
2002).The remaining urine was acidified using 15.8M HNO3 to 20% v/v and subjected to 
microwave digestion to prepare samples for measurement of total silicon and aluminium by 
THGFAAS.  
 
5.3.3 Statistics 
 
One-way ANOVA at ἀ = 0.05 was carried out on each individual data set to compare the means of 
Wk 1, Wk12, Wk 13 and Wk 24 (5 replicates per week per individual). Post-hoc Tukey’s paired 
comparisons were carried out to determine the significance between pairs of means, where tests 
for normality and equal variance showed a departure from either or both, log transformations 
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were carried out. Two-way ANOVA to compare patients, male and female was valid because of 
equal variance. The non-parametric Mann-Whitney U test was used to compare pairs of medians. 
Analyses were carried out using Minitab® 15. 
 
Differences in the urinary excretions between the control and treatment periods were 
determined using the paired t-test, and comparisons between males and females were performed 
using the 2-sample t-test. An aged matched healthy control group was not sought after for this 
study, but instead data available from other studies was used. 
 
5.3.4 EDSS Score 
 
The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple 
sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials 
and in the assessment of people with MS. The scale has been developed by John F. Kurtzke, (1983) 
(See Appendix 5 for the scale).  
 
Each individual completed the EDSS test prior to and following the treatment of the mineral water, 
this was performed by the qualified clinician. Comparisons between the initial and final score were 
used to determine whether the consumption of the mineral water had any influence on their mobility. 
An increase in EDSS score would indicate that the level of disability is worsening whereas a reduction 
in score would highlight an improvement in mobility and reduction in disability.  
Overall scores of the EDSS tests were provided by the clinical nurse on the completion of the urinary 
analysis. Detailed reports of the performance of the tests (i.e. scores of each section) were not made 
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available for this thesis as these reports carry confidential patient information. Patient questionnaires 
were collected post study to determine any improvements in health, wellbeing and general feedback. 
 
5.4.0 Results 
 
This chapter includes the statistical comparisons to the baseline period (week 1 to week 12) and the 
study period (week 13 to week 24).  Comparisons were made for each participant using one-way 
ANOVA to echo individual responses to the mineral water. Repeated-measures ANOVA were then 
performed for each patient to provide a general depiction of the effect of the mineral water on the 
urinary excretions. 
All spot sample results shown in this chapter have been creatinine corrected. Data for the 24 hour 
collections in Wk 1, 12, 13 and 24 have been creatinine corrected and expressed as total amount 
excreted in this 24 hour period. Individuals collected one urine sample a week for weeks 2-11, then 
14-23.  
Fifteen individuals, diagnosed as SPMS patients completed the study and informal indices, such as 
conversations and completion of questionnaires, suggested that compliance with study protocols was 
excellent. Data are summarized according to treatment group, gender and analysed below as 
treatment groups and as individuals. 
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5.4.1 Creatinine measurements 
 
 
Creatinine concentrations were measured for each sample in order to correct for differences in renal 
functioning between individuals and to take any dilution effects of the urine into consideration. There 
was no significant difference between males and females in mean creatinine concentrations, for both 
the control (t = 2.87: P = 0.012), and treatment (t = 1.71: P = 0.424) period, 4.44mM and 4.45mM 
respectively.  
Table 5.4.1.1. Mean (SD) urine creatinine concentrations (mM) collected from the whole MS 
study population for both baseline and treatment periods (n=20) 
 
 
 
 
 
 
 
 
 
 
4.0 (1.9) 4.5 (1.9)
ẍ 4.44 4.45
Mean (SD) urinary creatinine concentration for each MS patient
5.9 (2.6) 7.4 (3.0)
3.4 (1.7) 2.3 (0.6)
4.0 (1.6) 4.4 (1.6)
6.7 (2.4) 7.5 (2.8)
2.5 (1.6) 3.0 (1.6)
8.2 (3.8) 4.8 (2.1)
3.4 (0.8) 3.5 (1.4)
4.2 (1.4) 4.1 (2.2)
2.4 (0.5) 2.9 (1.1)
3.8 (1.0) 4.4 (1.6)
Baseline (mmol) Treatment (mmol)
2.3 (1.0) 2.6 (1.1)
5.1 (1.8) 4.1 (2.1)
4.5 (2.0) 4.6 (3.4)
6.2 (2.8) 6.2 (3.0)
ID
F001
M002
F003
M004
M005
F006
M007
F009
M010
M011
F012
F013
M014
F015
F016
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Mean urinary creatinine concentration remained constant for gender comparisons, although 
remaining higher for males throughout the studies. Mean baseline creatinine concentration for males 
and females was 5.7mM and 3.2mM respectively and mean creatinine concentration during the 
treatment period was noted at 5.5mmol and 3.5mmol, decreasing for males and increasing for 
females, this however was not a significant change (t = 1.05, p = 0.71). 
5.4.2 Volume measurements 
 
 
Total volume for the 24 hour collections periods were measured to accurately quantify amounts 
of Si and Al excreted over this time. Total urine volume was larger during the treatment period 
than the baseline study for 11 out of 15 participants, although these differences were notably 
small (P = 0.028). Urine volume increased significantly for one patient, ID F015, who saw their 
urine increase from 1867mL/24 hr to 3033ml/24 hr (Table 5.4.2.1). 
 
Table 5.4.2.1. Mean urine volumes collected from the whole MS study population during the 24 
hour studies for both baseline and treatment periods (n=7) 
 1591 (392)ẍ 1858 (199) 267
Mean (SD) urinary volume for the baseline and treatment 24 hour collections
187
970
-182
371
1166
4891207 (821)
106
402
-28
241
-146
49
152
-12
2472403 (206)
1944 (423)
2568 (345)
1853 (653)
1461 (303)
3033 (63)1867 (984)
718 (139)
1931 (494)
1875 (643)
1133 (574)
1639 (352)
1056 (420)
1362 (307)
2391 (636)
2017 (321)2029 (390)
2156 (408)
1757 (272)
1598 (636)
2035 (521)
1090 (212)
Difference in Volume
1825 (466)
1473 (331)
1161 (199)
F013
M014
F015
F016
Baseline volume (mL) Treatment volume (mL) 
1398 (267)
1202 (200)
1313 (256)
2239 (597)
F006
M007
F009
M010
M011
F012
ID
F001
M002
F003
M004
M005
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There was no significant difference between males and females in the mean volumes excreted 
for the control (t = -3.61: P = 0.001) and treatment (t = -1.44: P = 0.29) period (Table 5.4.2.2). 
 
Table 5.4.2.2. Mean urine volumes compared by gender in MS study population during the 24 
hour studies for both baseline and treatment periods (n=7) 
 
 
The amount of urine increased for both genders between baseline Wk 1, giving a mean value for males 
and females of 1620mL and 1587mL respectively. This value increases in both genders in the initial 
treatment Wk 13 to 1857mL and 1918mL respectively. 
 
5.4.3 Individual data for urinary Si excretion from week 1 to week 24 in 
the MS study group 
 
Si excretion in Wk1 ranged from 26-198µmol/mmol Crt with a mean value of 102µmol/mmol Crt. Si 
excretion in Wk 13 ranged from 118-481 µmol/mmol Crt with a mean of 253 µmol/mmol Crt (Table 
5.4.4.1and figure 5.4.4.1) Data for Wk13 showed an increase in Si excretion compared to Wk1 for 15 
out of 15 individuals (P <0.001). Mean urinary excretion of Si remained statistically consistent between 
control Wk 1 to control Wk 12 (P = 0018).  Si excretion in Wk 12 ranged from 22-224µmol/mmol Crt 
with a mean value of 84µmol/mmol Crt, see Table 5.4.4.1. 
1587 (709) 1550 (620) 1918 (797) 1787 (762)
Gender comparisons between urine volume in 24 hour collection weeks (n=7)
Volume Wk 1 Volume Wk 12 Volume Wk 13 Volume Wk 24
1620 (559) 1612 (535) 1857 (679) 1690 (558)
Gender
Male
Female
(mL) (mL) (mL) (mL) 
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Mean urinary excretion of Si for the final treatment week, Wk 24, ranged between 92-552 µmol/mmol 
Crt with a mean value of 225 µmol/mmol Crt. These values remain similar between treatments Wk 13 
and Wk 24, although when considered individually, in five out of the fifteen patients, Si excretion 
reduced significantly (>50%). In a further five of the fifteen patients, the concentration of urinary Si 
excretion remained statistically consistent (P < 0.001)., for example, patient ID M002 ranging from 135 
µmol/mmol Crt to 127.7 µmol/mmol Crt between Wk 13 and Wk 24. The excretion of Si continued to 
increase between treatment Wk 13 and Wk 24 in three of the fifteen patients, to highlight an example, 
patient ID M011 presented an increase in Si excretion of 328 -552 µmol/mmol Crt between Wk 13 and 
Wk 24 (Table 5.4.4.1). 
 
5.4.4 Creatinine corrected individual data for urinary Al excretion from 
week 1 to week 24 in the MS study group 
 
Al excretion in Wk1 ranged from 46-340nmol/mmol Crt with a mean value of 165nmol/mmol Crt. Al 
excretion in Wk 13 ranged from 42-735 nmol/mmol Crt with a mean of 280 nmol/mmol Crt, see table 
5… Data for Wk13 showed an increase in Al excretion compared to Wk1 for 13 out of 15 individuals (P 
<0.001). For a single patient, ID M002, Al excretion between Wk 1 and Wk 13 did not significantly alter 
( P = 0.008).  
Two out of fifteen patients revealed a lower Al excretion post Si water consumption. Patient ID F006 
indicated a significant (P = 0.004) reduction of Al between Wk 1 and Wk 13 of 219 – 72 nmol/mmol 
Crt. This is also seen in the data collected from patient ID F009 who indicated a drop from 101 – 42 
nmol/mmol Crt between control Wk 1 and treatment Wk 13. 
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Mean urinary excretion of Al remained statistically consistent between control Wk 1 to control Wk 12 
(P = 0.029, Pearson Correlation).  Al excretion in Wk 12 ranged from 75-555nmol/mmol Crt with a 
mean value of 134nmol/mmol Crt (Table 5.4.4.1). 
Mean urinary excretion of Al for the final treatment week, Wk 24, ranged between 254-827 
nmol/mmol Crt with a mean value of 429 µmol/mmol Crt. This value shows significant difference 
between (p = 0.008, ANOVA) treatments Wk 13 and Wk 24.  When considered individually, nine out 
of the fifteen patients showed a significant increase in Al excretion over the treatment weeks and 
excretion was larger in Wk 24 then Wk 13. An example of this is shown when looking at patient ID 
M002; this patient displays an increase in urinary Al concentration from 52 to 427 nmol/mmol Crt 
between treatment Wks 12 and 24. 
In the remaining six of the fifteen patients, the concentration of urinary Al  reduced significantly (P = 
0.012, ANOVA), for example, patient ID M007 ranging from 358 nmol/mmol Crt to 295 nmol/mmol 
Crt between Wk 13 and Wk 24.  
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Table 5.4.4.1: Mean (SD) urinary excretion of Si (μmol/mmol Crt) and Al (nmol/mmol Crt) for the 
24 hour data collected in Wk 1, Wk 12, Wk 13 and Wk 24. 
REF W1 W12 W13 W24 W1 W12 W13 W24
93.8 223.8 376.5 331.9 167.0 180.9 361.3 376.1
(9.8) (25.0) (77.4) (23.8) (60.1) (85.8) (158.9) (112.1)
59.4 70.3 135 127.7 48 91.6 51.9 426.5
(14.5) (13.6) (43.2) (64.9) (25.4) (40.3) (44.7) (123.7)
197.8 91.8 326.7 120 105.4 125.6 164.3 354.5
(22.7) (20.8) (104) (61.9) (29.7) (37.2) (51.2) (146.6)
87.8 69.8 121.5 194.5 75.3 78.8 108.1 827
(34.8) (25.9) (16.8) (117.6) (10.6) (30.5) (67.6) (356.3)
25.7 26.5 283.5 92 46.2 226.2 123.2 347.6
(2.8) (17.2) (90.3) (18.4) (23.2) (254.8) (54.6) (112.6)
94.3 107.6 476.1 267 219.3 133.4 71.5 699.2
(11.8) (49.5) (99.3) (52.7) (89.0) (74.6) (67.2) (80.9)
43.1 45.5 302.7 166.5 114 124.5 358 295.2
(20.3) (8.9) (83.5) (31.3) (25.1) (49.4) (115.2) (88.7)
165.1 111.1 481.1 272 100.9 102.2 42.4 803.1
(46.9) (26.4) (73.2) (48) (42.1) (93.5) (37.3) (102.1)
139.3 136.3 273.7 299.9 248.6 127.9 363.6 276.6
(29.2) (37.6) (15.7) (42.5) (86.8) (106.7) (110.1) (69.2)
65.1 83.1 128.1 209 125.9 197.9 233.5 256.8
(17.1) (32.1) (29.0) (81.9) (42.9) (85.9) (77.1) (114.7)
84.2 77.4 328.3 552.4 283.7 554.8 649.9 510.2
(29.5) (35.8) (103.7) (168.6) (75.3) (76.5) (156.2) (403.6)
153.5 21.9 299.2 179.8 334.2 100.8 735.3 404.8
(141.7) (4.5) (69.2) (79.6) (86.0) (33.4) (309.2) (110.1)
44.1 15.3 130.3 131.7 195.2 75.1 456.3 253.7
(12.0) (5.8) (36.1) (31.5) (24.3) (20.8) (143.4) (134.2)
159.6 88.3 220.1 328.9 339.7 95.9 472.2 297.5
(22.6) (22.8) (25.1) (85.0) (53.1) (31.4) (42.3) (75.9)
89.6 94.2 118.4 127.5 166.5 157.7 420.5 468.1
(28.5) (23.7) (7.8) (35.6) (52.8) (45.7) (212.9) (317.1)
P13
P14
P15
Patient
Mean (SD) Concentrations excreted (n = 5)
P7
P8
P9
P10
P11
P12
P1
P2
P3
P4
P5
P6
Silicon                                                    
(μmol/mmol creatinine)
Aluminium                                                               
(nmol/mmol creatinine)
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5.4.5 Group data for urinary Si and Al excretion from week 1 to week 
24 in the MS study group 
 
 
When comparing the group data, excretion of Si is significantly higher in the treatment weeks 
than the control week (P <0.001, 2-way ANOVA). By collating the data, the mean Si excretion for 
the control period is calculated at 92.8 μmol/mmol Crt and Si excretion for the treatment weeks 
is calculated at 238.85 μmol/mmol Crt (Table 5.4.5.1), this value is over two fold more than the 
control value.     
Table 5.4.5.1: Mean (SD) and median urinary concentrations of Si (μmol/mmol Crt) and Al 
(nmol/mmol creatinine) for patients (n = 15) 
 
 
 
When comparing the group data, excretion of Al is significantly higher in the treatment Wks 13 
and 24 than the control Wks 1 and 12 (P <0.001, ANOVA). Considering the data as a whole, the 
mean Al excretion for the control period is calculated to lie between 165nmol/mmol Crt and 
126nmol/mmol Crt. The standard deviation between these values is quite large, further indicating 
that Al is handled differently between patient. Al excretion under the influence of a high influx of 
bio-available Si was more than doubled in the first treatment Wk 13 at 280.2nmol/mmol Crt, then 
W1 W12 W13 W24 W1 W12 W13 W24
101.6 84.0 253.2 224.5 165.3 126.3 280.2 429.1
(42.8) (52.7) (126.8) (142.8) (103.5) (134.1) (212.3) (265.2)
Patient
Mean (SD) urinary concentrations for W1, W12, W13 and W24
Silicon (μmol/mmol Cre) Aluminium (nmol/mmol Cre)
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almost quadrupled by the final treatment Wk 24, presenting a mean value of 429nmol/mmol Crt. 
This data was normally distributed and statistically significant (t = 3.86, P = 0.012, t test). 
5.4.6 One way ANOVA analysis for Si and Al excretion between control 
and treatment weeks 
 
One-way ANOVA (Table 5.4.6.1 ) indicated that the increase in Si excretion between the baseline 
weeks (Wk 1 and Wk 12) and the initial treatment week (Wk 13) was statistically significant (P < 
0.001) for all but one individual from the patient group. The One-way ANOVA statistical testing 
revealed that data was significant (P < 0.03) for 14 out of 15 patients for Si. One-way ANOVA was 
manipulated for two data sets to see where the main differences were. The control weeks (Wk 1 
and Wk13) were compared with the first treatment week (Wk 13) and the two treatment weeks 
(Wk 13 and Wk 24) were compared with the last control week.  
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Table 5.4.6.1 Summary of One-way ANOVA - differences in the urinary excretion of Si 
(μmol/mmol Crt), and Al (nmol/mmol creatinine) between Wk1, Wk12 and Wk13 for each 
individual in the study group 
 
 
The One-way ANOVA statistical testing revealed that data was significant (P < 0.04) for 13 out of 
15 patients for Si (Table 5.4.6.2). Si excretion was greater in W13 than in W24 for 8 of the patients, 
although in some cases this value simply wasn’t considered as a significant difference (P = 0.81), 
therefore values may remain similar during W13 and W24 and these discrepancies can be related 
to Si content in the diet. 
 
 
REF F Crit/F Significant P F Crit/F Significant P
P1 F Crit < F  P=0.028 W1<W12 W12<W13 F Crit < F  P<0.001 W1<W12 W12<W13
P2 F Crit > F  P=0.17 W1<W12 W12>W13 F Crit < F  P=0.002 W1<W12 W12<W13
P3 F Crit > F  P=0.104 W1<W12 W12<W13 F Crit < F  P<0.001 W1>W12 W12<W13
P4 F Crit > F  P=0.445 W1<W12 W12<W13 F Crit < F  P=0.03 W1>W12 W12<W13
P5 F Crit > F  P=0.2 W1<W12 W12>W13 F Crit < F  P<0.001 W1<W12 W12<W24
P6 F Crit < F  P=0.033 W1>W12 W12>W13 F Crit < F  P<0.001 W1<W12 W12<W13
P7 F Crit < F  P<0.001 W1<W12 W12<W13 F Crit < F  P<0.001 W1<W12 W12<W13
P8 F Crit > F  P=0.27 W1<W12 W1>W12 F Crit < F  P<0.001 W1>W12 W12<W13
P9 F Crit < F  P=0.011 W1>W12 W12<W13 F Crit < F  P<0.001 W1>W12 W12<W13
P10 F Crit > F  P=0.09 W1<W12 W12<W13 F Crit < F  P=0.009 W1<W12 W12<W13
P11 F Crit < F  P=0.005 W1<W12 W12<W13 F Crit < F  P<0.001 W1>W12 W12<W13
P12 F Crit < F  P<0.001 W1>W12 W12<W13 F Crit < F  P<0.001 W1>W12 W12<W13
P13 F Crit < F  P<0.001 W1<W12 W12<W13 F Crit < F  P<0.001 W1>W12 W12<W13
P14 F Crit < F  P<0.001 W1>W12 W12<W13 F Crit < F  P<0.001 W1<W12 W12<W13
P15 F Crit < F  P=0.011 W1>W12 W12<W13 F Crit > F  P=0.124 W1<W12 W12<W13
Tukeys Tukeys
Patient                                                                                                                                                                                                                                         
Difference in urinary excretion btween weeks 1, 12 and 13 (dF=14)
Aluminium Silicon
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Table 5.4.6.2 Summary of One-way ANOVA - differences in the urinary excretion of Si 
(μmol/mmol Crt), and Al (nmol/mmol Crt) between W12, W13 and W24 for each individual in 
the study group 
 
 
One-way ANOVA (Table 5.4.6.1 and Table 5.4.6.2) indicated that there was a significant difference 
in Si excretion between control Wks (Wk1 and Wk 12) and treatment Wks (Wk 13 and Wk 24) the 
patient (P < 0.001) group.  
. 
 
Wilcoxon signed-rank was used to determine where any differences within the data lie. Males 
generally excreted less silicon, this was statistically significant during the entire study duration (P 
= 0.001). An example of Wk 12 shows a mean excretory value of 56.19μmol/mmol creatinine in 
W12 was seen for males compared to 99.46μmol/mmol Crt in W12 for females. 
REF F Crit/F Significant P F Crit/F Significant P
P1 F Crit < F  P=0.049 W13>W12 W24>W13 F Crit < F  P=0.001 W13>W12 W24<W13
P2 F Crit < F  P<0.001 W13<W12 W24>W12 F Crit > F  P=0.087 W13>W12 W24<W13
P3 F Crit < F  P=0.004 W13>W12 W24>W13 F Crit < F  P<0.001 W13>W12 W24<W13
P4 F Crit < F  P<0.001 W13>W12 W24>W13 F Crit < F  P=0.047 W13>W12 W24>W13
P5 F Crit > F  P=0.14 W13<W12 W24>W12 F Crit < F  P<0.001 W13>W12 W24<W13
P6 F Crit < F  P=0.002 W13<W12 W24>W13 F Crit < F  P<0.001 W13>W12 W24<W13
P7 F Crit < F  P=0.004 W13>W12 W24<W13 F Crit < F  P<0.001 W13>W12 W24<W13
P8 F Crit < F  P<0.001 W13<W12 W24>W13 F Crit < F  P<0.001 W13>W12 W24<W13
P9 F Crit < F  P=0.007 W13>W12 W24<W13 F Crit < F  P<0.001 W13>W12 W24>W13
P10 F Crit > F  P=0.62 W13<W12 W24>W13 F Crit < F  P=0.9 W13>W12 W24>W13
P11 F Crit > F  P=0.68 W13<W13 W24<W13 F Crit < F  P<0.001 W13>W12 W24>W13
P12 F Crit < F  P<0.001 W13>W12 W24<W13 F Crit < F  P<0.001 W13>W12 W24<W13
P13 F Crit < F  P<0.001 W13>W12 W24<W13 F Crit < F  P<0.001 W13>W12 W24>W13
P14 F Crit < F  P<0.001 W13>W12 W24>W13 F Crit < F  P<0.001 W13>W12 W24>W13
P15 F Crit > F  P=0.098 W13>W12 W24>W13 F Crit > F  P=0.14 W13>W12 W24>W13
Aluminium Silicon
Tukeys Tukeys
Patient                                                                                                                                                                                                                                         
Difference in urinary excretion btween weeks 12, 13 and 24 (dF=14)
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5.4.7 Long term effect of consuming a silicon rich mineral water 
 
Data from each patient show statistically linear trends in that Si and Al concentration are 
increased after the addition of a Si rich mineral water to the diet (P < 0.001). A visual 
representation of this relationship is shown in figure 5.4.7.1. Patients 7 and P12 present a trend 
of Si and Al excretion, implying that Si concentration in the gut may be directly linked to excretion 
of Al in these individuals, the amount of Si excreted directly correlated with the amount of Al 
excreted (P = 0.005).  
Si data is presented in orange, while Al data is presented in blue and weekly data is presented for 
each MS study participant.  
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Visual representation of changes in mean urinary excretions 
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Fig. 5.4.7.1: Mean and SD (n=15) urinary excretion of Si (μmol/mmol Crt) and Al (nmol/mmol Crt) 
for weeks 1, 12, 13 and 24 for each patient. 
 
When comparing the data as a whole, the means between W1 and W12 remain at a comparable 
value. Al excretion during W24 is on average much larger (429.1 nmol/mmol creatinine) than that 
of the initial treatment week, W13 (280.2nmol/mmol creatinine), although as in all cases here, 
the larger the average, the larger the deviation present between the values. 
Si dependent t-stat values between control Wk 1 and Wk 12 were calculated to be 4.14 with a P 
value < 0.001 and Pearson Correlation of 0.96. Patient t-stat values between treatment Wk 13 
and Wk 13 were calculated to be 2.63 with a P – value < 0.02 and Pearson correlation of 0.96 
(Table 5.4.7.1). Values for the treatment period are less correlated due to Si handling alternating 
between individuals. 
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Table 5.4.7.1: Summary of t-Test for paired means - differences in the urinary excretion of Si 
between baseline period Wk1 and Wk12 then study period Wk13 and Wk24 for each study 
participant 
 
 
 
 
 
 
 
Al dependent t-stat values between control Wk 1 and Wk 12 were calculated to be 1.52 with a P 
value < 0.15 and Pearson Correlation of 0.68. Patient t-stat values between treatment Wk 13 and 
Wk 24 were calculated to be -5.54 with a P – value < 0.001 and Pearson correlation of 0.93 (Table 
5.4.7.2). Values for the control are less correlated due to naturally fluctuating levels of Al in body 
biochemistry, levels of Al in the treatment period are more statistically linear (p < 0.001, P = 0.93). 
 
 
 
 
 
Function
t Stat
P one-tail
t Crit one-tail 
P two-tail
t Crit two-tail
Pearson Correlation
0.0010 0.02
2.14 2.14
0.96 0.96
4.14 2.63
0.0005 0.01
1.76 1.76
t-Test: Paired Two Sample for Means                                    
Silicon (n=15)
Week 1- Week 12 Week 13-Week 24
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Table 5.4.7.2: Summary of t-Test for paired means - differences in the urinary excretion of Al 
between baseline period Wk1 and Wk12 then study period Wk13 and Wk24 for each study 
participant 
 
 
 
 
 
 
 
5.4.8 Gender comparisons 
 
 
When comparing male and female data, the values were significant for weeks W13 and W24 for 
silicon for both genders. The p-value between genders for these weeks are below 0.04 (0.038) 
which is consistent with the idea that all patients are consuming the same amount of silicon during 
this time. The excretion of Al is more sporadic and p-value between these treatment weeks shows 
insignificance for W13 (P = 0.83), showing a large variation between genders during this treatment 
period (Table 5.4.8.1). 
 
 
 
 
Function
t Stat
P one-tail
t Crit one-tail 
P two-tail
t Crit two-tail
Pearson Correlation 0.68
2.14
0.93
1.76 1.76
0.15 7.29359E-05
2.14
Week 1- Week 12 Week 13-Week 24
1.52 -5.54
0.08 3.6468E-05
t-Test: Paired Two Sample for Means                  
Aluminium (n=15)
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Table 5.4.8.1: Summary of Wilcoxon signed-rank - differences between pairs of means of 
excretion for male (n = 7) and female groups (n = 8). 
 
 
  
 
 
 
 
 
When comparing the differences in excretion of Si and Al between genders, females appear to 
consistently excrete more Si and Al than males in both the control and treatment periods. These 
values were compared using Mann-Whitney U-test analysis to determine the significance of these 
differences (Table 5.4.8.2). In the first baseline Wk 1, males excreted a mean Si amount of 
75.7µmol/mmol CrT while females excreted a mean Si amount of 124.2µmol/mmol CrT. This 
difference was consistent throughout the study and in Wk 24, the final treatment week, males 
presented a mean Si excretion of 156.8µmol/mmol CrT while this value was noted at 
206.1µmol/mmol Crt for females. 
 
 
 
 
 
W1
W12
W13
W24 0.432
Male v Female Patients
Silicon Aluminium
P-Value P-Value
0.175 0.134
0.1 0.175
0.038 0.83
0.038
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Table 5.4.8.2: Differences in the excretions of Si (μmol/mmol Crt) and Al (nmol/mmol Crt) between 
males and females for the patient group. 
(Mann-Whitney U test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The relationship between Al and Si excretion is shown for females (Figure 5.4.8.1) and males 
(Figure 5.4.8.2).  In five out of the eight female MS patients (F1, F2, F4, F5, F8) and 4 out of 
the seven male MS patients (M1, M2, M3 and M4), a clear relationship can be seen between 
Si and Al excretion. The first half of the study, the baseline period, produces lower peaks in 
the data compared with the second half of the study, the treatment period, when the 
ΣW 120.7 206.1 0.09
W13 184.9 313 0.038
W24 156.8 283.7 0.038
W1 75.7 124.2 0.175
W12 65.3 103.3 0.1
Patient
Male                       
(n=7)
Female                            
(n=8) P-value
Silicon (μmol/mmol Cre)
ΣW 190.4 302.5 0.39
W13 248.6 307.8 0.83
W24 313.6 530.04 0.432
W1 118.6 206.2 0.134
W12 80.9 166 0.175
Aluminium (nmol/mmol Cre)
Patient
Male                       
(n=7)
Female                            
(n=8) P-value
Silicon (µ ol/ ol Crt) 
Alu i i  l l Crt) 
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incorporation of the Si rich mineral water in the diet commenced. Patient M5 would follow 
this trend but a sharp Si peak was noticed at 281µmol/mmol Crt during baseline Wk 7.  
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Figure 5.4.8.1: Creatinine corrected urinary excretion of Si (μmol/mmol Crt) and Al 
(nmol/mmol Crt) over the 24 week collection period – Female 
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Figure 5.4.8.2 Crt corrected urinary excretion of Si (μmol/mmol Crt) and Al (nmol/mmol Crt) over 
the 24 week collection period – Male 
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Excretions of Al and Si were compared with the urine volumes collected throughout the 24 hour 
baseline and treatment collection periods. Genders were considered individually, although there 
was no correlation between urine volume and amounts of Si and Al in either male (r = 0.24) (Figure 
5.4.8.4) or female (r = 0.18) (Figure 5.4.8.3) study populations. Patient F4 indicted the strongest 
positive correlation between urine volume and Si (r = 0.81) and Al (r = 0.75) excretion, although 
this is seen for the control period only. 
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Figure 5.4.8.3 Creatinine corrected elemental excretion comparisons to volume of urine excreted over 
the control and treatment period for each individual female. W1 and W12 24 hour collection 
data points are included for the control then W13 and W24 24 hour collection data are 
presented in the treatment study. Primary y-axis = Si (μmol/mmol Crt), secondary y-axis = Al 
(nmol/mmol Crt). 
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Figure 5.4.8.4 Crt corrected elemental excretion comparisons to volume of urine excreted over the control and 
treatment period for each individual male. W1 and W12 24 hour collection data points are included for the 
control then W13 and W24 24 hour collection data are presented in the treatment study. Primary y-axis = Si 
(μmol/mmol Crt), secondary y-axis = Al (nmol/mmol Crt). 
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5.4.9 Comparisons between creatinine corrected urinary excretions in 
the control and treatment periods – group data 
 
All study participants that excreted a larger concentration of silicon after consuming the Si rich 
mineral water correlated this with an increase in Al excretion (P < 0.001). The percentage 
difference between the control and treatment period of Si ranged from -0.2% to 158%. This figure 
is equivalent to the addition having no effect of Si excretion to it encouraging eight fold the 
excretion of Si compared to the normal expected value (Table 5.4.9.1). A single patient produced 
a minus percentage difference value of -0.2%. Patient F8 excreted less Si on average in their urine 
during the treatment period (Wks 13-Wk24) than the control period (Wks 1-Wks12). This value 
was not significant (P = 0.78). 
Table 5.4.9.1: Mean Crt corrected urinary excretions of Si (μmol/mmol Crt) and Al (nmol/mmol 
Crt) for the control and treatment groups and the percentage difference between the groups. 
 
Control Treatment % Difference Control Treatment % Difference
73.7 191 88.6 76.8 271.1 111.7
95.8 120.1 22.5 69.7 245.4 111.5
24.05 204.9 158.0 36.8 276.1 153.0
40.6 180 126.1 108.5 263.8 83.4
149.8 247.8 49.3 184.7 387.7 70.9
81 150.5 60.0 105.5 227.6 73.3
33.3 101.5 101.2 116.1 296.3 87.4
137.95 331.8 82.5 150.4 352.5 80.4
148.1 140.8 5.1 122.75 146.6 17.7
87.8 375.8 124.2 153.9 376.3 83.9
142.2 424 99.5 93 491.4 136.3
107.6 472.8 125.8 444.2 406.4 -8.9
55.3 221.2 120.0 198.5 547.1 93.5
104.7 295.2 95.3 208.1 401.4 63.4
125.5 125.3 -0.2 118 630.2 136.9F8
F3
F4
F5
F6
F7
M5
M6
M7
F1
F2
M1
M2
M3
M4
REF
Mean of the creatinine corrected urinary excretions over a 24-hour period
Silicon (μmol/mmol creatinine) Aluminium (nmol/mmol creatinine)
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All patients, excluding one, excreted more aluminium in the treatment period than the control 
period (P = 0.004). Patient F5 was the only member of the study to excrete less aluminium as a 
whole during the treatment period W13 to W24 compared to the control period, Wks 1 and Wk 
12, decreasing excretion by -9%. This value was not significant (P = 0.81). 
 
There is strong positive correlation between aluminium and silicon excretion for the treatment 
period (r = 0.96). Figure 5.4.9.1 highlights the relationship between aluminium and silicon, 
demonstrating the control period in dark grey (r = 0.51) and the treatment period in pale grey (r 
= 0.96). Correlation between the excretions of the elements is stronger during the treatment 
period (P < 0.005), although a higher quantity may encounter a lower error margin, resulting in a 
more linear relationship. R-values and p- values for these relationships are shown in table 5.4.9.2. 
 
 
 
 
 
 
 
 
 
Figure 5.4.9.1: Crt corrected excretion of Al (nmol/mmol Crt) for the control (●) and treatment 
(●) periods against Si excretion (μmol/mmol Crt). 
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Table 5.4.9.2: Correlation analysis between the Crt corrected excretion of Al (nmol/mmol Crt) 
with the excretion of Si (μmol/mmol Crt). 
 
 
 
 
 
5.4.10 Comparisons between total Al and Si excreted during 24 hour 
urinary collections in the control and treatment periods 
 
 
24-hour collections provide the most reliable information on urinary excretions and were 
collected for 5 consecutive days in two of the control weeks and two of the treatment weeks. 
Data from each individual is considered below and presented in concentrations of ng/24 hr for Al 
excretion and μg/24 hr for silicon excretion. When examined as a group, Al excretion shows strongly 
positive correlation with Si excretion (r = 0.965). This relationship indicates statistical significance for 
the MS treatment protocol for long term Si consumption as a method of removing bioavailable Al (P 
< 0.001). 
 
 
 
 
 
Relationship with Silicon
Aluminium
r-Value p-Value
Control
Treatment
0.51 <0.05
0.96 <0.05
210 | P a g e  
 
5.4.10.1 Individual data for 24 hour urinary Si excretion from week 1 to 
week 24 in the MS study group  
 
Si excretion in Wk1 (Baseline) ranged from 84-1153µg/24 hr with a mean value of 536 µg/24 hr 
(SD=317 µg/24 hr, n=15). Si excretion in Wk 13 (Treatment) ranged from 489-2391 µg/24 hr with a 
mean of 1710 µg/24 hr (SD=612 µg/24 hr, n=15), (Table 5.4.10.1). Data for Wk13 showed an increase 
in Si excretion compared to Wk1 for 15 out of 15 individuals (P <0.001). 
Mean urinary excretion of Si remained constant between control Wk 1 to control Wk 12, with means 
of 536 µg/24 hr and 432 µg/24 hr respectively (P = 0014).  Si excretion in Wk 12 ranged from 110-882 
µg/24 hr with a mean value of 432µg/24 hr (SD=254 µg/24 hr, n=15), see Table 5.4.10.2.1. 
Mean urinary excretion of Si for the final treatment week, Wk 24, ranged between 475-2465 µg/24 hr 
with a mean value of 1482 µg/24 hr (SD=682 µg/24 hr, n=15). This value remains consistent (Pearson 
correlation analysis, P = 0.018) between treatments Wk 13 and Wk 24, with a small distribution in the 
data (SD = 617 µg/24 hr in Wk13 -619 µg/24 hr in Wk 24) compared with differences in Si between the 
baseline weeks. Although, when considered individually, In seven out of the fifteen patients, Si 
excretion increased significantly between treatment Wk 13 and Wk 24, increasing from an average of 
1264 µg/24 hr to 1904 µg/24 hr. In a further seven of the fifteen patients, the concentration of urinary 
Si excretion dropped by a statistically significant amount during the treatment period (P < 0.001), from 
1878 µg/24 hr in Wk 13 to 934 µg/24 hr in Wk 24. Patient ID’s M002 and M004 gave the greatest 
reduction of Si excretion during this time. Patient M002 excreted an average of 2391 µg/24 hr Si in 
Week 13 compared to 831 µg/24 hr in Wk 24, and Patient M004 excreted an average of 2095 µg/24 
hr of Si in Wk 13 compared with 972 µg/24 hr in Wk 24.  
When considered as a group, the amount of silicon in the urine increased significantly during the entire 
treatment period (P < 0.001). 
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5.4.10.2 Individual data for 24 hour urinary Al excretion from week 1 
to week 24 in the MS study group  
 
 
Al excretion in Wk1 ranged from 204-2235 ng/24hr with a mean value of 939 ng/24 hr (SD=564ng/24 
hr, n=15). Al excretion in Wk 13 ranged from 275-2458 ng/24 hr with a mean of 2214 ng/24 hr (SD 
=1184ng/24hr, n=15), see table 5.4.10.2.1 Data for Wk13 showed an increase in Al excretion 
compared to Wk1 for 13 out of 15 individuals (P <0.001). For those patients of which Al decreased, 
the values altered from 859 to 275 ng/24 hr and 495 to 199 ng/24 hr between baseline Wk 1 and initial 
treatment Wk 13. Both of these patients were female and reductions of Al were significant between 
these weeks (P = 0.008 and P = 0.013 respectively). 
This is also seen in the data collected from patient ID F009 who indicated a drop from 101 – 42 ng/24 
hr between control Wk 1 and treatment Wk 13. Of the remaining individuals, ten out of the thirteen 
indicated a strong increase of Al after the addition of the Si rich mineral water, Al excretion more than 
doubled for these individuals, with an average increase of 898 to 2812 ng/24hr (P < 0.001). The last 
three participants, still presented a significant increase between this baseline and treatment week, 
with a mean increase of 1368 to 2203 ng/24 hr (P=0.014). 
Mean urinary excretion of Al remained statistically consistent between control Wk 1 to control Wk 12 
(P = 0.017).  Al excretion in Wk 12 ranged from 278-2300 ng/24 hr with a mean value of 862 ng/24 hr, 
see table 5.4.10.2.1. 
Mean urinary excretion of Al for the final treatment week, Wk 24, ranged between 1670 – 6252 ng/24 
hr with a mean value of 2505 nmol/24 hr. This mean value is consistent between treatments Wk 13 
and Wk 24 (Pearson correlation analysis, P = 0.002).  When considered individually, eight out of the 
fifteen patients showed a significant increase in Al excretion over the treatment weeks and excretion 
was larger in Wk 24 then Wk 13. Patient ID F009 displays an unusual increase in urinary Al 
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concentration from 199 ng/24 hr in treatment Wk 13 (compared to 508 ng/24 hr for their baseline 
average) to 6252 ng/24 hr in treatment Wk 24. Other patients showed a marked reduction in Al 
excretion over this time (P = 0.27) and patient ID F001 showed a very statistically similar excretion 
throughout this treatment period (P = 0.004) by excreting on average 2183 ng/24 hr in Wk 13 and 
2137 ng/24 hr in Wk 24. 
Deviation within this data was larger for the treatment period than the baseline study. Deviation 
ranged from 564-632 ng/24 hr between Wk 1 and Wk 12, whereas, between treatment Wk 13 and Wk 
24, deviation ranged from 1184-1440 ng/24 hr.  
Visual representation of this relationship throughout the study is shown in figure 5.4.10.2.1. 
During the control period, these values remain similar (Pearson correlation analysis, P = 0.011), 
although between treatment periods these values differ (P = 0.28). There is more variability 
between data collected during the treatment period. 
 
 
 
 
 
 
 
Figure 5.4.10.2.1: Twenty four hour excretion of Al (ng/24hr) for the control W1 and W12 and 
treatment W13 and W24 compared to Si excretion (μg/24hr) for the study group (n=15) 
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Table 5.4.10.2.1: Mean (SD) urinary excretion of Si (μg/24 hr) and Al (ng/24 hr) for the 24 hour 
data collected in Wk 1, Wk 12, Wk 13 and Wk 24. 
 
 
 
 
5.4.11 Silicon consumed compared to silicon excreted 
 
 
The amount of Si excreted can be directly related to that taken on in the form of Si rich mineral water. 
The amount of Si consumed per day in each study participant can be up to 24.19mg (864µmol), 
calculated from the average amount of Si in 1L of Spritzer mineral water, the amount being consumed 
by each patient per day of the treatment period. By calculating the difference in Si excretion between 
the control and treatment period, the difference in mineral water equating to that difference in Si can 
Al Si Al Si Al Si Al Si
F001 204 84 810 880 2183 495 2137 1951
M002 459 562 641 499 820 2391 2790 831
F003 300 573 707 513 918 1844 1674 590
M004 374 379 628 545 1855 2095 4454 972
M005 478 255 1548 224 649 1415 1670 475
F006 859 363 544 419 275 1892 3431 1321
M007 789 294 949 355 2769 2230 2481 1414
F009 495 854 516 561 199 2211 6252 2088
M010 1921 1086 836 882 3017 2263 2088 2289
M011 1247 648 1685 711 3362 1895 2616 2063
F012 1247 410 2300 284 4409 1264 2104 2426
F013 2235 1153 810 176 4458 1810 2828 1219
F014 1225 277 558 110 3654 1087 2639 1437
F015 1704 805 193 172 2944 1354 2199 2465
F016 551 299 278 157 1698 489 2505 696
Mean 939 (564) 536 (317) 862 (632) 432 (254) 2214 (1184) 1649 (612) 2791 (1440) 1482 (689)
Wk 1 Wk 12 Wk 13 Wk 24
Mean of the 24 hour urinary excretions over a 24-hour period (n=5)
Patient ID
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be calculated. This value ranged from 41-205% and there was no significant difference between 
genders (p = 0.79). Amounts were compared using measurements in µmol. Patient F5 saw the largest 
difference in Si, between the control and treatment period, Si increased by 1769µmol, allowing for a 
difference in Si of 204%. Patient M1 saw the smallest increase of 41% by silicon values increasing by 
352µmol between control and treatment periods. All patients saw an increase in Si excretion during 
the treatment period compared to the baseline study (Table 5.2.11.1). 
 
 
Table 5.2.11.1 Percentage of Si (µmol) consumed as mineral water which equates to the 
difference in Si excretion between the control and treatment period (n=15) 
 
 
 
 
Percentage difference of Si excreted varied between participants, there was very weak positive 
correlation between Si consumed and Si excreted (r = 0.71), when analysing these differences.  
 
M1
M2
M3
M4
M5
M6
M7
F1
F2
F3
F4
F5
F6
F7
F8 864 538.7 62.3
352.3
864 657.5 76.1
864 548.8 63.5
864 1233.6 142.8
864 1768.7 204.7
864 703.6 81.4
864 902.4 104.4
864 809.4 93.7
864 85.8
864 1176.7 136.2
864 1183.8 137.0
864 721.4 83.5
864 858.5 99.4
864
741.05
40.8
864 592.9 68.6
Amount of silicon consumed 
as mineral water (μmol)
REF
Difference in silicon excretion 
(Treatment – Control, μmol)
Percentage of mineral water which 
equates to the difference in silicon
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5.4.12 Secondary objective – measurement of disability 
 
A secondary outcome of the study was to measure the Kurtzke expanded disability status score for 
each participant before and after the study period. The results of this and other comparisons are made 
in this section.  
 
There is no significant relationship between disability level and excretion of Al and Si, as shown in 
figure 5.4.12.1 This was explored for both control and treatment periods. The r-value for the 
relationship between Si excretion and disability score for the control and treatment study was 
0.084 and 0.06 respectively. For Al, this relationship was weaker still, the corresponding r-value 
for the control period and treatment period was 0.04 and 0.001. At this point it was of interest to 
compare the creatinine levels in the urine to the disability scores. 
 
  
 
 
 
 
 
Figure 5.4.12.1 Correlation analysis between elemental excretion (n= 60) and EDSS scores of 
study participants (n=15) 
. 
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Figure 5.4.12.2 Correlation analysis between average elemental excretion (n= 60) and EDSS scores 
of study participants (n=15) for control Si ● and Al ● excretion and treatment Si ● and Al ● 
excretion. 
 
There is no significant relationship between disability level and urinary creatinine concentration 
(r = 0.012). Thirteen out of the fifteen patients had an EDSS score between 4 and 7. Two of the 
patients had an EDSS score of 1.5. The lower the score, the less the disability level. Although the 
CrT values of these patients were amongst the lowest (between 2.5 and 4.5mmol), patients with 
a more severe disability score of 6 presented with similar levels of CrT excretion in their urine. 
These values can be seen in table 5.4.12.1. 
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Table 5.4.12.1 Average creatinine content (n= 60) and EDSS scores of study participants (n=15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two out of the fifteen study participants showed marked improvements in their EDSS scores (>0.5 
point difference), while thirteen out of the fifteen patients showed no change during these 12 
weeks. No patients showed any decline in disability measure.  
 
 
 
 
 
 
 
P12
P13
P14
P15 7 4.2
ID EDSS Score Mean creatinine (mmol)
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
6.5 4.2
6 7.0
6 2.8
1.5 4.1
6 6.6
6 2.9
6.5 3.4
6 4.1
1.5 2.6
6.5 4.6
4 6.2
5 6.5
6 2.5
6 7.9
Correlation analysis between EDSS Score and Creatinine 
production (n=15)
218 | P a g e  
 
  
5.5 Summary of results for MS individuals  
 
 
• Creatinine concentration was negatively correlated with sample volume (Section 5.4.1.).  
• Males produced a larger urine volume during the control period while females produced a 
larger urine volume during the treatment period (Section 5.4.2). 
•Creatinine concentration was larger in males than females (Section 5.4.4) 
• Urinary excretions of Si and Al are significantly correlated during the treatment protocol 
(Section 5.4.9). 
• Urinary excretions of Si and Al are significantly increased following the consumption of the 
mineral water (Section 5.4.10).  
• The difference in Si excretion between the treatment and control periods corresponded to 99± 
42% of the amount of Si consumed as the mineral water. (Section 5.2.11). 
•Two out the fifteen participants indicated an improved EDSS score after the study period 
(Section 5.2.12) 
• No significant relationship was noted between EDSS score and urinary creatinine 
concentration (Section 5.4.12) 
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5.6 Discussion 
 
 
Comparing urinary volume and creatinine concentration 
 
24-hour collections provide the most reliable information on urinary excretions; however, 
creatinine corrected measurements were also documented. The negative correlation between 
creatinine concentration and sample volume verifies that creatinine concentration provides an 
acceptable indication of dilution effects. Creatinine concentration remained constant for males 
and females throughout the control and treatment protocol, at 4.44mM and 4.45mM 
respectively. A high level may mean that the kidneys are not working as they should. The amount 
of creatinine in the blood depends partly on the amount of muscle tissue present in the body. 
Men generally have higher creatinine levels than women. The measurements of volume and 
creatinine were comparable to literature values provided in Chapter 7.1, indicating that kidney 
function was normal for all study participants. 
 
EDSS scores 
 
There was no significant change in EDSS score for either the patient group. However, despite the 
relatively short treatment period, disability performance was improved (EDSS scores ≥ 0.5 points; 
Kujzke 1983) for 2 patients (F1 and F6), which highlights the potential use of silicic acid-rich mineral 
water in relieving the symptoms of multiple sclerosis. Longer term studies on larger populations are 
now needed to fully elucidate these findings and double blind studies should be used to determine 
any placebo effects. 
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The baseline Al excretion was variable between the individuals showing an improvement in EDSS 
score, there was also no pattern in the excretion of Al between these individuals. Participant F1 
showed a gradual decrease in Al over the treatment time after an initial sharp increase while 
participant F6 demonstrates a sporadic relationship with Al excretion, excreting high levels throughout 
the control and treatment, which fluctuate weekly. It may be suggested that this individual collected 
their spot samples at different periods of the day, leading to such fluctuations in elemental urine 
concentration. Urinary excretion of Al was higher in the treatment period than the baseline for both 
of these individuals. A linear relationship can be seen when looking at the excretion of Al and Si in 
participant F1, where a high urinary excretion for Si is noticed, a high urinary excretion is present also. 
Not one of the individuals in the study had a relapse during the entire study period, which over a 6 
month period is notable as individuals suffering with secondary progressive multiple sclerosis tend to 
suffer a relapse 1-2 times a year (Scalfari et al. 2010). 
 
Silicon handling was variable between individuals  
 
There is minimal data on the excretion of Si in urine, specifically concerning individuals suffering with 
MS. Urinary excretion of Si was variable between individuals, for example, the range of urinary Si at 
baseline was 84-1086µg/24hr (Table 5.4.10.2.1). As urinary Si is a good marker of absorbed Si, thus 
dietary differences between individuals may have contributed to these variations (Jugdaohsingh et al. 
2002; Sripanyakorn et al. 2009).  
Overall, an increase in urine volume was coupled with an increase in the excretion of Si. A mean 
increase in urine volume in the control period to the loading treatment period was twinned with 
an increase of Si in the urine. Si excretion decreased over the treatment period, in the initial 
treatment week, Si excretion was 1649µg/L (±612 µg/L) while by the final treatment week, Si 
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excretion had fallen to 1482µg/L (±619 µg/L). This may suggest that participants were not as 
enthusiastic when it came to drinking the mineral water as they initially were. This trend is not 
seen when looking at aluminium when considering the group as a whole. The urinary 
concentration of aluminium increases over the course of the treatment study, from 2214 µg/L 
(±1184 µg/L) in wk 13 to 2791 µg/L (±1440 µg/L) during Wk 24. There is however, large variation 
in this data. 
When looking at individual data, it is evident that aluminium follows silicon in the body of these 
individuals. When looking at Figure 5.4.8.1 and Figure 5.4.8.2, concurrent peaks can be seen for 
both aluminium and silicon throughout the study period. Participant F2 shows a very low plateau 
of silicon and aluminium urinary concentration up until Wk 12, then a sharp increase in silicon and 
aluminium excretion during initial treatment Wk 13. Over just a couple of weeks, this value 
returns to a level similar to the plateau we saw in the baseline period, suggesting that systemic 
aluminium had been ‘flushed out’ of stores during the spike. 
Consumption of the mineral water significantly increased the amount of Si excreted in the urine (P < 
0.001, Section 5.4.10), this was coincident with increased Al excretion (P < 0.001). This signifies that 
the consumption of silicic acid-rich mineral water successfully enhanced the urinary excretion of 
Al in people with multiple sclerosis. 
 
 
 
 
222 | P a g e  
 
Chapter 6 - Comparisons between the healthy volunteer and multiple 
sclerosis studies. 
 
 
This chapter compares the urinary excretions between the different study groups. 
 
The MS study (Chapter 5) was compared to the 24-hour protocol of the healthy volunteer study 
(Chapter 3). The Mann Whitney U test was used to determine whether there was any difference 
in the median urinary excretions between the groups before and following the treatment of the 
mineral water. 
 
It should be noted, as mentioned in the methods chapter, that the brand of mineral water 
provided is Spritzer. This brand of water was maintained for all investigations to ensure thorough 
consistency of data and controls. That the amount of Si taken in remained consistent between all 
volunteers. 
 
6.1 Creatinine  
 
Creatinine concentration was higher in MS patients (P = 0.003) and the younger age group of the 
healthy individual study (P = 0.007). Creatinine measurement wasn’t as crucial during the healthy 
volunteer study due to the fact that only 24 hour samples were collected, whereas spot samples 
were collected for the long term MS study. Creatinine values were collected for consistency.  
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6.2 Sample Volume 
 
Total 24-hour urine volume was larger in the MS study population than the healthy volunteers for 
females, healthy males excreted more urine than males with SPMS. On average, males excreted 
on average 1702mL/24 hr while females excreted on average 1710mL/24hr. In the healthy subject 
study, males excreted on average 1845mL/24hr while females excreted 1496ml/24hr. This 
difference remained consistent for both genders and in both sets of data, female urine volume 
was consistently larger for both control and treatment periods.  
In the healthy volunteer study, urine volume collected over the 24 hours was consistently larger 
for the dosing treatment than the loading treatment, for both males and female. 
6.3 Silicon  
 
Each study indicated an increase in the excretion of Si in the treatment period compared to the 
control. 
 
Urinary silicon concentration was significantly larger in the MS study population than in the 
healthy volunteers for the control and treatment periods. The median Si excretion for the MS 
patient control period was 484µg/24hr compared to 124µg/24hr for the HV group. This was 
consistent among genders. Men consistently excreted less Si than females (p = 0.002). Participants 
of the HV loading study were less likely to consume all of the total 1.5L volume of spritzer, leading 
to a lower Si excretion.  
The percentage of Si from the mineral water which equated to the difference in the urinary excretion 
between the control and treatment periods (i.e. treatment minus control) was 99 ± 42%, this was 
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statistically higher (P = 0.018) compared to the healthy volunteer study, 59 ± 31% for the loading 
treatment and 95± 25% for the dosing period. 
Silicon excretion in the healthy volunteer study was higher during the dosing treatment than the 
loading treatment (Table 6.4.1). 
 
The mean excretion of Si in the HV treatment period was significantly higher (t = -5.13, P < 0.001) than 
the control period; no individuals excreted more Si prior to drinking the mineral water. In the HV study, 
males excreted significantly more Si than females for the treatment period (t = 2.95, P = 0.008), but 
not for the control (t = 1.30, P = 0.208). 
 
There was a significant difference in the median Si excretion between males and females for the 
MS patient groups in both the control (t = 3.15, P = 0.008) and treatment (t = 2.98, P = 0.004) 
section of the investigation. Males generally excreted more silicon, in the control and treatment 
period. 
 
6.4 Aluminium 
 
Each study indicated an increase in the excretion of Al in the treatment period compared to the 
control. Excretion of Al in the healthy volunteer group was mostly smaller for the treatment 
period (P < 0.001) than that of patients in the MS study. MS patient excreted more Al during the 
treatment period. 
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There was no significant difference in the median urinary excretion of Al between the MS group 
and the healthy individual group for the control period; however, healthy volunteers excreted 
significantly less (P < 0.001) Al in the treatment period compared to the MS group. 
 
It is most sensible to relate the dosing HV data to the MS study data, this is because the MS study 
population were consuming the water throughout the day in a similar manner. Therefore, direct 
comparisons are made between dosing treatment data for the HV population and the MS 
treatment period. Loading treatment data is included for consistency. 
 
However, the manner in which these groups handled Al following the treatment of the mineral 
water were different (Table 6.4.2); the healthy individual group demonstrated a large increase in 
Al excretion (P = 0.004) during the Si loading treatment, which was coincident with an increase in 
Si excretion (P = 0.001). This was not the case for the MS study, where a smaller change in Al (P = 
0.41) was witnessed at the beginning of the long term treatment study with an alternating 
increase in Si (P = 0.28). In general, Al excretion was larger for the last treatment week than the 
initial treatment week (P = 0.009), shown in Table 6.4.3, suggesting a long term treatment with Si 
is more beneficial for lowering body bioburden of Al.  
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Table 6.4.1: Mean urinary excretions of Si before and after consuming the mineral water in 
healthy individuals (HV) and individuals with multiple sclerosis (MS) 
 
 
 
 
 
 
 
Table 6.4.2: Mean urinary excretions of Al before and after consuming the mineral water in 
healthy individuals (HV) and individuals with multiple sclerosis (MS) 
  
 
 
 
 
 
 
 
 
 
 
 
 
HV Loading 126 614 Spritzer 1.5L
HV Dose 126 951 Spritzer 1.5L
MS Dose 484 1596 Spritzer 1.5L
Group Therapy Control Treatment
Brand of 
water
Maximum water 
consumed
Urinary excretion of silicon (μg/24hr)
HV Loading 967 2814 Spritzer 1.5L
HV Dose 967 2085 Spritzer 1.5L
MS Dose 903 2503 Spritzer 1.5L
Urinary excretion of Al (μg/24hr)
Group Therapy Control Treatment
Brand of 
water
Maximum water 
consumed
(n / r) 
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Table 6.4.3 Differences in the median excretions of Si and Al during the control and treatment weeks 
between healthy individuals (n = 19) and patients with multiple sclerosis (n = 15) - Mann Whitney U 
test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HV MS P - value HV MS P - value
84 296 0.002 742 658 0.001
804 1224 0.096 1754 2206 0.004
Control
Treatment
Week
Silicon (μg/24hr)
Comparison of median excretions
Aluminium (μg/24hr)l i iu  (ng/2 r) 
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Chapter 7 – Discussion: Integrating silicic acid-rich mineral water into 
the diet is an effective, non-invasive method of reducing body burden 
of Al. 
 
 
This research was undertaken with the aim of illuminating the application of a commercial silicic acid-
rich mineral water as a non-invasive method of reducing Al body burden, when used as part of an 
individual’s normal diet. The primary objective was to investigate Si handling and the consequential 
effects on urinary Al excretion. 
 
Different protocols - healthy individuals 
 
 
Despite widespread evidence signifying a beneficial role of Si in biota, there is little reliable 
information on Si handling in humans, particularly regarding healthy individuals. In order to determine 
whether there is any change in Si handling in disease it is first important to explore Si handling in these 
‘normal’ individuals. Thorough investigations concerning healthy individuals were therefore 
performed, using two different protocols, exploring two different excretory mechanisms, sweat and 
urine. 
As Si is known to be rapidly absorbed and excreted (Popplewell et al. 1998), it was considered that a 
period of one week between each protocol would be sufficient to minimize any influence on Si 
excretion between each study. However, it could be thought that Al body burden would have been 
influenced, if not lowered, with each additional protocol. 
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Al intake in the diet is approximately 20 mg day-1 (Pennington & Jones, 1989); only 0.1% of this is 
absorbed (Day et al. 1991), leading to around 140 μg of Al possibly contributing to Al body burden 
from dietary exposure each week. As we bare this in mind, it is unlikely that the weekly time periods 
between each different protocol were sufficient to replenish the Al body burden removed from the 
elevated Si dose.  
However, as each protocol consisted of a control and treatment period in which the urinary excretions 
were compared, the overall effect on Al excretion could be explored. 
 
24-hour collections provide the most reliable information on urinary excretions; however, these 
were not sensible for the longer term studies, especially when these studies concern vulnerable 
individuals (i.e. MS patients). For this reason creatinine corrected measurements were also 
documented. The negative correlation between creatinine concentration and sample volume 
verifies that creatinine concentration provides an acceptable indication of dilution effects. The 
positive correlations between the urinary excretions of Si and Al when expressed as total amounts 
and when corrected for creatinine validate that both methods are appropriate for determining 
urinary excretions. 
 
The mean creatinine concentration at baseline (5.8 ± 1.7 mM) and volume of urine produced (1670 ± 
399 mL) correlates well with the literature values (Table 7.1), confirming that the healthy participants 
had normal kidney function. 
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Table 7.1: Comparisons of creatinine concentration and sample volume with other studies 
 
 
 
 
 
 
Consumption of total beverages was higher in the treatment period compared to the control (P < 
0.001) for the healthy volunteer population indicating that the participants consumed the mineral 
water in addition to, rather than in replacement of, their normal intake. This is likely to be due to 
the short time period over which the mineral water was consumed. From this, it could be argued 
that the increase in Si excretion is merely a reflection of the higher consumption of beverages, 
independent of their Si content.  However, a positive correlation was only witnessed between the 
excretion of Si with total beverages consumed during the treatment period, which verifies that 
the witnessed increase was due to the addition of the mineral water. 
 
Silicon handling was variable between individuals 
 
Urinary excretion of Si was variable between healthy individuals, the range of urinary Si at baseline 
was 61-231 μg/24h. As urinary Si is a good marker of Si absorbed, dietary differences between 
individuals would have contributed to these variations (Jugdaohsingh et al. 2002; Sripanyakorn et al. 
2009).  
Range Range
3.22-8.54 650-2350
2.6-11.5 550-1150
4.3-9.4 450-3250
9.1-15.8 1020-2740 (Powell et al. 1999a)
This study
(Rodriguez et al. 2004)
(Costa et al. 2007)
(Powell et al. 1999a)
Creatinine Concentration (mM) Sample Volume (mL)
Reference Reference
This study
(Morie et al. 1996)
(Rabinowitch 1933)
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Distinctions in Si handling between individuals were also highlighted. Assuming that the dietary 
intakes of Si, excluding the mineral water, were similar between the control and treatment 
periods for each individual, it would be expected that the difference in Si excretion equated to 
the amount of Si ingested as the mineral water. However, in the loading study only 59 ± 31% of Si 
ingested as the mineral water was excreted in the urine of health individuals; and this was highly 
variable between individuals. In the dosing study where a steady stream of Si was delivered 
throughout the day, this difference equated to 95 ± 25% of Si ingested as the mineral water 
excreted. This supports the variability between Si handling and suggests that a consistent dose of 
Si exposure throughout the day ensures more of this Si is bioavailable and becomes absorbed into 
the bloodstream. 
The changes in Si excretions (treatment minus control) between the 19 participants who 
consumed the full 1.5L of mineral water during the dosing protocol were considerably different. 
Two individuals (M1, F2) appear to have excreted less than 70% of the Si consumed as the mineral 
water (Table 3.1.3.2), suggesting that they have reduced Si handling. Seven individuals (M2, M3, 
M4, M6, M7, F8, F9) excreted more than the expected 100% Si following the consumption of the 
mineral water during the dosing protocol. It is possible that these individuals consumed other Si 
rich sources on this day.  
 
Effect that the mineral water had on urinary excretions 
 
 
The baseline urinary excretion of Si was 126 ± 55 μg/24 hours. This was significantly correlated (P = 
0.015) with Si excretion in both loading treatment period (614 ± 253 μg/24h) and dosing treatment 
period (951 ± 246 μg/24h), despite the single individual who excreted two fold more Si after 
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consuming the mineral water, fourteen out of the fifteen patients saw Si excretion increase by more 
than three-fold of the baseline concentration for the loading period, this value further increases when 
considering the dosing data. Positive correlations were also seen for Al (P < 0.001) which indicates that 
the amounts of Si and Al excreted in the treatment period were dependent on the baseline levels. 
Consumption of the mineral water significantly increased the amount of Si excreted in the urine of 
females (P < 0.001), although for males, this value increased only marginally (P = 0.41). Increases were 
coincident with increased Al excretion (P < 0.001). This signifies that the consumption of silicic acid-
rich mineral water successfully enhanced the urinary excretion of Al in healthy individuals. 
Males excreted more Si and Al than females. These differences were seen throughout the study, 
highlighting that both genders metabolise the elements similarly. Males excreted slightly more Si 
compared to females during the treatment periods, however, this was not surprising as males 
consumed, on average, more of the mineral water (P = 0.001) 
 
Co-excretion of Si and Al was apparent in the loading Si data; the relationship between Si and Al 
along with the rapid excretion of Si demonstrates that Al is excreted as a bolus following the 
consumption of the mineral water. In addition, regular consumption of the mineral water 
throughout the day was observed to promote lesser Al excretion, although may maintain this at 
a lower level; 17/19 healthy individuals showed a larger increase in Al excretion which was 
coincident with a loading effect of Si consumption. An increase in Al excretion was witnessed for 
2/19 individuals during the dosing treatment period, indicating that regular Si supplementation 
could prevent Al accumulation more efficiently in these individuals. It is anticipated that over a 
longer period of time Al excretion would be reduced in more individuals. 
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To summarise the healthy individual study; consumption of the mineral water significantly 
increased the urinary excretions of Si and Al. Al were rapidly excreted as a bolus during Si loading 
although Si excretion was at a higher level when a steady stream of Si was consumed throughout 
the day. Treatment over a long term period could result in reduced Al body burden. 
 
Baseline 24h urinary excretions of Si and Al were compared with literature values (Table 7.2). 
With the exceptions of the studies by Roberts et al. (1998) and Kazi et al. (2008), who used large 
populations, the group sizes presented in the other studies were much larger. These differences 
would have contributed to the higher fluctuations in urinary excretions between the literature 
sources. For instance, the urinary excretion of Al seems to be higher compared to other studies 
using a similar age range (Morie et al. 1996; Reffitt et al. 1999), however, these studies had 
population size of 6 and 5 respectively. In addition, the low excretion of Al in the study by Reffitt 
et al. (1999) may be attributed to the participants fasting. The higher excretion of Al within the 
healthy volunteer study could also be a reflection of a university student’s diet, which is typically 
high in processed foods and alcohol (Devine et al. 2006). Processed foods are generally high in Al 
(Pennington & Jones, 1989) and alcohol is known to increase gut permeability (Barchfeld & 
Deamer, 1988) which could augment Al uptake. Other dietary factors, such as citrate (Taylor et 
al. 1998) contributes to the absorption of Al, therefore, an individual who regularly consumes 
fruit juice may have an increased absorption of Al. 
 
The majority of individuals in the present study were also regular tea drinkers 13/19. Tea is a 
diuretic which contains high levels of Al (Forster et al. 1995). Despite the bioavailability of Al in 
tea being considered to be low (Powell et al. 1993; Gardner & Gunn, 1995), regular consumption 
is believed to contribute to enhanced absorption (Nieboer et al. 1995). However, it was 
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demonstrated that higher daily consumption of tea results in reduced Al excretion (see section 
3.1.10). A possible explanation of this is that Al is in too great an excess of Si to allow the complex 
to form and enable Al to be excreted. 
 
In the study by Reffitt et al. (1999), the participants fasted in order to investigate whether silicic 
acid promotes the urinary excretion of endogenous Al. Results of the study demonstrated no 
significant change in Al excretion (Table 7.2); however, in view of the young age of the group (and 
the small population size) it is unlikely that Al accumulation was unusually high and consequently, 
effect on eradicating Al from body stores would have been minimal. It would be of interest to 
carry out this study with a larger pool size of elderly participants, furthermore those with 
susceptibility to an increased bioburden of Al, like individuals with Alzheimer’s disease. 
 
Table 7.2: Comparisons in urinary excretion (mean ± SD) of silicon and aluminium with other 
studies. 
 
 
 
 
n = 19, 18-34y
n = 5, 24-31y
fasted
n = 115, 30-65y
healthy control
n = 19, 18-34y
n = 5, 24-31y fasted
n = 54, 30-65y
healthy control
22-23y, n = 6
69.2±4.4y, n = 6
667±222
2000±444
471±322
744± 589
950±820
967 ± 687
187±43
126 ± 55 
719±229
97±42
Notes
Summary of urinary excretions
Si (μg)
Al (ng)
This study
(Reffitt et al. 1999)
(Roberts et al. 1998)
This study
(Reffitt et al. 1999)
(Roberts et al. 1998)
(Morie et al. 1996)
(Morie et al. 1996)
Element Reference μg/ng/24h μg/ng/L
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Involvement of HAS  
 
The direct relationship highlighted between Si and Al supports the theory of HAS being involved in Al 
excretion. In the presence of free Si, Al is considered to exist as a low molecular weight HAS, giving 
the potential for reabsorption prevention and perhaps promoting its excretion. It is likely that this 
interaction predominantly occurs in the proximal convoluted tubule (Bellia et al. 1996), where Si 
becomes concentrated, at this point it may be allowed to exceed the critical level (0.1mM) required 
for the formation of HAS species (Birchall, 1992).  
The current literature has not yet demonstrated the formation of HAS in-vivo (Exley, 1998); however, 
a further study could potentially be measured using atomic force microscopy, which has been used to 
identify HAS in acidic solutions (Doucet et al. 2001). In order to fully uncover and add knowledge to 
the mechanisms behind the valuable effect of silicic acid-rich mineral waters, more research is needed, 
focusing on the biochemical interaction between Si and Al in-vivo.  
Silicic acid is a small, neutral molecule, composed of a single Si atom, a single O atom and four 
hydrogen atoms. Silicic acid is freely diffusible within the body and is rapidly absorbed and excreted 
(Popplewell et al. 1998); the desirable level of Si, to create its protective effect, is 0.1mM and may 
therefore not be withstanding in the body. Considering this, and also taking into account the effects 
of consuming Si in different doses in the HV study, in order to remove systemic Al, it may be necessary 
to regularly consume large quantities of mineral water over short time periods, rather than drinking 
small quantities throughout the day. 
The 24-hour loading study where the mineral water was consumed soon after waking, would have 
allowed surplus Si for this interaction to occur. Exact amounts consumed (quantities at specified times) 
for the dosing study were not available, so it was difficult to judge how often this critical level would 
have been reached, despite the entire volume of water being consumed by participants in the 24 
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hours, and a suggestion of 150mL per hour was made. This may explain some of the suggestions 
that Al absorption across the gut may actually be enhanced at lower Si concentrations (Birchall et 
al. 1996). 
It would have been interesting to analyse the relationships between Al excretion with the 
consumption of orange juice, beer and wine, however, the amount of data on these beverages was 
not sufficient to obtain a reliable outcome. 
 
Sweat 
 
It is interesting to note that in all sets of data, sweat production was slightly higher in the treatment 
set of data than the control, there is no current literature to suggest that fluid consumption would 
influence sweat volume production, only that, an appropriate amount of liquid needs to be taken on 
board to account for fluid loss in sweat.  
The volume of sweat collected during the study was consistently larger for males than females, 
indicating that men produce more sweat than women, although differences in thermoeffector 
function were largely determined morphologically, rather than being sex dependent (Notley et al. 
2017). The volume of sweat collected ranged from 0.66 to 1.55 mL and corresponded well with 
literature values for perspiration rates (Chen et al. 2012). 
The mean aluminium content in the control period was higher in females (341 ± 245 µg/L) than males 
(353 ± 141 µg/L) though the data for each group were not found to be significantly different from one 
another (P > 0.05). Contrary to this, the mean aluminium content in the treatment protocol was higher 
in males (1208 ± 433µg/L) than females (835 ± 334µg/L) and the data for each group were found to 
be significantly different from one another (P < 0.05).  
237 | P a g e  
 
The method blanks demonstrated a very low level of possible contamination by aluminium and were 
within the range of a previous study (Exley et al 2014).The latter demonstrated a high degree of 
confidence in the concentrations of aluminium measured herein which were towards the higher end 
of previous literature values (House et al 2012).  
When the concentrations of aluminium in collected sweat were adjusted to take account of the 
volume of sweat produced by men (1342 mL/24 h) and women (712 mL/24 h) in this age range (Manz 
et al 2012) and undergoing mild exercise the amount of aluminium excreted over 24 h ranged from 
135 to 421 µg/24 h for women to 96–770 µg/24 h for men during the control and from 274 to 875 
µg/24 h for women to 857–2250 µg/24 h for men (Table 4.4.7.2.1 and Table 4.4.7.2.2) with men 
excreting significantly more aluminium than women (P < 0.05). These data are significantly higher than 
those that describe the daily excretion of aluminium in urine, up to 100 µg/24 h (Exley, 2013) and 
therefore they heavily implicate sweating as the major route of excretion of systemic aluminium in 
humans, especially after the consumption of a Si rich mineral water. In doing so it may be that men, 
through perspiration, excrete aluminium from the body more effectively than women and it can be 
suggested that regular exercise might be a way to increase the excretion of aluminium from the body. 
If sweating is the major route for the removal of systemic aluminium from the body then this 
observation puts into question the practice of disrupting or blocking perspiration using antiperspirants 
and aluminium-based antiperspirants specifically. 
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Multiple sclerosis 
 
The project protocol was divided into two objectives; the primary objective was to measure the 
urinary excretions of Si and Al over a 24 week period during which patients consumed up to 1.5L 
of silicon-rich mineral water each day. The first 12 weeks of the study, referred to as the control, 
required each participant to provide urine samples following their normal diets, thus acting as 
their own control to determine individual changes. The secondary objective was to observe 
changes in mobility using EDSS scores at the beginning and end of the study. 
Consumption of total beverages was similar in the treatment period compared to the control (P 
< 0.001; Table 5.4.2.2) for the MS patient population indicating that the participants consumed 
the mineral water in replacement of their usual beverages. Urine volume was similar for the 
control and treatment period in this study population. 
 
The absorption of Si in the MS patient database is relatable to that of the dosing HV study. In this 
study, Si was incorporated into the diet of MS patients, replacing all normal water sources with 
the Si rich mineral water, therefore ensuring this constant stream of Si exposure throughout the 
day. The difference from the control and treatment period equated to a percentage difference of 
99 ± 42% of Si ingested as the mineral water was excreted in the urine of the MS patients. Despite 
this, eight out of the fifteen patients (M1, M2, M3, F1, F2, F6, F7, F8) excreted less than 90% of 
the additional Si consumed. Si handling may not be sufficient in these individuals, and therefore 
they may be more susceptible to Al toxicity. 
Of course, an individual’s dietary Si intake can fluctuate (Widner et al. 1998), therefore, this 
assumption may not be totally reliable. Nevertheless, the amount of bioavailable Si in mineral 
water is much higher compared to other dietary sources; intake from silicic acid-rich mineral 
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water significantly increased Si excretion compared to Si excreted from dietary sources, it is 
therefore reasonable to assume that the change in Si excretion is mainly due to the mineral water 
(Sripanyakorn et al. 2009. 
 
It is apparent that the interactions between Si and Al witnessed within the healthy volunteer study 
are also viable for patients with multiple sclerosis. 
Creatinine concentration was significantly lower (P = 0.003) in MS patients compared to young healthy 
individuals (Table: 6.1). However, it has been established that creatinine concentration decreases with 
age (Rodriguez et al. 2004) and the MS study population were also older than those taking part in the 
HV study.  
Regular consumption of silicic acid-rich mineral water successfully enhanced the urinary excretion 
of Al in individuals with MS. 
For two individuals (F006 and F009), an increase in Si excretion in W13 resulted in a decreased 
excretion of Al. This is comparable to the results seen in the preliminary study conducted by the 
silicon and aluminium research group at Keele (Exley et al. 2006a); where a significant increase in 
Si excretion (34.3 ± 15.2 to 55.7 ± 14.2 μmol/mmol creatinine) concomitantly reduced the urinary 
excretion of Al (86.0 ± 24.3 to 62.2 ± 23.2 nmol/mmol creatinine). 
The concentration of Al excreted in the final week (W13) of the treatment period was lower than the 
concentration at baseline (W1) for 8/15 patients (Figure 4.1); indicating a reduced body burden of Al. 
This is comparable to the preliminary study performed by this research group (Exley et al. 2006a), 
which showed that increased Si excretion (34.3 ± 15.2 to 55.7 ± 14.2 μmol/mmol creatinine) was 
concomitant with reduced Al excretion (86.0 ± 24.3 to 62.2 ± 23.2 nmol/mmol creatinine). However, 
240 | P a g e  
 
an enhancement in Al excretion was witnessed for 15/15 patients by the final treatment Wk 24; an 
observation not seen in the preliminary study. 
Multiple sclerosis patients are expected to have a greater Al body burden compared to controls, 
however, there was no overall difference (P = 0.844) in Al excretion between patients and control 
groups at baseline. Excretion of Al was higher for the MS patient group during the equivalent 
dosing treatment period, which may suggest that the mechanism to reduce body Al by enhanced 
excretion are less effective than in healthy individuals. After 12 weeks of drinking the Si rich mineral 
water, it may be suggested that some patients had become non-compliant with the protocol, 
explaining the decrease in Si excretion during this final treatment week. Despite this, all patients were 
said to be very compliant with following the protocol and consuming the 1.5L of mineral water 
provided for each day. The average percentage difference was 98.7%, suggesting that the increase in 
Si consumption through Si rich mineral water was mainly due to the Si rich mineral water added to 
the diet. 
 
As with many neurological conditions, gender plays a role in occurrence of the disease. In the case of 
MS, it is women that are more likely to develop the disease. The data surrounding disease severity 
and link to gender is sparse, but it may prove useful to determine whether those with a higher body 
bioburden of Al are further along with the progression of the disease. Females showed a significant 
difference in the overall excretions of Si and Al. Females excreted significantly more Si (P = 0.005) 
and Al (P = 0.012). This confirms the preliminary study (Exley et al. 2006a), where females 
excreted significantly more Si (P = 0.008) and Al (P = 0.007) compared to males. However, female 
healthy volunteers excrete less Al than male controls (P <0.001), and male healthy volunteers 
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excrete more Al (P = 0.058) compared to female healthy volunteers. The higher excretion of Al in 
female patients may be responsible for the higher incidence of MS in females compared to males.  
 
There was no significant change in EDSS score for either the patient group. However, despite the 
relatively short treatment period, disability level was improved (EDSS scores ≥0.5 points; Schrag 
& Schott, 2012) for 2 patients (F1 and F6), which highlights the potential use of silicic acid-rich 
mineral water in slowing the rate of decline in aged individuals and also suggests the possibility 
of relieving the symptoms of secondary progressive multiple sclerosis. Longer term studies on 
larger populations are now needed to fully elucidate these findings and double blind studies 
should be used to determine any placebo effects. 
 
The baseline Al excretion was variable between these individuals showing a marked improvement 
in mobility performance, there was also no pattern in the excretion of Al between these 
individuals. F8 demonstrated an initial increase in Al excretion in Wk 13 then a gradual decrease 
up until Wk 24 when Al excretion had reduced to a similar value (P < 0.001) to the initial baseline 
period. For patient F001, a large increase in Al excretion was seen during the initial treatment Wk 
and by Wk 24, this level had decreased to once similar to that of the initial treatment week.  
 
Suitability of Si-rich mineral water as a treatment against Al toxicity 
 
In young, healthy volunteers the application of a silicic acid-rich mineral water would be most 
effective as a prophylactic measure to prevent the accumulation of Al over time, which could 
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potentially slow the rate and progression of Al-related disorders. However, in aged individuals, 
where Al has presumably already accumulated, silicic acid-rich mineral water could be utilised as 
an Al chelator, removing systemic Al from body stores, which could potentially reduce the 
symptoms of Al toxicity. 
In comparison to other potential ‘treatments’ for Al toxicity, silicic acid is inexpensive, readily 
available, non-invasive and does not have any associated side effects (DFO has been connected 
with several side effects and its clinical application has been questioned in terms of its poor 
absorption and rapid degradation (reviewed in Liu et al. 2005).  
A large daily dose of silicic acid, as opposed to a steady dose, is the most effective way to remove 
systemic Al from the body. 
 
Could silicon remove brain aluminium?  
 
The improvements in cognitive function following the treatment of the mineral water could be 
attributed to reduced brain Al. The presence of aluminosilicates in senile plaques (Candy et al. 
1986) indicates that Si is able to cross the blood brain barrier and enter cerebral circulation. 
However, it is not certain whether the products of interaction, presumably HAS, will also be able 
to cross the blood brain barrier, to enable the removal of Al from the brain. Presently, 
confirmation of this would require brain biopsies both before and following the treatment of the 
water. Another possibility is that the Si-Al complex remains dormant in the brain, preventing Al 
from interfering with important biological molecules. This could also provide an explanation as to 
why aluminosilicates are also found within the brains of aged ‘normal’ individuals. 
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Conclusions 
 
This research brings new and exciting evidence to support the highly debated link between Si, Al 
and neurological disorders. Not only does it consolidate the application of bioavailable Si 
supplementation as a long-term chelation therapy against Al related neurodegenerative 
disorders, but it also suggests that reduced Si handling could be another risk factor, resulting in 
Al toxicity. 
As lower Si levels may increase susceptibility to Al toxicity, supplementing Si into the diet, by 
means of a silicic acid-rich mineral water, may be particularly beneficial for individuals with 
impaired Si handling, aging individuals (Si intake is estimated to reduce by 0.1mg with each year 
of a person’s age (Jugdaohsingh et al. 2002)) and to those residing in areas with geographically 
low Si (Taylor et al. 1995). 
Epidemiological studies have suggested that municipal waters containing silicic acid at 
concentrations above 0.2mM can protect against neurodegenerative disease (Rondeau et al. 
2009). Given the evidence, within the present study, that promoting Al excretion is most effective 
following a bolus of silicic acid-rich mineral water, the protective effects would be greater with Si 
concentrations above 0.5mM, such as those used within the present studies. 
Silicic acid-rich mineral water offers an inexpensive, easily available and non-invasive therapy 
against Al toxicity. Longer term studies are now warranted to determine whether incorporating 
silicic acid rich mineral water into a regular diet has any influence on the progression and 
symptoms of neurological disease. It would be of interest to explore the benefits of the loading 
dose of Si in SPMS patients as a method of promoting an increase in Al excretion in the urine. 
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Appendix 1 
 
Quality assurance - Replicates 
 
Concentration of analyte measured in repeated analytical runs of the same sample. Ref denotes the 
analysed sample, R denotes analytical run and % Diff denotes the percentage difference of the 
concentrations determined in each analytical run. Concentration (μg L-1) 
 
 
 
Silicon  Aluminium  
  
Ref  R1  R2  % Diff  Ref  R1  R2  % Diff  
        
24M5  150.2  153.5  -2.17  24M3  7.795  7.558  3.09  
        
24M9 98.68  95.42  3.36  24M4  13.36  12.96  3.04  
        
24F6  93.34  95.33  -2.11  24F7  7.334  7.183  2.08  
        
24M8 135.8  129.2  4.98  24F9  11.95  12.42  -3.86  
        
24M2  82.7  79.58  3.85  24M1  11.99  12.57  -4.72  
        
24F10 191.8  193.6  -0.93  24M7  6.229  6.118  1.80  
        
24F2 66.09  66.98  -1.34  24F5  5.104  5.063  0.81  
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Appendix 2 
Quality Assurance - Duplicates  
 
 
Concentration of analyte measured in replicated urine samples (i.e. urine sample was prepared 
twice). Ref denotes the sample which was duplicated, D denotes the number of duplicate 
samples and % Diff denotes the percentage difference in concentrations determined in the 
duplicate samples. Concentration (μg L-1). 
 
 
 
Silicon  Aluminium  
  
Ref  D1  D2  % Diff  Ref  D1  D2  % Diff  
        
24F1  162.5  167.1  -2.79  24M3  7.795  7.767  0.360  
        
24M1  212.3  218.4  -2.83  24F3  11.11  11.18  -0.628  
        
24M3  179.4  182.6  -1.77  24M5  6.650  6.587  0.952  
        
24F6  74.30  71.98  3.17  24M9  5.073  5.126  -1.039  
        
24M7  157.5  155.7  1.15  24M8  13.75  13.99  -1.730  
        
24F8  171.1  168.4  1.59  24F4 6.801  6.823  -0.323  
        
24M2  154.7  161.0  -3.99  24F10 6.676  6.742  -0.984  
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Appendix 3 
 
List of healthy individual questionnaires, sweat and urinary excretions (Template shown below) 
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Appendix 4 
 
 
Method blank data for aluminium (n=114) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
44 71 62 45 85 91
39 86 43 39 92 89
57 58 17 26 98 75
54 95 92 74 86 34
50 45 99 73 51 10
50 66 66 36 49 12
97 91 56 90 74 158
87 80 46 79 54 132
65 64 74 33 35 117
34 38 58 41 73 80
56 81 83 42 38 66
45 108 45 56 55 56
74 100 51 102 75 75
59 66 66 124 94 59
35 46 67 149 45 73
47 59 57 36 25 56
56 54 82 58 37 62
38 90 99 50 66 90
53 106 90 46 65 118
Amount of Al in digest (ng)
Mean Al in MD digest = 57ng
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Appendix 5 
 
 
EDSS Score Scale: 
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Annex 1 
 
NREC Ref: 14/YH/1115 Approval letter 
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Annex 2 
 
Supporting documents – MS Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
271 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
272 | P a g e  
 
 
 
 
 
 
 
 
273 | P a g e  
 
 
 
 
 
274 | P a g e  
 
Annex 3 -  
 
Patient diary template 
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Annex 4 
 
Research passport 
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Annex 5 
 
Ethical Approval documents – Healthy Volunteer Study  
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Ethical Application Document 
 
 
 
 
 
 
Project Title: Renal Handling of Silicon 
 
Project Leader: Krista Louise Jones 
 
07006754 
 
Project Supervisor: Professor Christopher Exley 
278 | P a g e  
 
 
 
 
Information for participants  
Outlined below is the relevant information about the study and the details of your involvement. 
 
Title of research: Renal Handling of Silicon in Humans. 
 
Overview of research: This PhD research project will investigate the renal handling of silicon in 
humans.  The primary aim of the study is to understand the absorption, retention and urinary 
excretion of silicon consumed as silicic acid rich mineral waters.  The secondary aim is to understand 
how drinking silicic acid rich mineral water influences the urinary excretion of aluminium and the 
essential metals, iron, copper and zinc.  
 
Invitation 
You are being invited to consider taking part in the research study, Renal Handling of Silicon in 
Humans.  This project is being undertaken by Miss Krista Jones, a PhD student of Professor Chris 
Exley. 
 
Before you decide whether or not you wish to take part, it is important for you to understand why 
this research is being done and what it will involve. Please take time to read this information 
carefully and discuss it with friends and relatives if you wish. Ask us if there is anything that is 
unclear or if you would like more information.  
 
Why have I been chosen? 
You have been chosen because you have shown enthusiasm towards the project through our emails 
and posters. You pass our inclusion criteria, as shown below, and are able to give your time to take 
part in the study. There will be around 20 others taking part. 
 
Inclusion/ Exclusion Criteria: 
 The inclusion criteria are as follows: 
- Individuals who are capable of giving informed consent. 
- Individuals who are capable of ingesting up to 1.5L of mineral water in a time period of up 
to 1.5 hours (time between primary and secondary urinary excretion) without causing any 
practical difficulties.  
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- Individuals within the age range of 18 – 35 years. 
The exclusion criteria are as follows: 
 -     Individuals who are not capable of giving informed consent. 
- Individuals who are not capable of ingesting up to 1.5L of mineral water in a time period of 
up to 1.5 hours (time between primary and secondary urinary excretion) without causing 
any practical difficulties. 
- Individuals outside the age range of 18 – 35 years. 
 
Do I have to take part? 
You are free to decide whether you wish to take part or not.  If you do decide to take part you will be 
asked to sign two consent forms, one is for you to keep and the other is for our records. You are free 
to withdraw from this study at any time and without giving reasons.  
 
Recruitment: Healthy volunteers (see inclusion criteria above) will be recruited by emails and 
posters, as seen in Appendix 2. The interested individuals will then converse with Miss Jones by 
email or in person, and given more information about the study. Once the health screening and 
consent form are completed the individuals will be given the questionnaire to complete. The 
recruited participants will then come to the Birchall centre to collect their water, labelled sample 
collection tubes, biohazard bags and food/drink consumption diary sheets 
 
What will happen if I take part? 
You will be given a questionnaire to complete and upon completion of this you will receive all of the 
components required to carry out the study. 
 
If I take part, what do I have to do? 
The first 24 hours of urine collection will be following your regular diet; for the second 24 hours of 
urine collection you will be required to incorporate up to 1.5L of the mineral water provided 
between your first and second urinary excretion.   
 
For the first 24 hours, collect all urine into the 3L container provided, ultrapure water will be 
provided to rinse the jug between excretions.  
 
Once you have woken on the second day, flush away your first urinary excretion, then begin to 
consume up to 1.5L of the silicon rich mineral water provided, in the time between your first and 
second urinary excretion, up to 1.5 hours.  Then continue to collect all subsequent urinations 
throughout the day into the second 3L container. The provided food diary and time of urination 
must be maintained throughout each day. 
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Duration of participation: Total of 2 days.   
 
Amount to be consumed: Up to 1.5L of Silicon rich mineral water provided by Mis Jones, in a time 
period of up to 1.5 hours (time between primary and secondary urinary excretion), allowing for 
1L/hour filtration rate. The bottle with any remaining water should be returned with the samples in 
order for the amount, which is actually consumed, to be measured. 
 
Retrieval: Samples will be collected at the end of the 48 hour period.  Volunteers are required to 
liaise with Miss Jones to arrange a time for collection that suits both the participant and Miss Jones. 
This can be at any time point over the week. 
 
Storage/ Disposal of samples: Each volunteer will be responsible for their samples. Samples are to 
be kept within the biohazard bags, provided by Miss Krista Jones, and retained in the participant’s 
fridge until collection. It is crucial to ensure that any individuals sharing amenities with the 
participant are aware of the use of their fridge for this purpose; this is to ensure that the sample 
isn’t accidentally ingested and that no offence is caused by its presence in the fridge.  Upon receipt 
at the Birchall Centre samples will be acidified to ca 20% v/v 15.8M HNO3 to render them acellular 
for longer-term keeping prior to analyses of Si and metals. Samples will then be kept in a designated 
fridge until use, after which, they will be disposed of appropriately. Since all samples will be 
converted to acid digests upon receipt then no samples of urine will be stored. Volunteers are 
advised to wash their hands after each urinary collection. 
 
Access to data and samples: Only Krista Jones and supervisor Prof. Chris Exley will have access to 
data and samples.  All data will be kept confidential and anonymous.  
 
Benefits/Risks: There are no known risk to the individual taking part of this study, the consumption 
of up to 1.5L water in a time period of up to 1.5 hours (time between primary and secondary urinary 
excretion) poses no risk to a healthy individual. Aprevious investigation, using the same protocol, by 
Samantha Ward saw no negative effects on participants. The standard clinical test, the water loading 
test, used by the NHS is a consistent method and apart from feeling slightly bloated, there are no 
risks reported with this test, which involves a considerable amount more than is being asked to be 
consumed in this study. Benefits of drinking a silicon rich mineral water have been seen in many 
scientific investigations. Silicon, as well as playing a vital role in bone growth, is believed to influence 
the excretion of aluminium, the lower the bioburden of aluminium on the body the lower the risk of 
developing aluminium related diseases (Exley, 2006). 
 
Funding: The study is being funded by Keele Acorn and additional support from Spritzer. 
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What if there is a problem?  It has been reported that in rare cases some people experience some 
dizziness under water loading, so if you begin to feel unwell then stop drinking the water. 
 
Contact the below for any queries: 
 
 
Nicola Leighton 
Research Governance Officer 
Research & Enterprise Services 
Dorothy Hodgkin Building 
Keele University  
ST5 5BG 
E-mail: n.leighton@uso.keele.ac.uk 
Tel: 01782 733306 
 
 
Krista Jones     
Email:  k.l.jones@keele.ac.uk                                                                
    
 
 Prof. Chris Exley 
Email:  c.exley@chem.keele.ac.uk 
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CONSENT FORM 
 
Title of Project:  Renal Handling of Silicon 
Name and contact details of Principal Investigator: Krista Jones, k.l.jones@keele.ac.uk, 
 
 
Please tick box if you  
agree with the statement 
 
1 I confirm that I have read and understand the information sheet for the above study and have 
had the opportunity to ask questions. 
 
□ 
2 I understand that my participation is voluntary and that I am free to withdraw at any time. □ 
3 I agree to take part in this study. □ 
4 I understand that data collected about me during this study will be anonymised before it is 
submitted for publication. 
 
□ 
 
_______________________ 
Name of participant 
 
___________________ 
Date 
 
_____________________ 
Signature 
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________________________  
Researcher 
___________________ 
Date 
_____________________ 
Signature 
 
 
 
 
 
 
Healthy Volunteer Questionnaire 
 
Gender: Male □ Female □ 
Age:  …….. 
Height:  …….. 
Weight: …….. 
 
For the following questions, please indicate the most suitable answer. 
 In an average week how often do you eat the following types of food? 
          Never Once a week A few times a week Every day  
Fresh foods   □           □                           □       □ 
Processed foods  □           □            □       □ 
Ready meals  □          □            □       □ 
Take Outs   □                     □            □       □ 
Other (please state)  □           □             □        □ 
………………………………………………………………………………………. 
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 In an average week how often do you consume the following soft beverages?   
        Never Once a week  A few times a week Every day 
Water (Tap)   □            □         □       □ 
Water (Bottle)                □            □         □       □ 
Milk/Milkshake               □            □         □       □ 
Fresh fruit Juice               □            □         □       □ 
Long life juice  □            □         □       □ 
Cordial                □            □         □       □ 
Fizzy drinks (Cans) □            □         □       □ 
Fizzy drinks (bottles)       □            □         □       □ 
Tea   □            □         □       □ 
Coffee   □            □         □       □ 
Other (please state)  □            □                  □        □ 
………………………………………………………………………………………. 
 If you consume bottle water, which brand do you prefer? 
………………………………………………………………………………………. 
 
 In an average week how often do you consume the following alcoholic beverages?   
        Never      Once a week  A few times a week Every day 
Beer (can)  □            □         □       □ 
Beer (bottle/draft) □            □         □       □ 
Cider (can)  □            □         □       □ 
Cider (bottle/draft) □            □         □       □ 
Wine   □            □         □       □ 
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Spirits   □            □         □       □  
Other (please state)  □            □   □        □ 
………………………………………………………………………………………. 
 
 How often a week do you use the following products? 
        Never      Once a week  A few times a week Every day 
Deodorant  □            □   □        □ 
Hairspray  □            □   □        □ 
Cosmetics  □            □   □        □ 
Soap/Shower gel □            □   □        □  
 
 Which best describes your smoking habits? 
Regular Smoker  □ 
Social Smoker                □ 
Ex-smoker  □ 
Non-smoker  □ 
 
 
 
 How often do you exercise in an average week? 
Every day  □ 
5-6 days  □ 
3-4 days  □ 
1-2 days  □ 
Never   □ 
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 How would you best describe your activity level? 
Strenuous  □ 
Moderate  □ 
Gentle   □ 
N/A   □ 
 
 
 Do you suffer from any medical conditions:  Yes □     No □ 
If yes, please specify……………………………………………………………….. 
 
 Are you currently taking any pharmaceuticals:  Yes□       No □ 
If yes, please select which type: 
Paracetemols  □ 
Aspirins               □ 
Ibuprofen  □ 
Antacids  □ 
Other   □ (please specify…………………………………………..) 
 
 How often are you taking pharmaceuticals? 
Daily     □ 
A few times a week   □  
Once a week    □ 
Less than once a week     □ 
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 Are you currently taking any vitamin supplements:     Yes □     No 
□ 
If yes, please specify……………………………………………………………….. 
 
 
 How often are you taking vitamin supplements? 
Daily     □ 
A few times a week   □  
Once a week    □ 
Less than once a week     □ 
 
Thank you for your time and participation.   
 
 
 
 
 
Record Card - 24hour sample Day 1 
 
Start Date: Start Time: 
Finish Date: Finish Time: 
 
Amount of Exercise (m): Level of Exercise: Gentle Moderate Strenuous 
 
Consumption of beverages: 
Beverages Consumed Time Consumed Amount Consumed 
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Record Card - 24hour sample Day 2 (addition of Spritzer) 
 
Start Date: Start Time: 
Finish Date: Finish Time: 
 
Amount of Exercise (m): Level of Exercise: Gentle Moderate Strenuous 
 
Consumption of beverages: 
Beverages Consumed Time Consumed Amount Consumed 
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 Poster for advertisement of the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants Needed 
 
I am looking for volunteers, aged 18-35, to 
participate within a PhD research project on the 
renal handling of silicon.  As a participant you will 
be asked to consume up to 1.5L silicic acid rich 
mineral water during in a time period of up to 1.5 
hours (time between primary and secondary 
urinary excretion).  You will also be required to fill 
out a lifestyle questionnaire and to maintain 
dietary records.  All information collected will 
remain anonymous. 
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Annex 6 
 
Sweat poster presentation given at the 11th Keele Meeting on Aluminium on 3th March 2015 at the 
Le Couvent Des Minimes Hotel & Spa in Lille, France. 
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Annex 7 
 
MS Patient feedback 
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Annex 8 
 
Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis 
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